



HU000033149T2

(19) **HU**(11) Lajstromszám: **E 033 149**(13) **T2****MAGYARORSZÁG****Szellemi Tulajdon Nemzeti Hivatala**

EURÓPAI SZABADALOM SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 12 820596**(22) A bejelentés napja: **2012. 08. 03.**

(96) Az európai bejelentés bejelentési száma:

EP 20120820596

(97) Az európai bejelentés közzétételi adatai:

EP 2740796 A1 **2013. 02. 07.**

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 2740796 B1 **2017. 05. 17.**(51) Int. Cl.: **C12N 15/09** (2006.01)**A61K 45/06** (2006.01)**A61P 35/00** (2006.01)**C12P 21/08** (2006.01)**C07K 16/28** (2006.01)**C07K 16/30** (2006.01)**A61K 39/395** (2006.01)**C07K 16/18** (2006.01)

(86) A nemzetközi (PCT) bejelentési szám:

PCT/JP 12/069862

(87) A nemzetközi közzétételi szám:

WO 13018894

(30) Elsőbbségi adatok:

2011171300**2011. 08. 04.****JP**

(73) Jogosult(ak):

Toray Industries, Inc., Tokyo, 103-8666 (JP)

(72) Feltaláló(k):

OKANO, Fumiyoshi, Kamakura-shi Kanagawa 248-8555 (JP)**KOBAYASHI, Shinichi, Kamakura-shi Kanagawa 248-8555 (JP)****MINAMIDA, Yoshitaka, Kamakura-shi Kanagawa 248-8555 (JP)****SAITO, Takanori, Kamakura-shi Kanagawa 248-8555 (JP)**

(74) Képviselő:

Gödölle, Kékes, Mészáros & Szabó**Szabadalmi és Védjegy Iroda, Budapest**

(54)

Gyógyászati készítmény rák kezelésére és/vagy megelőzésére

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmat az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 740 796 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
17.05.2017 Bulletin 2017/20

(21) Application number: **12820596.0**

(22) Date of filing: **03.08.2012**

(51) Int Cl.:
C12N 15/09 ^(2006.01) **A61K 39/395** ^(2006.01)
A61P 35/00 ^(2006.01) **C07K 16/30** ^(2006.01)
C12P 21/08 ^(2006.01) **C07K 16/28** ^(2006.01)
A61K 45/06 ^(2006.01) **C07K 16/18** ^(2006.01)

(86) International application number:
PCT/JP2012/069862

(87) International publication number:
WO 2013/018894 (07.02.2013 Gazette 2013/06)

(54) **PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PROPHYLAXIS OF CANCER**
PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG UND/ODER PRÄVENTION VON
KREBS
COMPOSITION PHARMACEUTIQUE DESTINÉE À TRAITER OU À PRÉVENIR LE CANCER

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **04.08.2011 JP 2011171300**

(43) Date of publication of application:
11.06.2014 Bulletin 2014/24

(60) Divisional application:
17163690.5

(73) Proprietor: **Toray Industries, Inc.**
Tokyo, 103-8666 (JP)

(72) Inventors:
• **OKANO, Fumiyoshi**
Kamakura-shi
Kanagawa 248-8555 (JP)
• **KOBAYASHI, Shinichi**
Kamakura-shi
Kanagawa 248-8555 (JP)

• **MINAMIDA, Yoshitaka**
Kamakura-shi
Kanagawa 248-8555 (JP)
• **SAITO, Takanori**
Kamakura-shi
Kanagawa 248-8555 (JP)

(74) Representative: **Denison, Christopher Marcus et al**
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE (GB)

(56) References cited:
WO-A1-2010/016525 WO-A1-2010/016526
WO-A1-2010/016526 WO-A1-2010/016527
WO-A1-2013/147169 WO-A1-2013/147176

• **ELLIS J.A. ET AL.: 'Identification and
Characterization of a Novel Protein (p137) Which
Transcytoses Bidirectionally in Caco-2 Cells.'**
J.BIOL.CHEM. vol. 270, no. 35, 1995, pages 20717
- 20723, XP008143762

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 740 796 B1

Description

Technical Field

- 5 **[0001]** The present invention relates to novel use of an antibody against CAPRIN-1 or a fragment thereof in a drug such as a therapeutic and/or preventive agent for cancer.

Background Art

- 10 **[0002]** Cancer is the leading cause of death. This disease is currently treated principally by surgical therapy, in combination with radiation therapy and/or chemotherapy. In spite of recent development of novel surgical techniques or discovery of novel anticancer agents, the existing treatment of cancer has an insufficiently improved outcome, except for some cancer types. With recent advances of molecular biology or cancer immunology, antibodies that specifically react with cancer, cancer antigens that are recognized by cytotoxic T cells, genes encoding such cancer antigens, and
15 the like have been identified, raising expectations on specific cancer therapy targeting the cancer antigens (Non Patent Literature 1).

- [0003]** For reducing the adverse reaction of cancer therapy, it is desired that peptides, polypeptides, or proteins recognized as antigens of the cancer should rarely exist in normal cells and specifically exist in cancer cells. In 1991, Boon et al. (Ludwig Institute for Cancer Research, Belgium) isolated a human melanoma antigen MAGE1 recognized
20 by CD8-positive T cells by a cDNA expression cloning method using autologous cancer cell lines and cancer-reactive T cells (Non Patent Literature 2). Then, a SEREX (serological identification of antigens by recombinant expression cloning) method has been reported, which adopts a gene expression cloning approach to identify tumor antigens recognized by antibodies produced in response to autologous cancer *in vivo* in a cancer patient (Non Patent Literature 3 and Patent Literature 1). According to this method, some cancer antigens that are rarely expressed in normal cells and
25 are specifically expressed in cancer have been isolated (Non Patent Literatures 4 to 9). In addition, cell therapy using immunocytes that specifically react with cancer antigens or cancer-specific immunotherapy using vaccines or the like comprising cancer antigens is under clinical trial targeting some of the isolated cancer antigens.

- [0004]** In recent years, various antibody drugs for cancer treatment targeting antigenic proteins on cancer cells have emerged in the world. These drugs have received attention because of their certain efficacy as cancer-specific therapeutic
30 agents. A large majority of antigenic proteins targeted by the drugs, however, are also expressed in normal cells. As a result of administering the antibodies, cancer cells as well as normal cells expressing the antigens are damaged, disadvantageously resulting in adverse reaction. Thus, if cancer antigens specifically expressed on the surface of cancer cells can be identified and antibodies targeting the antigens can be used as drugs, these antibody drugs can be expected to achieve treatment with less adverse reaction.

- 35 **[0005]** Cytoplasmic- and proliferation-associated protein 1 (CAPRIN-1) has been known as an intracellular protein that is expressed upon activation or cell division of resting normal cells and forms cytoplasmic stress granules with RNAs in cells to participate in the regulation of transport and translation of mRNAs. This protein has been found to be specifically expressed on the surface of cancer cells and is therefore under study as a target of antibody drugs for cancer treatment (Patent Literature 2).

40

Citation List

Patent Literature

- 45 **[0006]**

Patent Literature 1: U.S. Patent No. 5698396

Patent Literature 2: WO2010/016526

- 50 Non Patent Literature

[0007]

- 55 Non Patent Literature 1: Tsuyoshi Akiyoshi, "Japanese Journal of Cancer and Chemotherapy", 1997, Vol. 24, p. 55-519 (Japanese Journal of Cancer and Chemotherapy Publishers Inc., Japan)

Non Patent Literature 2: Bruggen P. et al., Science, 254: 1643-1647 (1991)

Non Patent Literature 3: Proc. Natl. Acad. Sci. USA, 92: 11810-11813 (1995)

Non Patent Literature 4: Int. J. Cancer, 72: 965-971 (1997)

Non Patent Literature 5: Cancer Res., 58: 1034-1041 (1998)
 Non Patent Literature 6: Int. J. Cancer, 29: 652-658 (1998)
 Non Patent Literature 7: Int. J. Oncol., 14: 703-708 (1999)
 Non Patent Literature 8: Cancer Res., 56: 4766-4772 (1996)
 Non Patent Literature 9: Hum. Mol. Genet. 6:33-39 (1997)

Summary of Invention

Technical Problem

[0008] An object of the present invention is to produce an antibody which targets CAPRIN-1 specifically expressed on the surface of cancer cells and has better antitumor activity than conventional antibodies, and provide the antibody for use as a therapeutic and/or preventive agent for cancer.

Solution to Problem

[0009] The present invention has the following aspects:

[0010] The present invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide having the amino acid sequence shown by SEQ ID NO: 5. The present invention also provides a pharmaceutical composition comprising the antibody or the fragment thereof as an active ingredient, and a pharmaceutical combination as defined in the claims. The invention also provides said pharmaceutical composition and said pharmaceutical combination, each for use in a method of treating and/or preventing cancer.

[0011] In one embodiment of the present invention, the cancer is breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.

[0012] In another embodiment, the antibody is a monoclonal antibody or a polyclonal antibody.

[0013] In an alternative embodiment, the antibody is a human antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, or a multispecific antibody (e.g. bispecific antibody).

Advantageous Effects of Invention

[0014] The antibody against CAPRIN-1 according to the present invention damages cancer cells. Thus, the antibody against CAPRIN-1 is useful in the treatment and/or prevention of cancer.

Description of Embodiments

[0015] The antibody according to the present invention is an antibody that recognizes and binds to a predetermined partial polypeptide of CAPRIN-1 and has antitumor activity. The antibody according to the present invention is more specifically an antibody that recognizes (i.e., has immunological reactivity with) a partial polypeptide of a CAPRIN-1 protein (partial CAPRIN-1 polypeptide) consisting of the amino acid sequence shown by SEQ ID NO: 5. The present invention has revealed that this antibody exhibits antitumor activity. The present invention relates to all antibodies that bind to the fragments of CAPRIN-1 proteins as described above and exhibit antitumor activity.

[0016] The antibody against CAPRIN-1 according to the present invention may be any type of antibody that can exert antitumor activity and includes, for example, recombinant antibodies, for example, synthetic antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized antibodies, chimeric antibodies, and single-chain antibodies (scFv), human antibodies, and their antibody fragments, for example, Fab, F(ab')₂, and Fv. These antibodies and fragments thereof can be prepared by methods known to those skilled in the art. Desirably, the antibody according to the present invention has immunological reactivity with a CAPRIN-1 protein or a partial polypeptide thereof, i.e., binds to the CAPRIN-1 protein through antigen-antibody reaction, preferably, specifically binds to the CAPRIN-1 protein. In this context, the phrase "specifically binding to the CAPRIN-1 protein" means that the antibody specifically binds to the CAPRIN-1 protein without substantially binding to other proteins. The antibody according to the present invention is preferably a monoclonal antibody. Alternatively, the antibody according to the present invention may be a polyclonal antibody as long as homogeneous antibodies can be stably produced. In the case of a human subject, a human antibody or a humanized antibody is desirable for avoiding or suppressing rejection.

[0017] The antibody against CAPRIN-1 polypeptide according to the present invention can be examined for its antitumor activity, as described later, by examining *in vivo* the inhibition of tumor growth in a cancer-bearing animal or by examining *ex vivo* the presence or absence of immunocyte- or complement-mediated cytotoxic activity exhibited by the antibody against tumor cells expressing the polypeptide.

[0018] The subject to receive the treatment and/or prevention of cancer according to the present invention is a mammal such as a human, a pet animal, livestock, or a sport animal, preferably a human.

[0019] Hereinafter, the present invention will be described in more detail.

5 <Preparation of antigen for antibody preparation>

[0020] Proteins or fragments thereof used as sensitizing antigens for obtaining the antibody against CAPRIN-1 according to the present invention are not limited by animal species serving as their origins, including humans, dogs, cattle, horses, mice, rats, and chickens. The proteins or the fragments thereof, however, are preferably selected in view of compatibility with parent cells for use in cell fusion. In general, mammal-derived proteins are preferred. Particularly, human-derived proteins are preferred. For example, when CAPRIN-1 is human CAPRIN-1, human CAPRIN-1 proteins, partial peptides thereof, or cells expressing human CAPRIN-1 can be used.

[0021] The nucleotide sequences and amino acid sequences of human CAPRIN-1 and homologs thereof are available, for example, by accessing GenBank (NCBI, USA) and using BLAST or FASTA algorithm (Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 90: 5873-5877, 1993; and Altschul et al., Nucleic Acids Res. 25: 3389-3402, 1997).

[0022] In the present invention, with reference to the nucleotide sequence (SEQ ID NO: 1 or 3) or amino acid sequence (SEQ ID NO: 2 or 4) of human CAPRIN-1, the target CAPRIN-1 is nucleic acids or proteins consisting of sequences having 70% to 100%, preferably 80% to 100%, more preferably 90% to 100%, further preferably 95% to 100%, for example, 97% to 100%, 98% to 100%, 99% to 100%, or 99.5% to 100% sequence identity to the nucleotide sequence or amino acid sequence of the ORF or mature portion of the reference sequence. In this context, the term "% sequence identity" means a percentage (%) of the number of identical amino acids (or nucleotide bases) to the total number of amino acids (or nucleotide bases) when two sequences are aligned such that the maximum degree of similarity (or identity) can be achieved with or without introduced gaps.

[0023] As the fragments of each CAPRIN-1 protein, those comprising an epitope (or an antigenic determinant), which is the smallest unit recognized by an antibody, and having lengths ranging from the amino acid length of the epitope to less than the full-length of the protein can be used. The epitope refers to a polypeptide fragment having antigenicity or immunogenicity in mammals, preferably humans. Its smallest unit consists of approximately 7 to 12 amino acids, for example, 8 to 11 amino acids. The fragment of CAPRIN-1 protein to be used in the preparation of the antibody according to the present invention consists of the amino acid sequence shown by SEQ ID NO: 5 recognized by the antibody of the present invention.

[0024] Polypeptide fragments comprising the above human CAPRIN-1 proteins and partial peptides thereof can be synthesized according to chemical synthesis methods, for example, Fmoc (fluorenylmethyloxycarbonyl) and tBoc (t-butyloxycarbonyl) methods (Seikagaku Jikken Koza (Biochemical Experimentation Course in English) 1, the Japanese Biochemical Society ed., Protein Chemistry IV, Chemical Modification and Peptide Synthesis, Tokyo Kagaku Dojin Co., Ltd. (Japan), 1981). Also, these polypeptides can be synthesized by conventional methods using various commercially available peptide synthesizers.

[0025] Alternatively, polynucleotides encoding the polypeptides may be prepared using genetic engineering approaches known in the art (Sambrook et al., Molecular Cloning, the 2nd edition, Current Protocols in Molecular Biology (1989), Cold Spring Harbor Laboratory Press; Ausubel et al., Short Protocols in Molecular Biology, the 3rd edition, A compendium of Methods from Current Protocols in Molecular Biology (1995), John Wiley & Sons; etc.) and incorporated into expression vectors, which are then introduced into host cells to produce the polypeptides in the host cells. In this way, the human CAPRIN-1 proteins or polypeptide fragments thereof of interest can be obtained.

[0026] The polynucleotides encoding the polypeptides can be readily prepared by genetic engineering approaches known in the art or conventional methods using commercially available nucleic acid synthesizers. For example, a DNA comprising the nucleotide sequence of human CAPRIN-1 gene can be prepared by PCR using a human chromosomal DNA or cDNA library as a template and a pair of primers designed so as to be capable of amplifying the nucleotide sequence. Reaction conditions for this PCR can be appropriately determined. Examples of the conditions can include, but not limited to, 30 cycles each involving reaction steps consisting of 94°C for 30 seconds (denaturation), 55°C for 30 seconds to 1 minute (annealing), and 72°C for 2 minutes (elongation) using thermostable DNA polymerase (e.g., Taq polymerase, Pfu polymerase or the like) and a Mg²⁺-containing PCR buffer, followed by reaction at 72°C for 7 minutes. The PCR approach, conditions, etc. are described in, for example, Ausubel et al., Short Protocols in Molecular Biology, the 3rd edition, A Compendium of Methods from Current Protocols in Molecular Biology (1995), John Wiley & Sons (particularly, Chapter 15).

[0027] Also, appropriate probes or primers can be prepared on the basis of information about the nucleotide sequences of CAPRIN-1 gene and the amino acid sequences of CAPRIN-1 proteins, and used in the screening of, for example, a human cDNA library, to isolate the desired DNA. Preferably, such a cDNA library is produced from cells, organs, or tissues expressing proteins of CAPRIN-1. Examples of such cells or tissues include cells or tissues derived from the testis or from cancers or tumors such as leukemia, breast cancer, lymphoma, brain tumor, lung cancer, pancreatic

cancer, and colorectal cancer. These operations, including the preparation of probes or primers, the construction of a cDNA library, the screening of the cDNA library, and the cloning of the gene of interest, are known to those skilled in the art and can be performed according to methods described in, for example, Sambrook et al., *Molecular Cloning*, the 2nd edition, *Current Protocols in Molecular Biology* (1989), and Ausubel et al. (*ibid.*). DNAs encoding the human CAPRIN-1 proteins and the partial peptides thereof can be obtained from the DNA thus obtained.

[0028] The host cells into which the expression vectors are introduced may be any cell capable of expressing the above polypeptides. Examples of prokaryotic cells include, but not limited to, *E. coli*. Examples of eukaryotic cells include, but not limited to: mammalian cells such as monkey kidney cells COS1 and Chinese hamster ovary cells CHO; a human embryonic kidney cell line HEK293; mouse embryonic skin cell line NIH3T3; yeast cells such as budding yeast and fission yeast cells; silkworm cells; and *Xenopus* egg cells.

[0029] In the case of using prokaryotic cells as the host cells, the expression vectors used may have an origin that permits replication in the prokaryotic cells, a promoter, a ribosomal binding site, a multicloning site, a terminator, a drug resistance gene, an auxotrophic complementary gene, etc. Examples of expression vectors for *E. coli* can include pUC series, pBluescript II, pET expression systems, and pGEX expression systems. The DNAs encoding the above polypeptides can be incorporated into such expression vectors, with which prokaryotic host cells are then transformed, followed by culture of the obtained transformants so that the polypeptides encoded by the DNAs are expressed in the prokaryotic host cells. In this respect, the polypeptides may be expressed as fusion proteins with other proteins.

[0030] In the case of using eukaryotic cells as the host cells, expression vectors for eukaryotic cells having a promoter, a splicing region, a poly(A) addition site, etc. may be used as the expression vectors. Examples of such expression vectors can include pKA1, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV, pRS, pcDNA3, and pYES2 vectors. In the same way as above, the DNAs encoding the above polypeptides can be incorporated into such expression vectors, with which eukaryotic host cells are then transformed, followed by culture of the obtained transformants so that the polypeptides encoded by the DNAs are expressed in the eukaryotic host cells. In the case of using expression vectors such as pIND/V5-His, pFLAG-CMV-2, pEGFP-N1, or pEGFP-C1, the polypeptides may be expressed as various fusion proteins tagged with His tag (e.g., (His)₆ to (His)₁₀), FLAG tag, myc tag, HA tag, GFP, or the like.

[0031] The expression vectors can be introduced into the host cells using well known methods such as electroporation, a calcium phosphate method, a liposome method, a DEAE dextran method, microinjection, viral infection, lipofection, and binding with cell-penetrating peptides.

[0032] The polypeptide of interest can be isolated and purified from the host cells by a combination of separation operations known in the art. Examples thereof include, but not limited to, treatment with a denaturant (e.g., urea) or a surfactant, ultrasonication, enzymatic digestion, salting-out, solvent fractionation and precipitation, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing electrophoresis, ion-exchange chromatography, hydrophobic chromatography, affinity chromatography, and reverse-phase chromatography.

[0033] In order to prepare the antibody according to the present invention, antigens thus prepared can be used as sensitizing antigens as described later.

<Structure of antibody>

[0034] Antibodies (immunoglobulin) are usually heteromultimeric glycoproteins each comprising at least two heavy chains and two light chains. The immunoglobulins, except for IgM, are heterotetrameric glycoproteins of approximately 150 kDa each composed of two identical light (L) chains and two identical heavy (H) chains. Typically, each light chain is connected to a heavy chain via a single covalent disulfide bond, though the number of disulfide bonds between heavy chains varies among different immunoglobulin isotypes. Each of the heavy and light chains also has an intrachain disulfide bond. Each heavy chain has a variable domain (VH region) at one end, followed by a series of constant regions. Each light chain has a variable domain (VL region) at one end and has a single constant region at the other end. The light chain constant region is aligned with the first heavy chain constant region, while the light chain variable domain is aligned with the heavy chain variable domain. Particular regions called complementarity determining regions (CDRs) in the antibody variable domains exhibit specific variability and impart binding specificity to the antibody. Portions relatively conserved in the variable regions are called framework regions (FRs). The complete heavy and light chain variable domains each comprise four FRs connected via three CDRs. These three CDRs are called CDRH1, CDRH2, and CDRH3 in this order from the N-terminus of the heavy chain. Likewise, the CDRs are called CDRL1, CDRL2, and CDRL3 in the light chain. CDRH3 is most important for the binding specificity of the antibody for its antigen. In addition, CDRs in each chain are kept close to each other by the FR regions and contribute to the formation of an antigen-binding site in the antibody, together with CDRs in the other chain. The constant regions do not directly contribute to antibody-antigen binding, but exhibit various effector functions, for example, involvement in antibody-dependent cellular cytotoxicity (ADCC), phagocytosis mediated by binding to an Fcγ receptor, half-life/clearance rate mediated by a neonatal Fc receptor (FcRn), and complement-dependent cytotoxicity (CDC) mediated by a C1q component in the complement cascade.

<Preparation of antibody>

[0035] The anti-CAPRIN-1 antibody according to the present invention means an antibody having immunological reactivity with a full-length CAPRIN-1 protein or a fragment thereof. Particularly, the anti-CAPRIN-1 antibody of the present invention is an antibody immunologically binding to a partial polypeptide of a CAPRIN-1 protein (partial CAPRIN-1 polypeptide) that is a peptide containing an epitope and consisting of the amino acid sequence shown by SEQ ID NO: 5. The antibody of the present invention preferably recognizes an epitope consisting of approximately 7 to 12 consecutive amino acids, for example, 8 to 11 consecutive amino acids, in the amino acid sequence shown by SEQ ID NO: 5. This anti-CAPRIN-1 antibody of the present invention can specifically bind to the full-length CAPRIN-1 protein. The antibody of the present invention can be obtained by selecting an antibody immunologically binding to a polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5, according to a routine method from among antibodies obtained with CAPRIN-1 proteins or fragments thereof as antigens.

[0036] In this context, the "immunological reactivity" means the property of the antibody binding to the CAPRIN-1 antigen (a full-length CAPRIN-1 protein or a partial polypeptide thereof) *in vivo*. Via such binding of the antibody of the present invention to the CAPRIN-1, the antibody exerts the function of damaging (e.g., killing, suppressing, or regressing) tumor cells. The antibody of the present invention can damage tumors such as breast cancer, kidney cancer, pancreatic cancer, colorectal cancer (e.g. colon cancer), lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma as a result of binding to the CAPRIN-1 protein.

[0037] The antibody of the present invention may be any type of antibody. Examples of the type of the antibody according to the present invention include monoclonal antibodies, polyclonal antibodies, synthetic antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, single-chain antibodies, and antibody fragments (e.g., Fab, F(ab')₂, and Fv). Also, the antibody is any class of immunoglobulin molecule, for example, IgG, IgE, IgM, IgA, IgD, or IgY, or any subclass, for example, IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2.

[0038] Further the antibody may be modified by acetylation, formylation, amidation, phosphorylation, PEGylation, or the like, as well as glycosylation.

[0039] Hereinafter, preparation examples of various antibodies will be shown.

[0040] When the antibody of the present invention is a monoclonal antibody, for example, breast cancer cell lines SK-BR-3 expressing CAPRIN-1 is administered to each mouse for immunization. The spleen is extracted from this mouse. After separation of spleen cells, the cells are fused with mouse myeloma cells. Clones producing antibodies having a cancer cell growth inhibitory effect are selected from among the obtained fusion cells (hybridomas). Alternatively, clones producing antibodies binding to a polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5 may be selected. The hybridomas producing monoclonal antibodies having a cancer cell growth inhibitory effect or the hybridomas producing monoclonal antibodies against the polypeptides of SEQ ID NO: 5, etc. are isolated and cultured. The antibody of the present invention can be prepared by purification from the culture supernatant according to a general affinity purification method.

[0041] The monoclonal antibody-producing hybridomas may be prepared, for example, as follows. First, animals are immunized with sensitizing antigens according to a method known in the art. This immunization method generally involves intraperitoneally or subcutaneously injecting the sensitizing antigens to mammals. Specifically, the sensitizing antigens are diluted with or suspended in PBS (phosphate-buffered saline), physiological saline, or the like into an appropriate amount and then mixed, if desired, with an appropriate amount of a conventional adjuvant, for example, a complete Freund's adjuvant. After emulsification, it is administered to each mammal several times every 4 to 21 days. Alternatively, an appropriate carrier may be used for the immunization with sensitizing antigens.

[0042] After confirmation of a rise in the level of the desired antibody in the serum of the animal (typically, mammal) thus immunized, immunocytes are collected from the animal and subjected to cell fusion. Preferred examples of the immunocytes particularly include spleen cells.

[0043] Mammalian myeloma cells, for example, can be used as partner parent cells to be fused with the immunocytes. Various cell lines known in the art, for example, P3U1 (P3-X63Ag8U1), P3 (P3x63Ag8.653) (J. Immunol. (1979) 123, 1548-1550), P3x63Ag8U.1 (Current Topics in Microbiology and Immunology (1978) 81, 1-7), NS-1 (Kohler, G. and Milstein, C. Eur. J. Immunol. (1976) 6, 511-519), MPC-11 (Margulies, D.H. et al., Cell (1976) 8, 405-415), SP2/0 (Shulman, M. et al., Nature (1978) 276, 269-270), FO (deSt. Groth, S.F. et al., J. Immunol. Methods (1980) 35, 1-21), S194 (Trowbridge, I.S. J. Exp. Med. (1978) 148, 313-323), and R210 (Galfre, G. et al., Nature (1979) 277, 131-133), are preferably used as the myeloma cells.

[0044] The cell fusion between the immunocytes and the myeloma cells can be performed basically according to a method known in the art, for example, the method of Kohler and Milstein (Kohler, G. and Milstein, C. Methods Enzymol. (1981) 73, 3-46).

[0045] More specifically, the cell fusion is carried out, for example, in the presence of a cell fusion promoter in a conventional nutrient medium. For example, polyethylene glycol (PEG) or hemagglutinating virus of Japan (HVJ) is used

as the fusion promoter. If desired, an auxiliary such as dimethyl sulfoxide may be further added in order to enhance fusion efficiency.

[0046] The ratio between the immunocytes and the myeloma cells used can be arbitrarily set. For example, the amount of the immunocytes is preferably set to 1 to 10 times the amount of the myeloma cells. Examples of the medium that can be used in the cell fusion include RPMI1640 and MEM media suitable for the growth of the myeloma cell lines as well as conventional media for use in this type of cell culture. In addition, a serum supplement such as fetal calf serum (FCS) may be used in combination with these media.

[0047] For the cell fusion, the immunocytes and the myeloma cells are well mixed in a predetermined amount of the medium. A PEG solution (average molecular weight: for example, approximately 1000 to 6000) preheated to approximately 37°C is usually added to the mixture at a concentration of 30 to 60% (w/v) and mixed therewith to form the hybridomas of interest. Subsequently, procedures of sequentially adding an appropriate medium and removing the supernatant by centrifugation are preferably repeated to remove cell fusion agents or the like unfavorable for the growth of the hybridomas.

[0048] The hybridomas thus obtained are cultured in a conventional selective medium, for example, a HAT medium (medium containing hypoxanthine, aminopterin, and thymidine) for selection. Culture in the HAT medium is continued for a period (usually, several days to several weeks) sufficient for the death of cells (non-fused cells) other than the hybridomas of interest. Subsequently, hybridomas producing the antibody of interest are screened for and cloned as single clones by a conventional limiting dilution method.

[0049] In addition to such obtaining of the hybridomas by the immunization of non-human animals with antigens, hybridomas producing human antibodies having the desired activity (e.g., cell growth inhibitory activity) may be obtained by sensitizing human lymphocytes, for example, EB virus-infected human lymphocytes, with proteins, protein-expressing cells, or lysates thereof *in vitro* and fusing the sensitized lymphocytes with human-derived myeloma cells capable of dividing permanently, for example, U266 (Accession No. TIB196).

[0050] The monoclonal antibody-producing hybridomas thus prepared can be subcultured in a conventional medium and can also be stored for a long period in liquid nitrogen.

[0051] Specifically, the desired antigens or cells expressing the desired antigens are used as sensitizing antigens in immunization according to a conventional immunization method. The obtained immunocytes are fused with parent cells known in the art according to a conventional cell fusion method. Monoclonal antibody-producing cells (hybridomas) can be screened for by a conventional screening method to prepare the hybridomas producing monoclonal antibodies of interest.

[0052] Another example of the antibody that may be used in the present invention is a polyclonal antibody. The polyclonal antibody can be obtained, for example, as follows:

[0053] Serum is obtained from small animals such as mice, human antibody-producing mice, or rabbits immunized with natural CAPRIN-1 proteins or recombinant CAPRIN-1 proteins expressed as fusion proteins with GST or the like in microorganisms such as *E. coli*, or partial peptides thereof. Alternatively, serum may be obtained from mammals immunized with CAPRIN-1 fragment polypeptides each comprising the amino acid sequence shown by SEQ ID NO: 5 or an amino acid sequence having 80% or higher, preferably 85% or higher, more preferably 90% or higher, further preferably 95% or higher sequence identity to the amino acid sequence (preferably, a polypeptide consisting of the amino acid sequence of SEQ ID NO: 5), or polypeptides each comprising (preferably, consisting of) an epitope consisting of approximately 7 to 12 consecutive amino acids, for example, 8 to 11 consecutive amino acids, in the amino acid sequence shown by SEQ ID NO: 5 or an amino acid sequence having 80% or higher, preferably 85% or higher, more preferably 90% or higher, further preferably 95% or higher sequence identity to the amino acid sequence, as sensitizing antigens. These serums are purified using, for example, ammonium sulfate precipitation, protein A or protein G columns, DEAE ion-exchange chromatography, or affinity columns coupled with CAPRIN-1 proteins or synthetic peptides to prepare the anti-CAPRIN-1 polyclonal antibody. The polyclonal antibody of the present invention includes antibodies obtained from human antibody-producing animals (e.g., mice) immunized with CAPRIN-1 proteins.

[0054] In this context, for example, KM mice (Kirin Pharma Co., Ltd./Medarex) and Xeno mice (Amgen Inc.) are known as the human antibody-producing mice (e.g., International Publication Nos. WO02/43478 and WO02/092812). Complete human polyclonal antibodies can be obtained from the blood of such mice immunized with CAPRIN-1 proteins or fragments thereof. Alternatively, spleen cells may be isolated from the mice thus immunized and fused with myeloma cells. In this way, human monoclonal antibodies can be obtained.

[0055] The antigens can be prepared according to, for example, a method using animal cells (JP Patent Publication (Kohyo) No. 2007-530068 A (2007)) or a method using baculovirus (e.g., International Publication No. WO98/46777). Antigens having low immunogenicity can be bound to immunogenic macromolecules such as albumin for immunization. Antigens may be administered with adjuvants for immunization.

[0056] Alternatively, the antibody of the present invention may be obtained as recombinant antibodies, which are produced using a genetic engineering technique which involves: cloning the antibody genes from hybridomas; incorporating the antibody genes into appropriate vectors; and introducing the vectors into hosts (see, e.g., Carl, A.K. Borrebaeck,

James, W. Larrick, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). Specifically, antibody variable region (V region) cDNAs are synthesized from the mRNAs of hybridomas using reverse transcriptase. After obtainment of DNAs encoding the antibody V regions of interest, the DNAs are ligated with DNAs encoding the desired antibody constant regions (C regions). The resulting ligation products are incorporated into expression vectors. Alternatively, the antibody V region-encoding DNAs may be incorporated into expression vectors containing antibody C region DNAs. These DNAs are incorporated into the expression vectors so as to be expressed under the control of expression control regions, for example, an enhancer and a promoter. Next, host cells can be transformed with the resulting expression vectors and allowed to express antibodies.

[0057] The anti-CAPRIN-1 antibody of the present invention is preferably a monoclonal antibody. Alternatively, the anti-CAPRIN-1 antibody of the present invention may be a polyclonal antibody, a genetically engineered antibody (chimeric antibody, humanized antibody, etc.), or the like.

[0058] The monoclonal antibody includes human monoclonal antibodies, non-human animal monoclonal antibodies (e.g., mouse, rat, rabbit, and chicken monoclonal antibodies), chimeric monoclonal antibodies, and the like. The monoclonal antibody may be prepared by the culture of hybridomas obtained by the fusion between spleen cells from non-human animals (e.g., mice or human antibody-producing mice, chickens, and rabbits) immunized with CAPRIN-1 proteins or fragments thereof and myeloma cells. Alternatively, genes of heavy and light chain variable regions from the spleen cells of non-human animals (e.g., mice, human antibody-producing mice, chickens, and rabbits) immunized with CAPRIN-1 proteins or fragments thereof may be incorporated via linkers into phagemid vectors, which are then introduced into *E. coli* so that single-chain antibodies are expressed via helper phages to prepare the antibodies of interest. The chimeric antibody is an antibody prepared from a combination of sequences derived from different animals and is, for example, an antibody composed of mouse antibody heavy and light chain variable regions and human antibody heavy and light chain constant regions. The chimeric antibody can be prepared using a method known in the art which involves, for example: ligating DNAs encoding the antibody V regions with DNAs encoding human antibody C regions; incorporating the resulting ligation products into expression vectors; and introducing the vectors into hosts so that antibodies are produced.

[0059] Monoclonal antibodies that have immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5 and have an antitumor effect are prepared by methods described later in Examples. These monoclonal antibodies each comprise, for example, a heavy chain variable (VH) region having the amino acid sequence of SEQ ID NO: 9, 19, 58, 63, 69, or 77 and a light chain variable (VL) region having the amino acid sequence of SEQ ID NO: 13, 23, 53, 62, 65, 73, or 81. In these monoclonal antibodies, the VH region can comprise CDR1 shown by the amino acid sequence of SEQ ID NO: 6, 16, 55, 66, or 74, CDR2 shown by the amino acid sequence of SEQ ID NO: 7, 17, 56, 67, or 75, and CDR3 shown by the amino acid sequence of SEQ ID NO: 8, 18, 57, 68, or 76, and the VL region can comprise CDR1 shown by the amino acid sequence of SEQ ID NO: 10, 20, 50, 59, 70, or 78, CDR2 shown by the amino acid sequence of SEQ ID NO: 11, 21, 51, 60, 64, 71, or 79, and CDR3 shown by the amino acid sequence of SEQ ID NO: 12, 22, 52, 61, 72, or 80.

[0060] The humanized antibody, also called reshaped human antibody, is an engineered antibody. The humanized antibody is constructed by grafting antibody CDRs derived from an immunized animal into the complementarity determining regions of a human antibody. A general gene recombination approach therefor is also known.

[0061] Specifically, for example, DNA sequences designed so as to link mouse, rabbit, and chicken antibodies CDRs and human antibody framework regions (FRs) are synthesized by PCR using several prepared oligonucleotides having terminal portions overlapping with each other. The obtained DNAs are ligated with DNAs encoding human antibody constant regions. Subsequently, the resulting ligation products are incorporated into expression vectors, which are then introduced into hosts for antibody production to obtain the antibody of interest (see European Patent Application Publication No. EP239400 and International Publication No. WO96/02576). The human antibody FRs connected via CDRs are selected such that the complementarity determining regions form a favorable antigen-binding site. If necessary, amino acids in the framework regions of antibody variable regions may be substituted such that the complementarity determining regions of the resulting reshaped human antibody form an appropriate antigen-binding site (Sato K. et al., Cancer Research 1993, 53: 851-856). In addition, these framework regions may be replaced with framework regions derived from various human antibodies (see International Publication No. WO99/51743).

[0062] The human antibody framework regions connected via CDRs are selected such that the complementarity determining regions form a favorable antigen-binding site. If necessary, amino acids in the framework regions of antibody variable regions may be substituted such that the complementarity determining regions of the resulting reshaped human antibody form an appropriate antigen-binding site (Sato K. et al., Cancer Research 1993, 53: 851-856).

[0063] Amino acids in variable regions (e.g., FRs) or constant regions of the chimeric antibody or the humanized antibody thus prepared may be substituted, for example, by other amino acids.

[0064] The amino acid substitution is the substitution of, for example, less than 15, less than 10, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less amino acids, preferably 1 to 5 amino acids, more preferably 1 or 2 amino acids. The substituted antibody should be functionally equivalent to an unsubstituted antibody. The substitution

is desirably conservative amino acid substitution, which is the substitution between amino acids similar in properties such as charge, side chains, polarity, and aromaticity. The amino acids can be classified in terms of similar properties into, for example: basic amino acids (arginine, lysine, and histidine); acidic amino acids (aspartic acid and glutamic acid); uncharged polar amino acids (glycine, asparagine, glutamine, serine, threonine, cysteine, and tyrosine); nonpolar amino acids (leucine, isoleucine, alanine, valine, proline, phenylalanine, tryptophan, and methionine); branched amino acids (leucine, valine, and isoleucine); and aromatic amino acids (phenylalanine, tyrosine, tryptophan, and histidine).

[0065] Examples of modified antibodies can include antibodies bound with various molecules such as polyethylene glycol (PEG). In the modified antibody of the present invention, the substance to be bound is not limited. In order to obtain such a modified antibody, the obtained antibody can be chemically modified. A method therefor has already been established in the art.

[0066] In this context, the phrase "functionally equivalent" means that an antibody concerned has biological or biochemical activity similar to that of the antibody of the present invention, specifically, the antibody concerned has the function of damaging tumor and essentially causes no rejection when applied to humans, for example. Examples of such activity can include cell growth inhibitory activity and binding activity.

[0067] A method for preparing a polypeptide functionally equivalent to a certain polypeptide, which involves introducing a mutation into a polypeptide, is well known to those skilled in the art. For example, those skilled in the art can introduce a mutation as appropriate into the antibody of the present invention using site-directed mutagenesis (Hashimoto-Gotoh, T. et al., (1995) *Gene* 152, 271-275; Zoller, MJ., and Smith, M. (1983) *Methods Enzymol.* 100, 468-500; Kramer, W. et al., (1984) *Nucleic Acids Res.* 12, 9441-9456; Kramer, W. and Fritz, HJ., (1987) *Methods Enzymol.* 154, 350-367; Kunkel, TA., (1985) *Proc. Natl. Acad. Sci. USA.* 82, 488-492; and Kunkel (1988) *Methods Enzymol.* 85, 2763-2766) or the like, thereby prepare an antibody functionally equivalent to the antibody of the present invention.

[0068] An antibody that recognizes an epitope of a CAPRIN-1 protein described above or a CAPRIN-1 polypeptide fragment including thereof can be obtained by a method generally known to those skilled in the art. For example, the antibody can be obtained by a method which involves determining the epitope of the CAPRIN-1 protein recognized by the anti-CAPRIN-1 antibody having a cancer cell growth inhibitory effect obtained by the above by a conventional method (e.g., epitope mapping or a method for identifying an epitope as described later) and preparing an antibody using a polypeptide having an amino acid sequence contained in the epitope as an immunogen, or a method which involves determining an epitope for an antibody prepared by a conventional method and selecting an antibody that recognizes the same epitope as that for the anti-CAPRIN-1 antibody. In this context, the "epitope" refers to a polypeptide fragment having antigenicity or immunogenicity in mammals, preferably humans. Its smallest unit consists of approximately 7 to 12 amino acids, preferably 8 to 11 amino acids.

[0069] The antibody of the present invention is an antibody having immunological reactivity with CAPRIN-1, an antibody specifically recognizing CAPRIN-1, or an antibody specifically binding to CAPRIN-1 and exhibits cytotoxic activity or tumor growth inhibitory effect on cancer. The antibody preferably has a structure that causes little or no rejection in recipient animals. Examples of such antibodies include human antibodies, humanized antibodies, chimeric antibodies (e.g., human-mouse chimeric antibodies), single-chain antibodies, and bispecific antibodies when the recipient animals are humans. These antibodies have heavy and light chain variable regions derived from a human antibody or have heavy and light chain variable regions consisting of complementarity determining regions (CDR1, CDR2, and CDR3) derived from a non-human animal antibody and framework regions derived from a human antibody. Alternatively, these antibodies are recombinant antibodies having heavy and light chain variable regions derived from a non-human animal antibody and heavy and light chain constant regions derived from a human antibody. The antibody of the present invention is preferably the former two antibodies.

[0070] Such recombinant antibodies can be prepared as follows: DNAs encoding monoclonal antibodies (e.g., human, mouse, rat, rabbit, and chicken monoclonal antibodies) against human CAPRIN-1 are cloned from the antibody-producing cells such as hybridomas and used as templates to prepare DNAs encoding the light and heavy chain variable regions of the antibodies by RT-PCR or the like. The respective sequences of the light and heavy chain variable regions and the respective sequences of CDR1, CDR2, and CDR3 in each region are determined on the basis of the Kabat EU numbering system (Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institute of Health, Bethesda, Md. (1991)).

[0071] A DNA encoding each variable region or a DNA encoding each CDR is prepared using a genetic engineering technique (Sambrook et al., *Molecular Cloning A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1989)) or a DNA synthesizer. The above-mentioned human monoclonal antibody-producing hybridomas can be prepared by immunizing human antibody-producing animals (e.g., mice) with human CAPRIN-1 and then fusing spleen cells excised from the immunized animals with myeloma cells. Separately, DNAs encoding light or heavy chain variable and constant regions derived from a human antibody are prepared, if necessary, using a genetic engineering technique or a DNA synthesizer.

[0072] For the humanized antibody, a DNA encoding the humanized antibody can be prepared by producing DNAs in which the CDR coding sequences in DNAs encoding a human antibody-derived light or heavy chain variable regions

are substituted by corresponding CDR coding sequences of a non-human animal (e.g., mouse, rat, rabbit, or chicken)-derived antibody, ligating the resulting DNAs with the DNAs encoding human antibody-derived light or heavy chain constant regions, respectively.

[0073] For the chimeric antibody, a DNA encoding the chimeric antibody can be prepared by ligating DNAs encoding light or heavy chain variable regions of a non-human animal (e.g., mouse, rat, rabbit, or chicken)-derived antibody with DNAs encoding human antibody-derived light or heavy chain constant regions.

[0074] The single-chain antibody means an antibody in which heavy and light chain variable regions are linearly linked to each other via a linker. A DNA encoding the single-chain antibody can be prepared by ligating a DNA encoding the heavy chain variable region, a DNA encoding the linker, and a DNA encoding the light chain variable region. In this context, the heavy and light chain variable regions are both derived from a human antibody or derived from a human antibody in which CDRs alone are substituted by CDRs of a non-human animal (e.g., mouse, rat, rabbit, or chicken)-derived antibody. The linker consists of 12 to 19 amino acids. Examples thereof include $(G_4S)_3$ consisting of 15 amino acids (G.B. Kim et al., Protein Engineering Design and Selection 2007, 20 (9): 425-432).

[0075] The bispecific antibody (diabody) means an antibody capable of specifically binding to two different epitopes. A DNA encoding the bispecific antibody can be prepared by, for example, ligating a DNA encoding a heavy chain variable region A, a DNA encoding a light chain variable region B, a DNA encoding a heavy chain variable region B, and a DNA encoding a light chain variable region A in this order, wherein the DNA encoding the light chain variable region B and the DNA encoding the heavy chain variable region B are ligated via a DNA encoding a linker as described above. In this context, the heavy and light chain variable regions are all derived from a human antibody or derived from a human antibody in which CDRs alone are substituted by CDRs of a non-human animal (e.g., mouse, rat, rabbit, or chicken)-derived antibody.

[0076] The recombinant DNAs thus prepared can be incorporated into one or more appropriate vectors, which are then introduced into host cells (e.g., mammalian cells, yeast cells, and insect cells), and the DNAs are (co)expressed to produce recombinant antibodies (see, P.J. Delves., ANTIBODY PRODUCTION ESSENTIAL TECHNIQUES., 1997 WILEY, P. Shepherd and C. Dean., Monoclonal Antibodies., 2000 OXFORD UNIVERSITY PRESS; and J.W. Goding., Monoclonal Antibodies: principles and practice., 1993 ACADEMIC PRESS).

[0077] Examples of the antibody of the present invention prepared by any of the methods described above include the following antibodies (a) to (g) obtained in Examples described later:

(a) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 10, 11, and 12 (e.g., an antibody having a heavy chain variable region of SEQ ID NO: 9 and a light chain variable region of SEQ ID NO: 13);

(b) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 16, 17, and 18 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 20, 21, and 22 (e.g., an antibody constructed using a heavy chain variable region of SEQ ID NO: 19 and a light chain variable region of SEQ ID NO: 23);

(c) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 50, 51, and 52 (e.g., an antibody constructed using a heavy chain variable region of SEQ ID NO: 9 and a light chain variable region of SEQ ID NO: 53);

(d) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 55, 56, and 57 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 59, 60, and 61 (e.g., an antibody constructed using a heavy chain variable region of SEQ ID NO: 58 and a light chain variable region of SEQ ID NO: 62);

(e) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 55, 56, and 57 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 59, 64, and 61 (e.g., an antibody constructed using a heavy chain variable region of SEQ ID NO: 63 and a light chain variable region of SEQ ID NO: 65);

(f) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 66, 67, and 68 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 70, 71, and 72 (e.g., an antibody constructed using a heavy chain variable region of SEQ ID NO: 69 and a light chain variable region of SEQ ID NO: 73);

(g) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 74, 75, and 76 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 78, 79, and 80 (e.g., an antibody constructed using a heavy chain variable region of SEQ ID NO: 77 and a light chain variable region of SEQ ID NO: 81);

[0078] In this context, the amino acid sequences shown by SEQ ID NOs: 6, 7, and 8, and SEQ ID NOs: 16, 17, and 18 correspond to CDR1, CDR2, and CDR3, respectively, of a mouse antibody-derived heavy chain variable region. The amino acid sequences shown by SEQ ID NOs: 10, 11, and 12, SEQ ID NOs: 20, 21, and 22, and SEQ ID NOs: 50, 51, and 52 correspond to CDR1, CDR2, and CDR3, respectively, of a mouse antibody-derived light chain variable region. The amino acid sequences shown by SEQ ID NOs: 55, 56, and 57, SEQ ID NOs: 66, 67, and 68, and SEQ ID NOs: 74, 75, and 76 correspond to CDR1, CDR2, and CDR3, respectively, of a chicken antibody-derived heavy chain variable region. The amino acid sequences shown by SEQ ID NOs: 59, 60, and 61, SEQ ID NOs: 59, 64, and 61, SEQ ID NOs: 70, 71, and 72, and SEQ ID NOs: 78, 79, and 80 correspond to CDR1, CDR2, and CDR3, respectively, of a chicken antibody-derived light chain variable region.

[0079] Examples of the humanized antibody, the chimeric antibody, the single-chain antibody, or the bispecific antibody of the present invention include antibodies described below. The following antibodies are illustrative embodiments of the antibody (a), but there may be also similar embodiments of the other antibodies (b) to (g).

[0080]

(i) an antibody comprising a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 6, 7, and 8 and the amino acid sequences of human antibody-derived framework regions and a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12 and the amino acid sequences of human antibody-derived framework regions.

(ii) an antibody comprising a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 6, 7, and 8 and the amino acid sequences of human antibody-derived framework regions, a heavy chain constant region comprising a human antibody-derived amino acid sequence, a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12 and the amino acid sequences of human antibody-derived framework regions, and a light chain constant region comprising a human antibody-derived amino acid sequence.

(iii) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 9, a heavy chain constant region comprising a human antibody-derived amino acid sequence, a light chain variable region comprising the amino acid sequence of SEQ ID NO: 13, and a light chain constant region comprising a human antibody-derived amino acid sequence.

[0081] The sequences of the constant and variable regions of human antibody heavy and light chains are available from, for example, NCBI (USA; GenBank, UniGene, etc.). For example, the following sequences can be referred to: Accession No. J00228 for a human IgG1 heavy chain constant region; Accession No. J00230 for a human IgG2 heavy chain constant region; Accession No. X03604 for a human IgG3 heavy chain constant region; Accession No. K01316 for a human IgG4 heavy chain constant region; Accession Nos. V00557, X64135, and X64133 for a human light chain κ constant region; and Accession Nos. X64132 and X64134 for a human light chain λ constant region.

[0082] Preferably, these antibodies have cytotoxic activity and can thereby exert an antitumor effect.

[0083] The above particular sequences of the heavy and light chain variable regions and CDRs in the above-mentioned antibodies are provided merely for illustrative purposes, and it is clear that the antibody of the present invention is not limited by the particular sequences. Hybridomas capable of producing anti-human CAPRIN-1 human antibodies or non-human animal antibodies (e.g., mouse antibodies) different from those specifically described above are prepared, and monoclonal antibodies produced by the hybridomas are recovered and it is determined whether or not the recovered antibodies are the antibodies of interest using the immunological binding activity against human CAPRIN-1 and cytotoxic activity as indicators. The monoclonal antibody-producing hybridomas of interest are thereby identified. Then, DNAs encoding heavy and light chain variable regions of the antibodies of interest are prepared from the hybridomas and sequenced, as described above. The DNAs are used for the preparation of different antibodies.

[0084] The antibody described above may be any of the antibodies (a) to (g), etc. having the substitution, deletion, or addition of one or several amino acids, in particular, in a region other than CDRs, for example, in a framework region sequence and/or a constant region sequence, as long as the antibody has such specificity that it can specifically recognize CAPRIN-1. Herein, the term "several" preferably means 2 to 5, more preferably 2 or 3.

[0085] The antibody of the present invention has an affinity constant K_a (k_{on}/k_{off}) of preferably at least 10^7 M⁻¹, at least 10^8 M⁻¹, at least 5×10^8 M⁻¹, at least 10^9 M⁻¹, at least 5×10^9 M⁻¹, at least 10^{10} M⁻¹, at least 5×10^{10} M⁻¹, at least 10^{11} M⁻¹, at least 5×10^{11} M⁻¹, at least 10^{12} M⁻¹, or at least 10^{13} M⁻¹ for the CAPRIN-1 protein or the fragment thereof.

[0086] The antibody of the present invention can be conjugated with an antitumor agent. The conjugation of the antibody with the antitumor agent can be performed via a spacer having a group reactive with an amino group, a carboxyl group, a hydroxy group, a thiol group, or the like (e.g., a succinimidyl group, a formyl group, a 2-pyridylthio group, a maleimidyl group, an alkoxycarbonyl group, or a hydroxy group).

[0087] Examples of the antitumor agent include the following antitumor agents known by literatures, etc.: paclitaxel, doxorubicin, daunorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, thiotepa, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretamine, triethylenemelamine, triethylenephosphoramidate, triethyl-

enethiophosphoramidate, trimethylolmelamine, bullatacin, bullatacinone, camptothecin, bryostatin, callystatin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, eleutherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin, dynemicin, clodronate, esperamicin, aclacinomycin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin, carabacin, carminomycin, carzinophilin, chromomycin, dactinomycin, detorbicin, 6-diazo-5-oxo-L-norleucine, Adriamycin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, androgens (e.g., calusterone, dromostanolone propionate, epitiolesterol, mepitiolesterol, and testolactone), aminoglutethimide, mitotane, trilostane, frolic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elfornithine, elliptinium acetate, epothilone, etoglucid, lentinan, lonidamine, maytansine, ansamitocin, mitoguazone, mitoxantrone, mopidanmol, nitraerine, pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid, 2-ethylhydrazide, procarbazine, razoxane, rhizoxin, schizophyllan, spirogermanium, tenuazonic acid, triaziquone, roridin A, anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, docetaxel, chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, oxaliplatin, carboplatin, vinblastine, etoposide, ifosfamide, mitoxantrone, vincristine, vinorelbine, novantrone, teniposide, edatrexate, daunomycin, aminopterin, Xeloda, ibandronate, irinotecan, topoisomerase inhibitors, difluoromethylornithine (DMFO), retinoic acid, capecitabine, and pharmaceutically acceptable salts and derivatives thereof.

[0088] Alternatively, the antibody of the present invention can be administered in combination with an antitumor agent to produce a higher therapeutic effect. This approach is adaptable to a patient with a cancer expressing CAPRIN-1 either before or after surgical operation. This approach can be applied, particularly after surgery, to CAPRIN-1-expressing cancer, which has been treated conventionally with an antitumor agent alone, to produce higher prevention of cancer recurrence or prolongation of survival time.

[0089] Examples of the antitumor agent used in the combined administration with the antibody of the present invention include the following antitumor agents known by literatures, etc.: paclitaxel, doxorubicin, daunorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, thiotepa, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretamine, triethylenemelamine, triethylenephosphoramidate, triethylenethiophosphoramidate, trimethylolmelamine, bullatacin, bullatacinone, camptothecin, bryostatin, callystatin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, eleutherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin, dynemicin, clodronate, esperamicin, aclacinomycin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin, carabacin, carminomycin, carzinophilin, chromomycin, dactinomycin, detorbicin, 6-diazo-5-oxo-L-norleucine, Adriamycin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiolesterol, mepitiolesterol, testolactone, aminoglutethimide, mitotane, trilostane, frolic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elfornithine, elliptinium acetate, epothilone, etoglucid, lentinan, lonidamine, maytansine, ansamitocin, mitoguazone, mitoxantrone, mopidanmol, nitraerine, pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid, 2-ethylhydrazide, procarbazine, razoxane, rhizoxin, schizophyllan, spirogermanium, tenuazonic acid, triaziquone, roridin A, anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, docetaxel, chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, oxaliplatin, carboplatin, vinblastine, etoposide, ifosfamide, mitoxantrone, vincristine, vinorelbine, novantrone, teniposide, edatrexate, daunomycin, aminopterin, Xeloda, ibandronate, irinotecan, topoisomerase inhibitors, difluoromethylornithine (DMFO), retinoic acid, capecitabine, and pharmaceutically acceptable salts (known in the art) and derivatives (known in the art) thereof. Of these antitumor agents, cyclophosphamide, paclitaxel, docetaxel, or vinorelbine is particularly preferably used.

[0090] The antibody of the present invention may be bound to a radioisotope known by literatures, etc., such as ^{211}At , ^{131}I , ^{125}I , ^{90}Y , ^{186}Re , ^{188}Re , ^{153}Sm , ^{212}Bi , ^{32}P , ^{175}Lu , or ^{176}Lu . Preferably, a radioisotope effective for the treatment or diagnosis of tumor is used. Such a radioisotope is also included in the scope of the antitumor agent according to the present invention.

<Identification of epitope>

[0091] The antibody of the present invention recognizes the amino acid sequence shown by SEQ ID NO: 5 as an epitope, as shown below in Examples. One example of a method for confirming the epitope for the antibody of the present invention comprises immobilizing the polypeptide of SEQ ID NO: 5 (epitope) onto a plate and evaluating the antibody for its reactivity against this epitope. Specifically, the polypeptide of SEQ ID NO: 5 is immobilized onto a plate through reaction with an electrophilic functional group attached via a spacer of e.g., oligoethylene glycol to the plate, and then reacted with the antibody of the present invention. For example, a HRP (horseradish peroxidase)-labeled secondary antibody capable of binding to the antibody of the present invention can be reacted therewith to evaluate the reactivity of the antibody (to confirm the epitope for the antibody of the present invention). The polypeptide of SEQ ID NO: 5 to be immobilized on a plate may be used as a form consisting of the sequence of SEQ ID NO: 5 or a partially modified form (e.g., a modified form of the polypeptide at the N- or C-terminal residue with any several amino acids or a protein such as KLH or a modified form of the polypeptide with a MAP protein), as long as the antibody of the present invention binds to these polypeptide forms.

[0092] Some antibodies of the present invention may not react with the polypeptide of SEQ ID NO: 5 (i.e., the epitope not being confirmed) in the above method. In such a case, the epitope for the antibody of the present invention can be confirmed by reacting the antibody with the antigen under solution conditions that facilitate antigen-antibody binding as described in Example 2, obtaining the resulting antigen-antibody complex by an immunoprecipitation method, and then separating a polypeptide moiety bound to the antibody, and determining its amino acid sequence. The antigen may be a polypeptide consisting of the sequence of SEQ ID NO: 5, its partially modified one, or a CAPRIN-1 protein as long as an epitope reactive with the antibody of the present invention can be confirmed therefor by the above-mentioned methods.

<Antitumor effect>

[0093] It is considered that the antitumor effect of the anti-CAPRIN-1 antibody to be used in the present invention on CAPRIN-1-expressing cancer cells is brought about by the following mechanism: Antibody-dependent effector cell-mediated cytotoxicity (ADCC) against the CAPRIN-1-expressing cells and complement-dependent cytotoxicity (CDC) against the CAPRIN-1-expressing cells. However, the scope of the present invention is not intended to be limited by the mechanism.

[0094] The antitumor effect based on the mechanism is known to correlate with the number of antibody-binding target molecules expressed on the surface of cancer cells (Niwa R., Clinical Cancer Research (2005) Mar 15; 11 (6): 2327-2336). The number of target molecules expressed on the surface of cancer cells can be examined using an existing assay kit capable of measuring the number of molecules on cell surface. Specifically, the number of antibody-binding target molecules can be determined by: reacting cancer cells with, for example, antibodies against the target molecules as primary antibodies; reacting therewith fluorescently labeled antibodies against the primary antibodies, together with calibration curve beads with the preliminarily known number of molecules; measuring the mean fluorescence intensity of the samples; and determining the number of the target molecules on the basis of the obtained calibration curve.

[0095] Thus, the anti-CAPRIN-1 antibody to be used in the present invention can be assayed for its activity by determining *ex vivo* the ADCC activity or the CDC activity against CAPRIN-1-expressing cancer cells or by examining the number of CAPRIN-1 molecules expressed on the surface of cancer cells in the case of using the anti-CAPRIN-1 antibody according to the present invention as a primary antibody as specifically shown below in Examples.

[0096] The anti-CAPRIN-1 antibody to be used in the present invention binds to CAPRIN-1 proteins on cancer cells and exhibits an antitumor effect through the activity. Thus, the anti-CAPRIN-1 antibody of the present invention is considered to be useful in the treatment or prevention of cancer. Specifically, the present invention provides a pharmaceutical composition for treatment and/or prevention of cancer, comprising the anti-CAPRIN-1 antibody as an active ingredient. The anti-CAPRIN-1 antibody to be used for the purpose of administration to human bodies (antibody therapy) is preferably a human antibody or a humanized antibody for reducing immunogenicity.

[0097] The anti-CAPRIN-1 antibody with higher binding affinity for a CAPRIN-1 protein on the surface of cancer cells exerts stronger antitumor activity. Thus, the antibody according to the present invention can be expected to have a stronger antitumor effect due to the high binding affinity for the CAPRIN-1 protein, and therefore it can be used as a pharmaceutical composition for use in the treatment and/or prevention of cancer. Preferably, the antibody according to the present invention has high binding affinity with association constant (affinity constant) K_a (k_{on}/k_{off}) of preferably at least 10^7 M⁻¹, at least 10^8 M⁻¹, at least 5×10^8 M⁻¹, at least 10^9 M⁻¹, at least 5×10^9 M⁻¹, at least 10^{10} M⁻¹, at least 5×10^{10} M⁻¹, at least 10^{11} M⁻¹, at least 5×10^{11} M⁻¹, at least 10^{12} M⁻¹, or at least 10^{13} M⁻¹, as described above.

[0098] A larger number of CAPRIN-1 molecules that can bind to anti-CAPRIN-1 antibodies on the surface of cancer cells produces stronger antitumor activity. Desirably, in order to produce the expected antitumor effect, the number of CAPRIN-1 molecules to which the antibodies bind is 10^4 or more, preferably 10^5 or more CAPRIN-1 molecules per cancer cell, as measured using the anti-CAPRIN-1 antibody of the present invention. Tumor (cancer cells) having a

large number of CAPRIN-1 molecules on its cell surface is particularly preferred as cancer subject to the administration of the antibody of the present invention.

<Binding to antigen-expressing cells>

[0099] The ability of the antibody to bind to CAPRIN-1 can be determined by use of binding assay using, for example, ELISA, Western blot, immunofluorescence, and flow cytometry analysis, as described in Examples.

<Immunohistochemical staining>

[0100] The antibody that recognizes CAPRIN-1 can be tested for its reactivity with CAPRIN-1 by an immunohistochemical method well known to those skilled in the art using a paraformaldehyde- or acetone-fixed frozen section or paraformaldehyde-fixed paraffin-embedded tissue section of a tissue obtained from a patient during surgical operation or from a xenograft tissue-carrying animal inoculated with a cell line expressing CAPRIN-1 either spontaneously or after transfection.

[0101] For immunohistochemical staining, the antibody reactive with CAPRIN-1 can be stained by various methods. For example, the antibody can be visualized through reaction with a horseradish peroxidase-conjugated goat anti-mouse antibody, goat anti-rabbit antibody, or goat anti-chicken antibody.

<Pharmaceutical composition, and means for treating and/or preventing cancer>

[0102] A target of the pharmaceutical composition for treatment and/or prevention of cancer of the present invention is not particularly limited as long as the target is cancer (cells) expressing a CAPRIN-1 gene.

[0103] The terms "tumor" and "cancer" used herein mean malignant neoplasm and are used interchangeably with each other.

[0104] The cancer targeted in the present invention is cancer expressing a CAPRIN-1 protein-encoding gene and is preferably breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.

[0105] Specific examples of these cancers include, but not limited to, breast adenocarcinoma, complex-type breast adenocarcinoma, malignant mixed tumor of mammary gland, intraductal papillary adenocarcinoma, lung adenocarcinoma, squamous cell cancer, small-cell cancer, large-cell cancer, glioma which is tumor of neuroepithelial tissue, ventricular ependymoma, neuronal tumor, embryonal neuroectodermal tumor, neurilemmoma, neurofibroma, meningioma, chronic lymphocytic leukemia, lymphoma, gastrointestinal lymphoma, alimentary lymphoma, small to medium cell-type lymphoma, cecal cancer, ascending colon cancer, descending colon cancer, transverse colon cancer, sigmoid colon cancer, rectal cancer, epithelial ovarian cancer, germ cell tumor, stromal cell tumor, pancreatic ductal carcinoma, invasive pancreatic ductal carcinoma, pancreatic adenocarcinoma, acinar cell carcinoma, adenosquamous carcinoma, giant cell tumor, intraductal papillary-mucinous neoplasm, mucinous cystic neoplasm, pancreatoblastoma, serous cystadenocarcinoma, solid papillary tumor, gastrinoma, glucagonoma, insulinoma, multiple endocrine neoplasia type-1 (Wermer's syndrome), nonfunctional islet cell tumor, somatostatinoma, and VIPoma.

[0106] The subject (patient) as the recipient is preferably mammals, for example, mammals including primates, pet animals, livestock, and sport animals, and particularly preferably humans, dogs, and cats.

[0107] When using the antibody of the present invention in a pharmaceutical composition, the pharmaceutical composition can be formulated by a method known to those skilled in the art. For example, the pharmaceutical composition can be used in the form of a parenteral injection of an aseptic solution or suspension with water or any other pharmaceutically acceptable liquid. For example, the pharmaceutical composition may be formulated with the antibody mixed in a unit dosage form required for generally accepted pharmaceutical practice, in combination with pharmacologically acceptable carriers or media, specifically, sterilized water, physiological saline, plant oil, an emulsifier, a suspending agent, a surfactant, a stabilizer, a flavoring agent, an excipient, a vehicle, a preservative, a binder, etc., as appropriate. The amount of the active ingredient in such a preparation is determined such that an appropriate dose within the indicated range can be achieved.

[0108] An aseptic composition for injection can be formulated according to conventional pharmaceutical practice using a vehicle such as injectable distilled water.

[0109] Examples of aqueous solutions for injection include physiological saline, isotonic solutions containing glucose and other adjuvants, for example, D-sorbitol, D-mannose, D-mannitol, and sodium chloride. These solutions may be used in combination with an appropriate solubilizer, for example, an alcohol (particularly, ethanol) or a polyalcohol (e.g., propylene glycol and polyethylene glycol), or a nonionic surfactant, for example, polysorbate 80 (TM) or HCO-60.

[0110] Examples of oily solutions include those using sesame oil or soybean oil. The solutions may be used in com-

bination with a solubilizer such as benzyl benzoate or benzyl alcohol. A buffer (e.g., a phosphate buffer solution or a sodium acetate buffer solution), a soothing agent (e.g., procaine hydrochloride), a stabilizer (e.g., benzyl alcohol or phenol), or an antioxidant may be added to the solutions. The injection solutions thus prepared are generally charged into appropriate ampules.

[0111] The pharmaceutical composition of the present invention is administered orally or parenterally, preferably parenterally. Specific examples of its dosage forms include injections, intranasal administration agents, transpulmonary administration agents, and percutaneous administration agents. Examples of the injections include intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection, through which the pharmaceutical composition can be administered systemically or locally.

[0112] Also, the administration method can be appropriately selected depending on the age, weight, sex, symptoms, etc. of a patient. The dose of a pharmaceutical composition containing the antibody or a polynucleotide encoding the antibody can be selected within a range of, for example, 0.0001 to 1000 mg/kg of body weight per dose. Alternatively, the dose can be selected within a range of, for example, 0.001 to 100000 mg/body of a patient, though the dose is not necessarily limited to these numeric values. Although the dose and the administration method vary depending on the weight, age, sex, symptoms, etc. of a patient, those skilled in the art can appropriately select the dose and the method.

[0113] The pharmaceutical composition including the antibody of the present invention or fragments thereof can be administered to a subject to treat and/or prevent cancer, preferably breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.

[0114] The present invention further encompasses means for treating and/or preventing cancer, by administering the pharmaceutical composition of the present invention in combination with the antitumor agent as exemplified above or a pharmaceutical composition comprising the antitumor agent to a subject. The antibody of the present invention or the fragment thereof may be administered simultaneously with or separately from the antitumor agent to the subject. In the case of separately administering these pharmaceutical compositions, either one may be administered first or later. Their dosing intervals, doses, administration routes, and the number of doses can be appropriately selected by a specialist. The other pharmaceutical dosage forms to be administered simultaneously also include, for example, pharmaceutical compositions formulated by mixing the antibody of the present invention or the fragment thereof or the antitumor agent into a pharmacologically acceptable carrier (or medium). The above descriptions about composition, formulation, administration routes, doses, cancer, etc. as to the pharmaceutical compositions and dosage forms containing the antibody of the present invention are also applicable to any of the above-mentioned pharmaceutical compositions and dosage forms containing the antitumor agent.

[0115] Thus, the present invention also provides a pharmaceutical combination as defined in the claims, comprising the pharmaceutical composition of the present invention and a pharmaceutical composition comprising the antitumor agent as exemplified above, and a method for treating and/or preventing cancer, comprising administering thereof. The present invention also provides a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or the fragment thereof of the present invention and the antitumor agent together with a pharmacologically acceptable carrier.

<Polypeptide and DNA>

[0116] The present invention further provides a DNA encoding the antibody of the present invention or the fragment (antibody-binding fragment) thereof. The DNA may be a DNA encoding the heavy and/or light chains of the antibody or may be a DNA encoding the heavy and/or light chain variable regions of the antibody. The DNA may also be a DNA encoding each or a combination of the complementarity determining regions of antibody. Such a DNA includes, for example, a heavy chain variable region-encoding DNA comprising nucleotide sequences encoding the amino acid sequences of SEQ ID NOs: 6, 7, and 8, and a light chain variable region-encoding DNA comprising nucleotide sequences encoding the amino acid sequences of SEQ ID NOs: 10, 11, and 12, in the case of the above-mentioned antibody (a).

[0117] The complementarity determining regions (CDRs) encoded by the DNA having these sequences serve as regions that determine the specificity of the antibody. Sequences encoding the other regions (i.e., constant regions and framework regions) of the antibody may therefore be sequences derived from other antibodies. In this context, "other antibodies" also include antibodies derived from non-human organisms, but are preferably those derived from humans from the viewpoint of reducing adverse reactions. Specifically, in the DNA of the present invention, regions encoding each framework region and each constant region in the heavy and light chains preferably comprise nucleotide sequences encoding corresponding human antibody-derived amino acid sequences.

[0118] Further examples of the DNA encoding the antibody of the present invention include a DNA encoding a heavy chain variable region comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 9, and a DNA encoding a light chain variable region comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 13, in the case of the above-mentioned antibody (a). In this context, an example of nucleotide sequences

encoding the amino acid sequence of SEQ ID NO: 9 is the nucleotide sequence of SEQ ID NO: 14. An example of nucleotide sequences encoding the amino acid sequence of SEQ ID NO: 13 is the nucleotide sequence of SEQ ID NO: 15. When such a DNA comprises regions encoding constant regions of the heavy and light chains, each of the regions preferably comprises a nucleotide sequence encoding a corresponding human antibody-derived amino acid sequence (amino acid sequence of each constant region of the heavy and light chains).

[0119] These antibody DNAs can be obtained, for example, by the methods described above, or the following method. First, total RNAs are prepared from hybridomas producing the antibody of the present invention using a commercially available RNA extraction kit, and cDNAs are synthesized therefrom using reverse transcriptase and random primers or the like. Subsequently, the antibody-encoding cDNAs are amplified by PCR using oligonucleotide primers for conserved sequences of variable regions in known mouse antibody heavy or light chain genes. Sequences encoding the constant regions can be obtained by PCR amplification of the known sequences. The nucleotide sequence of the DNA can be incorporated into a plasmid or a phage for sequencing, for example, and determined according to a conventional method.

[0120] The present invention further provides the following polypeptides and DNAs related to the above-mentioned antibodies (a) to (g):

- (i) a polypeptide comprising any of amino acid sequences of SEQ ID NOs: 9, 19, 58, 63, 69, and 77, and a DNA encoding the polypeptide (e.g., a DNA comprising any of the nucleotide sequences of SEQ ID NOs: 14 and 24);
- (ii) a polypeptide comprising any of amino acid sequences of SEQ ID NOs: 13, 23, 53, 62, 65, 73, and 81, and a DNA encoding the polypeptide (e.g., a DNA comprising any of the nucleotide sequences of SEQ ID NOs: 15, 25, and 54);
- (iii) heavy chain CDR polypeptides selected from the group consisting of amino acid sequences shown by SEQ ID NOs: 6, 7, and 8, SEQ ID NOs: 16, 17, and 18, SEQ ID NOs: 55, 56, and 57, SEQ ID NOs: 66, 67, and 68, and SEQ ID NOs: 74, 75, and 76, and a DNA encoding the polypeptides; and
- (iv) light chain CDR polypeptides selected from amino acid sequences shown by SEQ ID NOs: 10, 11, and 12, SEQ ID NOs: 20, 21, and 22, SEQ ID NOs: 50, 51, and 52, SEQ ID NOs: 59, 60, and 61, SEQ ID NOs: 59, 64, and 61, SEQ ID NOs: 70, 71, and 72, and SEQ ID NOs: 78, 79, and 80, and a DNA encoding the polypeptides.

[0121] These polypeptides and DNAs can be prepared using genetic engineering techniques as described above.

Examples

[0122] Hereinafter, the present invention will be described specifically with reference to Examples. However, the scope of the present invention is not intended to be limited by these specific examples.

Example 1 Analysis of CAPRIN-1 expression in each tissue

[0123] CAPRIN-1 gene expression in canine and human normal tissues and various cell lines was examined by RT-PCR according to Example 1(4) of WO2010/016526. As a result, strong expression was observed in the testis among the healthy canine tissues, whereas expression was observed in canine breast cancer and adenocarcinoma tissues. Further, as a result of examining the expression in human tissues, the expression was observed only in the testis among normal tissues, as with the canine CAPRIN-1 gene. By contrast, the expression was detected in many types of cancer cell lines, including 8 human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-20, MDA-MB-231V, and MRK-nu-1) and 4 pancreatic cancer cell lines (Capan-2, MIAPaCa-2, Panc-1, and BxPc-3), among cancer cells. These results demonstrated that CAPRIN-1 expression is not found in normal tissues other than the testis, whereas CAPRIN-1 is expressed in the breast cancer cell lines and the pancreatic cancer cell lines.

Example 2 Preparation of mouse monoclonal antibody against CAPRIN-1

(1) Preparation of mouse monoclonal antibody #1

[0124] 100 μ g of human CAPRIN-1 proteins (having the amino acid sequence of SEQ ID NO: 2) prepared in Example 3 of WO2010/016526 was mixed with an equal amount of MPL+TDM adjuvant (Sigma-Aldrich Corp.). This mixture was used as an antigen solution per mouse. The antigen solution was intraperitoneally administered to each 6-week-old Balb/c mouse (prepared by Japan SLC, Inc.). Then, 7 administrations were performed every 1 week to complete immunization. Three days after the final immunization, the spleen of each mouse was excised and ground between two sterilized glass slides. Procedures of washing with PBS(-) (manufactured by Nissui Pharmaceutical Co., Ltd.) and centrifuging at 1500 rpm for 10 minutes to remove the supernatant were repeated three times to obtain spleen cells. The obtained spleen cells were mixed with mouse myeloma cells SP2/0 (purchased from ATCC) at a ratio of 10:1. A PEG

solution prepared by mixing 200 μ l of an RPMI1640 medium containing 10% FBS, which was heated to 37°C, with 800 μ l of PEG1500 (manufactured by Boehringer Ingelheim GmbH) was added to the cell mixture, and then it was left to stand for 5 minutes for cell fusion. After removal of the supernatant via centrifugation at 1700 rpm for 5 minutes, the cells were suspended in 150 ml of an RPMI1640 medium containing 15% FBS supplemented with 2% equivalent of a

HAT solution (Gibco) (HAT selective medium). This suspension was seeded onto fifteen 96-well plates (Nunc) at 100 μ l/well. The spleen cells and the myeloma cells were fused by culturing for 7 days at 37°C, 5% CO₂ to obtain hybridomas. **[0125]** The prepared hybridomas were screened for the binding affinity of antibodies produced by the hybridomas against CAPRIN-1 proteins as an indicator. A 1 μ g/ml solution of the CAPRIN-1 protein prepared in Example 3 of WO2010/016526 was added to a 96-well plate at 100 μ l/well and left to stand at 4°C for 18 hours. Each well was washed three times with PBS-T. Then, a 0.5% bovine serum albumin (BSA) solution (manufactured by Sigma-Aldrich Corp.) was added thereto at 400 μ l/well and left to stand at room temperature for 3 hours. The solution in each well was removed, and each well was washed three times with 400 μ l of PBS-T. Then, the culture supernatant of each hybridoma obtained above was added thereto at 100 μ l/well and left to stand at room temperature for 2 hours. Each well was washed three times with PBS-T. Then, HRP-labeled anti-mouse IgG (H+L) antibodies (manufactured by Invitrogen Corp.) diluted 5000-fold with PBS were added thereto at 100 μ l/well and left to stand at room temperature for 1 hour. Each well was washed three times with PBS-T. Then, a TMB substrate solution (manufactured by Thermo Fisher Scientific Inc.) was added thereto at 100 μ l/well and left to stand for 15 to 30 minutes to cause color reaction. After the color development, the reaction was terminated by the addition of 1N sulfuric acid at 100 μ l/well. The absorbance was measured at 450 nm and 595 nm using an absorption spectrometer. As a result, several hybridomas producing antibodies having high absorbance were selected.

[0126] The selected hybridomas were added to a 96-well plate at 0.5 cells/well and cultured in the plate. One week later, hybridomas forming single colonies in the wells were observed. The cells in these wells were further cultured, and the cloned hybridomas were screened for the binding affinity of antibodies produced by the hybridomas to the CAPRIN-1 protein as an indicator. A 1 μ g/ml solution of the CAPRIN-1 protein prepared in Example 3 of WO2010/016526 was added to a 96-well plate at 100 μ l/well and left to stand at 4°C for 18 hours. Each well was washed three times with PBS-T. Then, a 0.5% BSA solution was added thereto at 400 μ l/well and left to stand at room temperature for 3 hours. The solution in each well was removed, and each well was washed three times with 400 μ l of PBS-T. Then, the culture supernatant of each hybridoma obtained above was added thereto at 100 μ l/well and left to stand at room temperature for 2 hours. Each well was washed three times with PBS-T. Then, HRP-labeled anti-mouse IgG (H+L) antibodies (manufactured by Invitrogen Corp.) diluted 5000-fold with PBS were added thereto at 100 μ l/well and left to stand at room temperature for 1 hour. Each well was washed three times with PBS-T. Then, a TMB substrate solution (manufactured by Thermo Fisher Scientific Inc.) was added thereto at 100 μ l/well and left to stand for 15 to 30 minutes to cause color reaction. After the color development, the reaction was terminated by the addition of 1N sulfuric acid at 100 μ l/well. The absorbance was measured at 450 nm and 595 nm using an absorption spectrometer. As a result, 88 hybridoma lines producing monoclonal antibodies reactive with the CAPRIN-1 protein were obtained.

[0127] Next, these monoclonal antibodies were screened for antibodies reactive with the surface of breast cancer cells expressing CAPRIN-1. Specifically, 10⁶ cells of a human breast cancer cell line MDA-MB-231V were centrifuged in a 1.5-ml microcentrifuge tube. 100 μ l of the culture supernatant of the hybridoma obtained above was added thereto and left to stand for 1 hour on ice. After washing with PBS, FITC-labeled goat anti-mouse IgG antibodies (manufactured by Invitrogen Corp.) diluted 500-fold with PBS containing 0.1% FBS were added thereto and left to stand for 1 hour on ice. After washing with PBS, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company). On the other hand, the same operation as above was performed using the serum of each untreated 6-week-old Balb/c mouse diluted 500-fold with a medium for hybridoma culture, instead of the antibodies, to prepare a control. As a result, one monoclonal antibody (#1) having stronger fluorescence intensity than that of the control, i.e., reactive with the surface of the breast cancer cells, was selected.

(2) Identification of CAPRIN-1 epitope recognized by anti-CAPRIN-1 monoclonal antibody #1

[0128] The cancer cell surface-reactive anti-CAPRIN-1 monoclonal antibody #1 obtained in the section (1) was used to identify a CAPRIN-1 epitope region recognized thereby. 100 μ g of recombinant CAPRIN-1 proteins was dissolved in a protein inhibitor-free dissolution buffer and reacted with the mouse monoclonal antibody #1. A digestive enzyme trypsin or chymotrypsin was added to the solution to perform digestion reaction at an adequate temperature. After the reaction, a protein G Sepharose carrier was added to the reaction mixture, reacted therewith, and precipitated by centrifugation. After removal of the supernatant, the carrier was washed with a dissolution buffer and PBS and dissolved in 0.1% formic acid, and the supernatant was recovered. The recovered supernatant sample was applied to a reverse-phase column (HLB Extraction Cartridge (Oasis)) for antibody removal to obtain a sample solution. The obtained sample was subjected to reverse-phase liquid chromatography (Chromatography Nanosystem (KYA Tech Corp.)) to recover a solution containing only peptides, which was then introduced to a tandem mass spectrometer quadrupole-TOF mass spectrometer

(Waters-MicroMass) for MS/MS analysis to detect the peptides contained in the sample. As a result, a polypeptide consisting of the amino acid sequence of SEQ ID NO: 5 was identified as a partial CAPRIN-1 sequence recognized by the anti-CAPRIN-1 monoclonal antibody #1.

(3) Preparation of mouse monoclonal antibodies #2 and #3

[0129] In a similar way to that described in the section (1), a fusion protein of the amino acid sequence of SEQ ID NO: 5 identified in the section (2) and a carrier protein KLH (keyhole limpet haemocyanin) was mixed as an immunogen with an equal amount of an adjuvant TiterMax Gold^(R) (CytRx Corp.), and this mixture was subcutaneously administered at a dose of 20 µg/shot to each mouse at 7-day intervals. After administration with four shots in total, spleen cells were obtained from the mouse 3 days after the final immunization and fused with mouse myeloma cells in the same way as in the section (1) to produce hybridomas. Then, antibodies were screened for, as an indicator, the reactivity of the antibodies contained in the culture supernatants of the produced hybridomas with a 1 µg/ml solution of CAPRIN-1 proteins prepared in Example 3 of WO2010/016526 or a fusion protein (used as an immunogen) of the amino acid sequence of SEQ ID NO: 5 and a carrier protein KLH. The 1 µg/ml solution of CAPRIN-1 proteins prepared in Example 3 of WO2010/016526 and the fusion protein (30 µg/ml) of the amino acid sequence of SEQ ID NO: 5 and a carrier protein KLH were each added at 100 µl/well to 96-well plates and left to stand at 4°C for 18 hours. Each well was washed with PBS-T. Then, a Blockace (DS Pharma Biomedical Co., Ltd.) solution was added thereto at 400 µl/well and left to stand at room temperature for 3 hours. The solution in each well was removed, and each well was washed with PBS-T. Then, the culture supernatant of each hybridoma obtained above was added thereto at 100 µl/well and left to stand at room temperature for 2 hours. Each well was washed with PBS-T. Then, HRP-labeled anti-mouse IgG (H+L) antibodies (manufactured by Invitrogen Corp.) diluted 5000-fold with PBS were added thereto at 100 µl/well and left to stand at room temperature for 1 hour. Each well was washed with PBS-T. Then, a TMB substrate solution (manufactured by Thermo Fisher Scientific Inc.) was added thereto at 100 µl/well and left to stand for 5 to 30 minutes to cause color reaction. After the color development, the reaction was terminated by the addition of 1N sulfuric acid at 100 µl/well. The absorbance was measured at 450 nm and 595 nm using an absorption spectrometer. As a result, hybridomas producing antibodies having high absorbance were selected.

[0130] The selected hybridomas were added to a 96-well plate at 0.3 cells/well and cultured in the plate. One week later, hybridomas forming single colonies in the wells were observed. The cells in these wells were further cultured, and the cloned hybridomas were screened in the same way as above for the binding affinity of antibodies produced by the hybridomas to the amino acid sequence of SEQ ID NO: 5 as a partial CAPRIN-1 sequence as an indicator to obtain hybridomas producing antibodies against the amino acid of SEQ ID NO: 5.

[0131] Monoclonal antibodies produced by the obtained hybridomas were screened for antibodies reactive with the surface of breast cancer cells expressing CAPRIN-1. Specifically, 10⁶ cells of a human breast cancer cell line MDA-MB-231 V were centrifuged in a 1.5-ml microcentrifuge tube. 100 µl of the culture supernatant of the hybridoma obtained above was added thereto and left to stand for 1 hour on ice. After washing with PBS, FITC-labeled goat anti-mouse IgG antibodies (manufactured by Invitrogen Corp.) diluted 500-fold with PBS containing 0.1% FBS were added thereto and left to stand for 1 hour on ice. After washing with PBS, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company). On the other hand, the same operation as above was performed to prepare a sample using the serum of each untreated 6-week-old Balb/c mouse diluted 500-fold with a medium for hybridoma culture or prepare a negative control sample by the reaction only with secondary antibodies, instead of the antibodies. As a result, 2 monoclonal antibodies (#2 and #3) having stronger fluorescence intensity than that of the negative control, i.e., reactive with the surface of the breast cancer cells, were obtained.

[0132] The obtained mouse monoclonal antibodies #2 and #3 were examined for their specific reaction with the amino acid sequence of SEQ ID NO: 5 as a partial CAPRIN-1 sequence used as an immunogen. A 30 µg/ml solution of the amino acid sequence of SEQ ID NO: 5 prepared with a 0.1 M aqueous sodium carbonate solution and a partial CAPRIN-1 sequence free from the amino acid sequence of SEQ ID NO: 5 were each added to a 96-well plate Immobilizer Amino for ELISA (Nunc) at 100 µg/ml and reacted for one whole day and night at 4°C to bind the peptides to the wells. A 0.1 M aqueous sodium carbonate solution containing 10 mM ethanolamine was added to the peptide-bound wells and left to stand at room temperature for 1 hour. The solution in each well was removed, and each well was then washed with PBS-T. Then, a Blockace solution was added thereto at 400 µl/well and left to stand at room temperature for 3 hours. The solution in each well was removed, and each well was washed with PBS-T. Then, the culture supernatant containing the mouse monoclonal antibody #2 was added thereto at 50 µl/well and reacted at room temperature for 1 hour. Then, each well was washed with PBS-T, and HRP-labeled anti-mouse IgG (H+L) antibodies (manufactured by Invitrogen) diluted 5000-fold with a Blockace solution were added thereto at 50 µl/well and left to stand at room temperature for 1 hour. Each well was fully washed with PBS-T. Then, a TMB substrate solution (manufactured by Thermo Fisher Scientific Inc.) was added thereto at 100 µl/well and left to stand for 5 to 30 minutes to cause color reaction. After the color development, the reaction was terminated by the addition of 1N sulfuric acid at 100 µl/well. The absorbance was measured

at 450 nm and 595 nm using an absorption spectrometer. As a result, the mouse monoclonal antibodies #2 and #3 did not react with the partial CAPRIN-1 sequence free from the amino acid sequence of SEQ ID NO: 5, but specifically reacted only with the amino acid sequence of SEQ ID NO: 5. The results demonstrated that the polypeptide of SEQ ID NO: 5 contains an epitope region for the anti-CAPRIN-1 antibodies #2 and #3.

Example 3 Preparation of chicken monoclonal antibody against CAPRIN-1

[0133] Chicken-derived monoclonal antibodies were prepared using as an immunogen a fusion protein of the amino acid sequence of SEQ ID NO: 5 identified in Example 2(2) and a carrier protein KLH (keyhole limpet haemocyanin). 300 µg of the immunogen was mixed with an equal amount of a complete Freund's adjuvant. This mixture was used as an antigen solution per chicken. The antigen solution was intraperitoneally administered to each 7-week-old chicken. Then, 7 administrations were performed every 4 weeks to complete immunization. Four days after the final immunization, the spleen of each chicken was excised and ground between two sterilized glass slides. Procedures of washing with PBS(-) (manufactured by Nissui Pharmaceutical Co., Ltd.) and centrifuging at 1500 rpm for 10 minutes to remove the supernatant were repeated three times to obtain spleen cells. The obtained spleen cells were mixed with light chain-deficient chicken myeloma cells established from chickens by transformation using avian reticuloendotheliosis virus, at a ratio of 5:1. A PEG solution prepared by mixing 200 µl of an IMDM medium containing 10% FBS, which was heated to 37°C, with 800 µl of PEG1500 (manufactured by Boehringer Ingelheim GmbH) was added to the cell mixture, and then it was left to stand for 5 minutes for cell fusion. After removal of the supernatant via centrifugation at 1700 rpm for 5 minutes, the cells were suspended in 300 ml of an IMDM medium containing 10% FBS supplemented with 2% equivalent of a HAT solution (Gibco) (HAT selective medium). This suspension was seeded onto thirty 96-well plates (Nunc) at 100 µl/well. The spleen cells and the chicken myeloma cells were fused by culturing for 7 days at 37°C, 5% CO₂ to obtain hybridomas. Then, the antibodies were screened for, as an indicator, the reactivity of the antibody contained in the culture supernatants of the prepared hybridomas with a solution of CAPRIN-1 proteins prepared as described in Example 3 of WO2010/016526 or a fusion protein (used as an immunogen) of the amino acid sequence of SEQ ID NO: 5 and a carrier protein BSA. Specifically, the 1 µg/ml solution of CAPRIN-1 proteins prepared in Example 3 of WO2010/016526 and the fusion protein (1 µg/ml) of the amino acid sequence of SEQ ID NO: 5 and the carrier protein BSA were each added at 50 µl/well to 96-well plates and left to stand at 4°C for 18 hours. Each well was washed with PBS-T. Then, a Blockace (DS Pharma Biomedical Co., Ltd.) solution was added thereto at 300 µl/well and left to stand at room temperature for 3 hours. The solution in each well was removed, and each well was washed with PBS-T. Then, the culture supernatant of each hybridoma obtained above was added thereto at 50 µl/well and left to stand at room temperature for 1 hour. Each well was washed with PBS-T. Then, HRP-labeled anti-chicken IgY antibodies (manufactured by KPL, Kirkegaard & Perry Laboratories, Inc.) diluted 1000-fold with PBS were added thereto at 100 µl/well and left to stand at room temperature for 1 hour. Each well was washed three times with PBS-T. Then, an OPD substrate solution was added thereto at 50 µl/well and left to stand for 5 to 15 minutes to cause color reaction. After the color development, the reaction was terminated by the addition of 2N sulfuric acid at 50 µl/well. The absorbance was measured at 490 nm and 630 nm using an absorption spectrometer. As a result, several hybridomas producing antibodies having high absorbance were selected.

[0134] The selected hybridomas were added to a 96-well plate at 0.5 cells/well and cultured in the plate. One week later, hybridomas forming single colonies in the wells were observed. The cells in these wells were further cultured, and the cloned hybridomas were screened for, as an indicator, the binding affinity of antibodies produced by the hybridomas to the CAPRIN-1 proteins or the reactivity of the antibodies against the fusion protein (used as an immunogen) of the amino acid sequence of SEQ ID NO: 5 and the carrier protein BSA, to obtain chicken monoclonal antibodies.

[0135] Next, these monoclonal antibodies were screened for antibodies reactive with the surface of breast cancer cells expressing CAPRIN-1. Specifically, 2×10^5 cells of a human breast cancer cell line MDA-MB-231V were centrifuged in a 1.5-ml microcentrifuge tube. 50 µl of the culture supernatant of each hybridoma obtained above was added thereto and left to stand for 1 hour on ice. After washing with PBS, FITC-labeled goat anti-chicken IgG (H+L) antibodies (manufactured by SouthernBiotech) diluted 100-fold with PBS containing 0.5% FBS were added thereto and left to stand for 1 hour on ice. After washing with PBS, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company). On the other hand, the same operation as above was performed using a medium for hybridoma culture to prepare a negative control sample. As a result, 4 chicken monoclonal antibodies (chicken monoclonal antibodies #1, #2, #3, and #4) having stronger fluorescence intensity than that of the control, i.e., reactive with the surface of breast cancer cells expressing CAPRIN-1, were selected. These antibodies can bind to CAPRIN-1 expressed on the surface of breast cancer cells.

Example 4 Characterization of selected monoclonal antibody

(1) Characterization of mouse monoclonal antibody

[0136] Amplification fragments of genes encoding the variable regions of the mouse monoclonal antibodies obtained in Example 2 were obtained according to a method described in Example 5 of WO2010/016526 and analyzed for their gene sequences and amino acid sequences encoded thereby. The resulting gene sequence encoding the heavy chain variable region of the mouse-derived monoclonal antibody #1 is shown in SEQ ID NO: 24, and the amino acid sequence is shown in SEQ ID NO: 19; and the gene sequence encoding the light chain variable region thereof is shown in SEQ ID NO: 25, and the amino acid sequence is shown in SEQ ID NO: 23. The resulting gene sequence encoding the heavy chain variable region of the mouse-derived monoclonal antibody #2 is shown in SEQ ID NO: 14, and the amino acid sequence is shown in SEQ ID NO: 9; and the gene sequence encoding the light chain variable region thereof is shown in SEQ ID NO: 15, and the amino acid sequence is shown in SEQ ID NO: 13. The resulting gene sequence encoding the heavy chain variable region of the mouse-derived monoclonal antibody #3 is shown in SEQ ID NO: 14, and the amino acid sequence is shown in SEQ ID NO: 9; and the gene sequence encoding the light chain variable region thereof is shown in SEQ ID NO: 54, and the amino acid sequence is shown in SEQ ID NO: 53.

[0137] In other words, the mouse monoclonal antibody #1 was found to comprise the heavy chain variable region of SEQ ID NO: 19 and the light chain variable region of SEQ ID NO: 23, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 16, 17, and 18, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 20, 21, and 22, respectively. The mouse monoclonal antibody #2 was found to comprise the heavy chain variable region of SEQ ID NO: 9 and the light chain variable region of SEQ ID NO: 13, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively. The mouse monoclonal antibody #3 was found to comprise the heavy chain variable region of SEQ ID NO: 9 and the light chain variable region of SEQ ID NO: 53, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 50, 51, and 52, respectively.

(2) Characterization of chicken monoclonal antibody

[0138] Amplification fragments of genes encoding the variable regions of the chicken monoclonal antibodies (chicken monoclonal antibodies #1, #2, #3, and #4) obtained in Example 3 were obtained according to the method described in Example 4 of WO2011/096519 and analyzed for their gene sequences and amino acid sequences encoded thereby. The resulting amino acid sequence of the heavy chain variable region of the chicken monoclonal antibody #1 is shown in SEQ ID NO: 58, and the amino acid sequence of the light chain variable region thereof is shown in SEQ ID NO: 62. The amino acid sequence of the heavy chain variable region of the chicken monoclonal antibody #2 is shown in SEQ ID NO: 63, and the amino acid sequence of the light chain variable region thereof is shown in SEQ ID NO: 65. The amino acid sequence of the heavy chain variable region of the chicken monoclonal antibody #3 is shown in SEQ ID NO: 69, and the amino acid sequence of the light chain variable region thereof is shown in SEQ ID NO: 73. The amino acid sequence of the heavy chain variable region of the chicken monoclonal antibody #4 is shown in SEQ ID NO: 77, and the amino acid sequence of the light chain variable region thereof is shown in SEQ ID NO: 81.

[0139] In other words, the chicken monoclonal antibody #1 was found to comprise the heavy chain variable region of SEQ ID NO: 58 and the light chain variable region of SEQ ID NO: 62, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 55, 56, and 57, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 59, 60, and 61, respectively. The chicken monoclonal antibody #2 was found to comprise the heavy chain variable region of SEQ ID NO: 63 and the light chain variable region of SEQ ID NO: 65, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 55, 56, and 57, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 59, 64, and 61, respectively. The chicken monoclonal antibody #3 was found to comprise the heavy chain variable region of SEQ ID NO: 69 and the light chain variable region of SEQ ID NO: 73, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 66, 67, and 68, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 70, 71, and 72, respectively. The chicken monoclonal antibody #4 was found to comprise the heavy chain variable region of SEQ ID NO: 77 and the light chain variable region of SEQ ID NO: 81, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 74, 75, and 76, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 78,

79, and 80, respectively.

Example 5 Preparation of polyclonal antibody against partial CAPRIN-1 polypeptide present on cancer cell surface

[0140] For the purpose of obtaining polyclonal antibodies against partial CAPRIN-1 polypeptides present on cancer cell surface, a polypeptide (CAPRIN-1-derived peptide shown in SEQ ID NO: 5) comprising the epitope regions for the anti-CAPRIN-1 monoclonal antibodies #1, #2, and #3, a polypeptide having a region of amino acid residues 50 to 98 in the human CAPRIN-1 amino acid sequence of SEQ ID NO: 2, and a polypeptide having a region of amino acid residues 233 to 305 of SEQ ID NO: 2 were synthesized. 1 mg of these peptides were each mixed as an antigen with an equal volume of an incomplete Freund's adjuvant (IFA) solution. This mixture was subcutaneously administered to rabbit four times every two weeks. Then, blood was collected therefrom to obtain antiserum containing polyclonal antibody against each antigen. The antiserum was further purified using a protein G carrier (manufactured by GE Healthcare Bio-Sciences Ltd.), followed by replacement with PBS, to obtain polyclonal antibodies against partial CAPRIN-1 polypeptides present on cancer cell surface. In addition, the serum of a rabbit that received no antigen was prepared by purification using a protein G carrier in the same way as above and used as a control antibody.

Example 6 Analysis of CAPRIN-1 protein expression on cancer cell

[0141] Next, 8 human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-20, MDA-MB-231V, and MRK-nu-1) observed to have a high level of CAPRIN-1 gene expression were examined for their expression of CAPRIN-1 proteins on the cell surface. 5×10^5 cells of the human breast cancer cell lines that were observed above to have the gene expression were each centrifuged in a 1.5-ml microcentrifuge tube. After adding 2 μ g (5 μ l) of the polyclonal antibodies against CAPRIN-1-derived peptides prepared as described above in Example 5 thereto, the cells were further mixed with 95 μ l of PBS containing 0.1% fetal bovine serum, and left to stand for 1 hour on ice. After washing with PBS, the resulting solution was mixed with 2 μ l of Alexa 488-labeled goat anti-rabbit IgG antibodies (manufactured by Invitrogen Corp.) and 98 μ l of PBS containing 0.1% fetal bovine serum (FBS) and left to stand for 30 hours on ice. After washing with PBS, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company). On the other hand, the same operation as above was performed using the control antibodies prepared as described above in Example 5 instead of the polyclonal antibodies against CAPRIN-1-derived peptides to prepare a control. As a result, the cancer cells treated with the anti-CAPRIN-1 antibodies all exhibited fluorescence intensity at least 35% stronger than that of the control. This demonstrated that CAPRIN-1 proteins are expressed on the cell membrane surface of the human cancer cell lines. The rates of enhancement in the fluorescence intensity are expressed as the rates of increase in mean fluorescence intensity (MFI) in respective cell lines, which are calculated according to the following formula.

$$\text{Rate of increase in mean fluorescence intensity (Rate of enhancement in fluorescence intensity) (\%)} = ((\text{MFI of cells reacted with the anti-CAPRIN-1 antibodies}) - (\text{Control MFI})) / (\text{Control MFI}) \times 100$$

[0142] Also, the fluorescence intensity was measured in 3 kidney cancer cell lines (Caki-1, Caki-2, and A498), a urinary bladder cancer cell line (T24), an ovary cancer cell line (SKOV3), a lung cancer cell line (QG56), a prostate cancer cell line (PC3), a uterine cervix cancer cell line (HeLa), a fibrosarcoma cell line (HT1080), 2 brain tumor cell lines (T98G and U87MG), a gastric cancer cell line (MNK28), a colorectal cancer cell line (Lovo), and pancreatic cancer cell lines (Capan-2, MIA PaCa-2, Panc-1, and BxPC-3) using the same approach as above. As a result, all the cancer cells had fluorescence intensity at least 35% stronger than that of the control.

[0143] As with the results obtained above, CAPRIN-1 expression was also confirmed using the anti-CAPRIN-1 monoclonal antibody (mouse monoclonal antibody #1) having the heavy chain variable region of SEQ ID NO: 19 and the light chain variable region of SEQ ID NO: 23, the anti-CAPRIN-1 monoclonal antibody (mouse monoclonal antibody #2) having the heavy chain variable region of SEQ ID NO: 9 and the light chain variable region of SEQ ID NO: 13, and the anti-CAPRIN-1 monoclonal antibody (mouse monoclonal antibody #3) having the heavy chain variable region of SEQ ID NO: 9 and the light chain variable region of SEQ ID NO: 53, which were obtained in Example 2, and the anti-CAPRIN-1 chicken monoclonal antibody #1 having the heavy chain variable region of SEQ ID NO: 58 and the light chain variable region of SEQ ID NO: 62, the anti-CAPRIN-1 chicken monoclonal antibody #2 having the heavy chain variable region of SEQ ID NO: 63 and the light chain variable region of SEQ ID NO: 65, the anti-CAPRIN-1 chicken monoclonal antibody #3 having the heavy chain variable region of SEQ ID NO: 69 and the light chain variable region of SEQ ID NO: 73, and the anti-CAPRIN-1 chicken monoclonal antibody #4 having the heavy chain variable region of SEQ ID NO: 77 and the

light chain variable region of SEQ ID NO: 81 (chicken monoclonal antibodies #1 to #4), which were obtained in Example 3.

Example 7 Immunohistochemical staining

(1) CAPRIN-1 expression in mouse and canine normal tissues

[0144] A mouse (Balb/c, female) and a dog (beagle, female) were exsanguinated under ether anesthesia and under ketamine/isoflurane anesthesia and subjected to abdominal section. Then, each organ (stomach, liver, eyeball, thymus, muscle, bone marrow, uterus, small intestine, esophagus, heart, kidney, salivary gland, large intestine, mammary gland, brain, lung, skin, adrenal gland, ovary, pancreas, spleen, and urinary bladder) was transferred to a 10-cm dish containing PBS. Each organ was cut open in PBS and perfusion-fixed overnight in a 0.1 M phosphate buffer solution (pH 7.4) containing 4% paraformaldehyde (PFA). The perfusate was discarded, and the tissue surface of each organ was rinsed with PBS. Each tissue was placed in a PBS solution containing 10% sucrose in a 50-ml centrifuge tube and shaken at 4°C for 2 hours using a rotor. The solution was replaced with a PBS solution containing 20% sucrose, and the resulting solution was left to stand at 4°C until the tissue was precipitated. Then, the solution was replaced with a PBS solution containing 30% sucrose, and the resulting solution was left to stand at 4°C until the tissue was precipitated. The tissue was taken out, and necessary portions were cut off with a surgical knife. Next, OCT compound (Tissue Tek) was poured onto the tissue surface and spread over the surface. Then, the tissue was mounted on Cryomold. The Cryomold was placed on dry ice to quickly freeze the tissue, and then the tissue was sliced into 10 to 20 μ m thick using Cryostat (manufactured by Leica Biosystems), and dried in air, together with the glass slide, for 30 minutes using a hair dryer to prepare a glass slide with a tissue slice placed thereon. Next, the glass slide was placed in a staining bottle filled with PBS-T (physiological saline containing 0.05% Tween 20), and procedures of replacing PBS-T with a fresh one every 5 minutes were performed three times. Redundant water around each section was wiped off with Kimwipe. The section on the glass slide was encircled with a Dako pen (manufactured by Dako Japan Inc.). Then, MOM mouse Ig blocking reagent (Vectastain) for the mouse tissues and a PBS-T solution containing 10% FBS for the canine tissues were applied thereto as blocking solutions, and the glass slide was left to stand at room temperature for 1 hour in a moist chamber.

[0145] Next, a cancer cell surface-reactive polyclonal antibody against the CAPRIN-1-derived peptide (SEQ ID NO: 5) prepared in Example 5 was prepared into a 10 μ g/ml solution with a blocking solution, and this solution was applied thereto. The glass slide was left to stand overnight at 4°C in a moist chamber. After washing with PBS-T for 10 minutes three times, MOM biotin-labeled anti-IgG antibodies (Vectastain) diluted 250-fold with a blocking solution were applied thereto, and the glass slide was left to stand at room temperature for 1 hour in a moist chamber. After washing with PBS-T for 10 minutes three times, Avidin-Biotin ABC reagent (Vectastain) was applied thereto, and the glass slide was left to stand at room temperature for 5 minutes in a moist chamber. After washing with PBS-T for 10 minutes three times, a DAB staining solution (10 mg of DAB + 10 μ l of 30% H₂O₂ / 50 ml of 0.05 M tris-HCl (pH 7.6)) was applied thereto, and the glass slide was left to stand at room temperature for 30 minutes in a moist chamber. After rinsing with distilled water, a hematoxylin reagent (manufactured by Dako Japan Inc.) was applied thereto, and the glass slide was left to stand at room temperature for 1 minute and then rinsed with distilled water. The glass slide was placed in 70%, 80%, 90%, 95%, and 100% ethanol solutions in this order for 1 minute per solution and then left to stand overnight in xylene. The glass slide was taken out and mounted in Glycergel Mounting Medium (manufactured by Dako Japan Inc.), followed by observation. As a result, the intracellular expression of CAPRIN-1 was slightly observed in respective tissues of the salivary gland, kidney, colon, and stomach. Its expression, however, was not observed on the cell surface of these tissues. In addition, no expression was observed in tissues derived from the other organs.

(2) Expression of CAPRIN-1 in canine breast cancer tissue

[0146] Frozen breast cancer tissues of dogs pathologically diagnosed as malignant breast cancer were used in the preparation of frozen section slides and immunohistochemical staining using the polyclonal antibodies against the CAPRIN-1-derived peptide (SEQ ID NO: 5) prepared in Example 5, in the same way as above. As a result, the expression of CAPRIN-1 was observed in the canine breast cancer tissues.

(3) Expression of CAPRIN-1 in various human cancer tissues

[0147] Paraffin-embedded human various cancer tissue array samples (manufactured by US Biomax, Inc.) were used in immunohistochemical staining using the polyclonal antibodies (prepared in Example 5) against the CAPRIN-1-derived peptide (SEQ ID NO: 5) in the same way as above. As a result, the expression of CAPRIN-1 was observed in esophageal cancer, colon cancer, rectal cancer, lung cancer, pancreatic cancer, kidney cancer, urinary bladder cancer, and uterine cervix cancer.

Example 8 Preparation of human-mouse chimeric monoclonal antibody

[0148] The gene amplification fragment prepared in Example 4 comprising the sequence (SEQ ID NO: 14) of the heavy chain variable region of the mouse monoclonal antibody #2 was treated at both ends with a restriction enzyme, then purified, and inserted according to a conventional method into a vector pcDNA4/myc-His (manufactured by Invitrogen Corp.) already having gene inserts of a mouse antibody-derived leader sequence and a human IgG₁ H chain constant region comprising the amino acid sequence of SEQ ID NO: 48. Also, the gene amplification fragment comprising the sequence (SEQ ID NO: 15) of the light chain variable region of the mouse monoclonal antibody #2 was treated at both ends with a restriction enzyme, then purified, and inserted according to a conventional method into a vector pcDNA3.1/myc-His (manufactured by Invitrogen Corp.) already having gene inserts of a mouse antibody-derived leader sequence and a human IgG₁ L chain constant region comprising the amino acid sequence of SEQ ID NO: 49.

[0149] Next, the recombinant vector having the insert of the nucleotide sequence encoding the heavy chain variable region (SEQ ID NO: 14) of the mouse monoclonal antibody #2 and the recombinant vector having the insert of the nucleotide sequence encoding the light chain variable region (SEQ ID NO: 15) of the mouse monoclonal antibody #2 were introduced into CHO-K1 cells (obtained from Riken Cell Bank). Specifically, 2×10^5 CHO-K1 cells were cultured in a Ham's F12 medium (manufactured by Invitrogen Corp.) containing 1 ml of 10% FBS per well in a 12-well culture plate, and washed with PBS(-). Then, a fresh Ham's F12 medium containing 1 ml of 10% FBS per well was added thereto. 250 ng each of the vectors in 30 μ l of OptiMEM (manufactured by Invitrogen Corp.) was mixed with 30 μ l of Polyfect transfection reagent (manufactured by Qiagen N.V.), and this mixture was added to each well. The CHO-K1 cells cotransfected with the recombinant vectors were cultured in a Ham's F12 medium containing 10% FBS supplemented with 200 μ g/ml Zeocin (manufactured by Invitrogen Corp.) and 200 μ g/ml Geneticin (manufactured by Roche Diagnostics K.K.) and then seeded in a 96-well plate at 0.5 cells/well to prepare a cell line stably producing a human-mouse chimeric monoclonal antibody #1 (#1) having the variable regions of the mouse monoclonal antibody #1. Cell lines stably producing a human-mouse chimeric monoclonal antibody #2 (#2) or a human-mouse chimeric monoclonal antibody #3 (#3) were also prepared in the same way as above as to the mouse monoclonal antibodies #2 and #3.

[0150] Each prepared cell line was cultured for 5 days in a 150-cm² flask at 5×10^5 cells/ml in 30 ml of a serum-free OptiCHO medium (manufactured by Invitrogen Corp.) to obtain culture supernatants containing #1, #2, or #3.

[0151] Also, cell lines stably producing human-mouse chimeric comparative antibodies 1 to 11 were prepared in the same way as above respectively, on the basis of the following anti-CAPRIN-1 mouse-derived monoclonal antibodies disclosed in WO2010/016526 as comparative antibodies: a comparative antibody 1 having the heavy chain variable region of SEQ ID NO: 26 and the light chain variable region of SEQ ID NO: 27; a comparative antibody 2 having the heavy chain variable region of SEQ ID NO: 28 and the light chain variable region of SEQ ID NO: 29; a comparative antibody 3 having the heavy chain variable region of SEQ ID NO: 30 and the light chain variable region of SEQ ID NO: 31; a comparative antibody 4 having the heavy chain variable region of SEQ ID NO: 32 and the light chain variable region of SEQ ID NO: 33; a comparative antibody 5 having the heavy chain variable region of SEQ ID NO: 34 and the light chain variable region of SEQ ID NO: 35; a comparative antibody 6 having the heavy chain variable region of SEQ ID NO: 36 and the light chain variable region of SEQ ID NO: 37; a comparative antibody 7 having the heavy chain variable region of SEQ ID NO: 38 and the light chain variable region of SEQ ID NO: 39; a comparative antibody 8 having the heavy chain variable region of SEQ ID NO: 40 and the light chain variable region of SEQ ID NO: 41; a comparative antibody 9 having the heavy chain variable region of SEQ ID NO: 42 and the light chain variable region of SEQ ID NO: 43; a comparative antibody 10 having the heavy chain variable region of SEQ ID NO: 44 and the light chain variable region of SEQ ID NO: 45; and a comparative antibody 11 having the heavy chain variable region of SEQ ID NO: 46 and the light chain variable region of SEQ ID NO: 47. Each prepared cell line was cultured for 5 days in a 150-cm² flask at 5×10^5 cells/ml in 30 ml of a serum-free OptiCHO medium (manufactured by Invitrogen Corp.) to obtain culture supernatants containing respective human-mouse chimeric comparative monoclonal antibodies 1 to 11.

Example 9 Preparation of human-chicken chimeric monoclonal antibody

[0152] On the basis of the chicken monoclonal antibody #1 obtained in Example 3, a cell line stably producing a human-chicken chimeric antibody #1 having the variable regions of the chicken monoclonal antibody #1 was prepared according to the method described in Example 4(2) of WO2011/096519 on the basis of. The prepared cell line was cultured for 5 days in a 150-cm² flask at 5×10^5 cells/ml in 30 ml of a serum-free OptiCHO medium (manufactured by Invitrogen Corp.) to obtain a culture supernatant containing human-chicken chimeric antibody #1.

[0153] Also, on the basis of the chicken monoclonal antibodies #2, #3, and #4, cell lines stably producing a human-chicken chimeric antibody #2, #3, or #4 were also prepared using the same approach as above. Each prepared cell line was used to obtain culture supernatants containing the human-chicken chimeric antibody #1, #2, #3, or #4.

[0154] Example 10 Expression analysis of CAPRIN-1 on surface of various cancer cells using mouse monoclonal antibodies #1, #2, and #3 and chicken monoclonal antibodies #1, #2, #3, and #4

[0155] Next, the human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-20, MDA-MB-231V, and MRK-nu-1), the kidney cancer cell lines (Caki-1, Caki-2, A498, and ACHN), the urinary bladder cancer cell line (T24), the ovary cancer cell line (SKOV3), the lung cancer cell lines (QG56 and A549), the pancreatic cancer cell lines (Capan-2 and MIA PaCa-2), the prostate cancer cell line (PC3), the uterine cervix cancer cell line (SW756), the fibrosarcoma cell line (HT1080), the brain tumor cell lines (T98G, U87MG, U251, SNB19, and U373), the gastric cancer cell lines (MNK28 and MNK45), the colorectal cancer cell lines (HT29, Lovo, CaCo2, SW480, and HCT116), the leukemia cell line (AML5), and the lymphoma cell line (Ramos) observed to have CAPRIN-1 gene expression were examined for their expression of CAPRIN-1 proteins on the cell surface using the culture supernatants respectively containing #1, #2, and #3 obtained in Example 2 and the chicken monoclonal antibodies #1, #2, #3, and #4 obtained in Example 3. 10^6 cells of each cell line were centrifuged in each 1.5-ml microcentrifuge tube. Each culture supernatant (100 μ l) containing any of the antibodies #1, #2, and #3 and the chicken monoclonal antibodies #1, #2, #3, and #4 was added to the tube and left to stand for 1 hour on ice. After washing with PBS, FITC-labeled goat anti-mouse IgG (H+L) antibodies (manufactured by Jackson ImmunoResearch Laboratories, Inc.) diluted with PBS containing 0.1% FBS for the mouse-derived antibodies or FITC-labeled goat anti-chicken IgG (H+L) antibodies (manufactured by SouthernBiotech) diluted 100-fold with PBS containing 0.1% FBS for the chicken-derived antibodies were added thereto and left to stand at 4°C for 30 minutes. After washing with PBS, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company). The negative control used was cells reacted only with secondary antibodies. As a result, all the cells each treated with any of the antibodies #1, #2, and #3 and the chicken monoclonal antibodies #1 to #4 had fluorescence intensity at least 35% stronger than that of the negative control. This demonstrated that CAPRIN-1 proteins are expressed on the cell membrane surface of the human cancer cell lines. The rates of enhancement in the fluorescence intensity was expressed as the rates of increase in mean fluorescence intensity (MFI) in respective cell lines, which are calculated according to the following formula.

$$\text{Rate of increase in mean fluorescence intensity (Rate of enhancement in fluorescence intensity) (\%)} = ((\text{MFI of cells reacted with the anti-CAPRIN-1 antibodies}) - (\text{Control MFI})) / (\text{Control MFI}) \times 100$$

Example 11 Antitumor activity against cancer cells of antibody against CAPRIN-1-derived peptide (SEQ ID NO: 5)

[0156] In order to evaluate the antibodies against the CAPRIN-1-derived peptide (SEQ ID NO: 5) for the strength of its cytotoxicity against cancer cells expressing CAPRIN-1, ADCC activity was determined. The polyclonal antibodies (prepared in Example 5) against the peptide shown in SEQ ID NO: 5 were used in this evaluation. Similar evaluation was conducted using polyclonal antibodies against other human CAPRIN-1-derived peptides (polyclonal antibodies against amino acid residues 50 to 98 in the amino acid sequence of human CAPRIN-1 and polyclonal antibodies against amino acid residues 233 to 305 in the amino acid sequence of human CAPRIN-1, which were prepared in Example 5) as antibodies for comparison or the rabbit serum-derived control antibodies prepared in Example 5 as a negative control.

[0157] 10^6 cells of the human breast cancer cell line MCF7, the human colorectal cancer cell line HCT-116, the human pancreatic cancer cell line MIA PaCa-2, the human kidney cancer cell line Caki-2, and the human lung cancer cell line QG56 observed to have CAPRIN-1 expression were each collected into a 50-ml centrifuge tube, and 100 μ Ci of chromium 51 was then added thereto, followed by incubation at 37°C for 2 hours. Then, the cells were washed three times with an RPMI1640 medium containing 10% fetal calf serum and added at 2×10^3 cells/well to a 96-well V-bottom plate. The polyclonal antibodies against the human CAPRIN-1-derived peptide (SEQ ID NO: 5) and two types of polyclonal antibodies against other human CAPRIN-1-derived peptides (polyclonal antibodies against amino acid residues 50 to 98 of human CAPRIN-1 and polyclonal antibodies against amino acid residues 233 to 305 of human CAPRIN-1) were each added thereto at 1 μ g/well. Lymphocytes separated from human peripheral blood according to a conventional method were further added thereto at 4×10^5 cells/well and cultured for 4 hours at 37°C, 5% CO₂. After the culture, the amount of chromium (Cr) 51 released from damaged cancer cells was measured in the culture supernatant to calculate the ADCC activity against the cancer cells due to the polyclonal antibodies against the human CAPRIN-1-derived peptides. As a result, all the polyclonal antibodies obtained by immunization with the human partial CAPRIN-1 peptides having the amino acid sequence of amino acid residues 50 to 98 or amino acid residues 233-305 of human CAPRIN-1 had activity less than 10% against the human breast cancer cell line MCF7, the human colorectal cancer cell line HCT-116, the human pancreatic cancer cell line MIA PaCa-2, the human kidney cancer cell line Caki-2, and the human lung cancer cell line QG56. By contrast, the groups of the cells treated with the polyclonal antibodies against the human CAPRIN-1-derived peptide (SEQ ID NO: 5) exhibited 25% or higher cytotoxic activity against all the cancer cell lines. The negative control antibodies had activity less than 4% against all the cancer cells. These results revealed that antibodies against

CAPRIN-1 shown in SEQ ID NO: 5 exerts strong cytotoxic activity against cancer cells expressing CAPRIN-1.

[0158] These results were obtained via determination of cytotoxic activity by, as described above, mixing the anti-CAPRIN-1 antibody used in the present invention, lymphocytes, and 2×10^3 cells of each cancer cell line with incorporated chromium 51; culturing the cells for 4 hours; after the culture, measuring the amount of chromium 51 released into the medium; and calculating the cytotoxic activity against each cancer cell line according to the following formula*.

$$\text{*Expression: Cytotoxic activity (\%)} = \frac{\text{[Amount of chromium 51 released from the target cells treated with the antibody against CAPRIN-1 and lymphocytes]}}{\text{[Amount of chromium 51 released from target cells treated with 1N hydrochloric acid]}} \times 100$$

[0159] The human-mouse chimeric monoclonal antibodies #1, #2, and #3 obtained in Example 8 and the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 obtained in Example 9 were evaluated for their cytotoxic activity against human cancer cells. The culture supernatant of each cell line producing any of #1, #2, and #3 and the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 was purified using Hitrap Protein A Sepharose FF (manufactured by GE Healthcare Bio-Sciences Ltd.). After replacement with PBS(-), the solution was filtered through a 0.22- μ m filter (manufactured by Millipore Corp.). The resulting antibody was used for activity assay. 10^6 cells each of the human breast cancer cell line MCF7, the human colorectal cancer cell line HCT-116, the human pancreatic cancer cell line MIAPaCa-2, the human kidney cancer cell line Caki-2, and the human lung cancer cell line QG56 were collected into a 50-ml centrifuge tube, and 100 μ Ci of chromium 51 was then added thereto, followed by incubation at 37°C for 2 hours. Then, the cells were washed three times with an RPMI1640 medium containing 10% FBS and added at 2×10^3 cells/well to a 96-well V-bottom plate to prepare target cells. The purified antibodies (human-mouse chimeric monoclonal antibodies #1, #2, and #3 and human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4) and the human-mouse chimeric comparative monoclonal antibodies 1 to 11 obtained in Example 8 were each added thereto at 1.3 μ g/well. A cell population containing human NK cells was separated using a conventional method from human peripheral blood lymphocytes prepared according to a conventional method. The cell population containing human NK cells that was used in this evaluation was prepared as follows: human peripheral blood mononuclear cells separated using a specific gravity separation solution Histopaque for peripheral blood mononuclear cell separation (Sigma-Aldrich Corp.) were reacted with FITC fluorescent dye-labeled antibodies (anti-human CD3 antibody, anti-human CD20 antibody, anti-human CD19 antibody, anti-human CD11c antibody, or anti-HLA-DR antibody (Becton, and Dickinson and Company)); and a cell population containing NK cells unstained with the antibodies was separated therefrom using a cell sorter (FACS Vantage SE (Becton, and Dickinson and Company)), or a cell population was separated with human NK cell separation kit (manufactured by Miltenyi Biotec K.K.). The separated cell population containing NK cells was added to the plate at 2×10^5 cells/well and cultured for 4 hours at 37°C, 5% CO₂. After the culture, the amount of chromium 51 released from damaged tumor cells was measured in the culture supernatant to calculate the cytotoxic activity of each anti-CAPRIN-1 antibody against the cancer cells. The negative control used was cells treated with isotype control antibodies. As a result, the isotype control antibodies used and the human-mouse chimeric comparative monoclonal antibodies 1 to 11 had cytotoxic activity of less than 5% against MCF7, less than 3% against HCT-116, 7% against MIAPaCa-2, less than 8% against Caki-2, and less than 5% against QG56. By contrast, the human-mouse chimeric monoclonal antibody #1 and the human-chicken chimeric monoclonal antibodies #1 to #4 had cytotoxic activity of 30% or higher against MCF7, 19% or higher against HCT-116, 28% or higher against MIAPaCa-2, 34% or higher against Caki-2, and 10% or higher against QG56. Also, the human-mouse chimeric monoclonal antibodies #2 and #3 had cytotoxic activity of 32% or higher against MCF7, 18% or higher against HCT-116, 32% or higher against MIAPaCa-2, 18% or higher against Caki-2, and 10% or higher against QG56. Likewise, the isotype control antibodies used and the comparative antibodies 1 to 11 used had cytotoxic activity less than 4% against all other cancer cells: breast cancer cell lines ZR75-1, T47D, Hs578T, BT-20, SK-BR-3, MDA-MB-231V, and MRK-nu-1, glioma cell lines T98G and U373, a lung cancer cell line A549, kidney cancer cell lines Caki-1 and ACHN, a uterine cervix cancer cell line SW756, a urinary bladder cancer cell line T24, gastric cancer cell lines MKN28 and MKN45, a colorectal cancer cell line SW480, a leukemia cell line AML5, and a lymphoma cell line Ramos. By contrast, the human-mouse chimeric monoclonal antibodies #1, #2, and #3 and the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 were observed to have 10% or higher cytotoxic activity against these cell lines. These results showed that the obtained monoclonal antibodies #1, #2, and #3 and human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 against CAPRIN-1 damage CAPRIN-1-expressing cancer cells through their ADCC activity, and it was demonstrated that the human-mouse chimeric monoclonal antibodies #1, #2, and #3 and the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 exhibit stronger cytotoxic activity against human cancer cells than that of the comparative antibodies 1 to 11.

[0160] Also, the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 were evaluated in the same way

as above for their cytotoxic activity against the human breast cancer cell line MDA-MB-436, the human kidney cancer cell line Caki-1, the human lung cancer cell line A549, the human pancreatic cancer cell line Panc-1, and the human colorectal cancer cells DLD-1 observed to have CAPRIN-1 gene expression. Further, human-chicken chimeric antibodies #1 and #2 against CAPRIN-1 described in Example 4 of WO2011/096517 were used as comparative antibodies 12 and 13, respectively; a human-chicken chimeric antibody #1 against CAPRIN-1 described in Example 4 of WO2011/096519 was used as a comparative antibody 13; a human-chicken chimeric antibody #1 and mouse monoclonal antibodies #2, #3, #4, #5, and #6 against CAPRIN-1 described in Example 4 of WO2011/096528 were used as comparative antibodies 14, 15, 16, 17, 18, and 19 respectively; mouse monoclonal antibodies #1, #2, and #3 against CAPRIN-1 described in Example 3 of WO2011/096533 were used as comparative antibodies 20, 21, and 22, respectively; and mouse monoclonal antibodies #1, #2, and #3 against CAPRIN-1 described in Example 3 of WO2011/096534 were used as comparative antibodies 23, 24, and 25, respectively, for evaluation of the cytotoxic activity. Specifically, 10^6 cells of the human colorectal cancer cell line DLD-1 were collected into a 50-ml centrifuge tube, and 100 μ Ci of chromium 51 was then added thereto, followed by incubation at 37°C for 1 hour. Then, the cells were washed three times with an RPMI1640 medium containing 10% FBS and added at 2×10^3 cells/well to a 96-well V-bottom plate to prepare target cells. Next, the human-chicken chimeric monoclonal antibodies #1 to #4 and the comparative antibodies 12 to 25 were each added thereto at 1 μ g/well. A cell population containing human NK cells prepared according to a conventional method was further added thereto at 10^5 cells/well and cultured for 4 hours at 37°C, 5% CO₂. After the culture, the amount of chromium 51 released from damaged tumor cells was measured in the culture supernatant to calculate the cytotoxic activity of each anti-CAPRIN-1 antibody against the cancer cells. Cytotoxicity against MDA-MB-436, Caki-1, A549, and Panc-1 was also evaluated in the same way as above. As a result, all the comparative antibodies 12 to 25 had 5% or lower cytotoxic activity against MDA-MB-436, whereas the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 exhibited 18% or higher cytotoxic activity against this cell line. All the comparative antibodies 12 to 25 had 5% or lower cytotoxic activity against Caki-1, whereas the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 exhibited 14% or higher cytotoxic activity against this cell line. All the comparative antibodies 12 to 25 had 5% or lower cytotoxic activity against A549, whereas the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 exhibited 12% or higher cytotoxic activity against this cell line. All the comparative antibodies 12 to 25 had 5% or lower cytotoxic activity against Panc-1, whereas the human-chicken chimeric monoclonal antibodies #1, #2, #3 and #4 exhibited 18% or higher cytotoxic activity against this cell line. All the comparative antibodies 12 to 25 had 7% or lower cytotoxic activity against DLD-1, whereas the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 exhibited 15% or higher cytotoxic activity against this cell line.

[0161] These results were obtained via determination of cytotoxic activity by, as described above, mixing the anti-CAPRIN-1 antibody used in the present invention, lymphocytes (cell population containing NK cells), and 2×10^3 cells of each cancer cell line with incorporated chromium 51; culturing the cells for 4 hours; after the culture, measuring the amount of chromium 51 released into the medium; and calculating the cytotoxic activity against each cancer cell line according to the following formula*.

$$\text{*Expression: Cytotoxic activity (\%)} = \frac{\text{[Amount of chromium 51 released from the target cells treated with the antibody against CAPRIN-1 and lymphocytes (cell population containing NK cells)]}}{\text{[Amount of chromium 51 released from target cells treated with 1N hydrochloric acid]}} \times 100$$

Example 12 The number of CAPRIN-1 molecules on surface of various cancer cells recognized by anti-CAPRIN-1 monoclonal antibodies #1, #2, and #3

[0162] Human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-20, MDA-MB-231V, and MRK-nu-1), kidney cancer cell lines (Caki-1, Caki-2, A498, and ACHN), a urinary bladder cancer cell line (T24), an ovary cancer cell line (SKOV3), lung cancer cell lines (QG56 and A549), pancreatic cancer cell lines (MIA PaCa-2 and Capan-2), a prostate cancer cell line (PC3), a uterine cervix cancer cell line (SW756), a fibrosarcoma cell line (HT1080), brain tumor cell lines (T98G, U87MG, U251, SNB19, and U373), gastric cancer cell lines (MNK28 and MNK45), colorectal cancer cell lines (HT29, Lovo, CaCo2, SW480, and HCT116), a leukemia cell line (AML5), and a lymphoma cell line (Ramos) were examined using an assay kit for the number of molecules "QIFIKIT" (manufactured by Dako Japan Inc.) for the number of CAPRIN-1 molecules on their cell surface recognized by the mouse monoclonal antibodies #1, #2, and #3 obtained in Example 2. Similarly, the number of CAPRIN-1 molecules on the surface of these various cancer cells was also examined using the comparative monoclonal antibodies 1 to 11.

[0163] Specifically, according to the protocol attached to the kit, each antibody (mouse monoclonal antibodies #1, #2, and #3 and comparative antibodies 1 to 11) was diluted into 5 µg/ml at final concentration with PBS, and this dilution was added to each cell line and reacted for 30 minutes. After washing with PBS, fluorescently labeled anti-mouse IgG antibodies attached to the kit were added as secondary antibodies, together with calibration beads attached to the kit, to each cell line and left to stand for 45 minutes on ice. Each cell line and the calibration beads were washed with PBS. Then, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company) to obtain a mean fluorescence intensity value (mean) for all the antibodies described above. The negative control used was cells reacted with isotype control antibodies, and a mean was also obtained. Each mean fluorescence intensity value (mean) was used to calculate the number of molecules according to the protocol attached to the kit. As a result, the number of CAPRIN-1 molecules on the surface of various cancer cells recognized by the mouse monoclonal antibodies #1, #2, and #3 was 10⁵ or more per cell for all the examined human cancer cell lines. On the other hand, the number of molecules recognized by the comparative antibodies 1 to 11 was less than 10⁵ per cell.

Industrial Applicability

[0164] The antibody of the present invention is useful in the treatment and/or prevention of cancer.

SEQUENCE LISTING

[0165]

<110> Toray Industries, Inc.

<120> Pharmaceutical Composition for Treatment and Prevention of Cancer

<130> PH-5299-PCT

<150> JP 2011-171300

<151> 2011-08-04

<160> 81

<170> PatentIn version 3.1

<210> 1

<211> 5562

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (190)..(2319)

<223>

<400> 1

EP 2 740 796 B1

	cagagggctg ctggctggct aagtcctcc cgctcccggc tctcgctca ctaggagcgg	60
	ctctcggtgc agcgggacag ggcgaagcgg cctgcgcca cggagcgcgc gacactgcc	120
5	ggaagggacc gccacccttg cccctcagc tgcccactcg tgatttccag cggcctccgc	180
	gcgcgcacg atg ccc tcg gcc acc agc cac agc ggg agc ggc agc aag tcg	231
	Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser	
	1 5 10	
10	tcc gga ccg cca ccg ccg tcg ggt tcc tcc ggg agt gag gcg gcc gcg	279
	Ser Gly Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala	
	15 20 25 30	
15	gga gcc ggg gcc gcc gcg ccg gct tct cag cac ccc gca acc ggc acc	327
	Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr	
	35 40 45	
20	ggc gct gtc cag acc gag gcc atg aag cag att ctc ggg gtg atc gac	375
	Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp	
	50 55 60	
25	aag aaa ctt cgg aac ctg gag aag aaa aag ggt aag ctt gat gat tac	423
	Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr	
	65 70 75	
30	cag gaa cga atg aac aaa ggg gaa agg ctt aat caa gat cag ctg gat	471
	Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp	
	80 85 90	
35	gcc gtt tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca aaa	519
	Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys	
	95 100 105 110	
40	gaa tta cag agg agt ttc atg gca cta agt caa gat att cag aaa aca	567
	Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr	
	115 120 125	
45		
50		
55		

EP 2 740 796 B1

	ata aag aag aca gca cgt cgg gag cag ctt atg aga gaa gaa gct gaa	615
	Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu	
	130 135 140	
5	cag aaa cgt tta aaa act gta ctt gag cta cag tat gtt ttg gac aaa	663
	Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys	
	145 150 155	
10	ttg gga gat gat gaa gtg cgg act gac ctg aaa caa ggt ttg aat gga	711
	Leu Gly Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly	
	160 165 170	
15	gtg cca ata ttg tcc gaa gag gag ttg tca ttg ttg gat gaa ttc tat	759
	Val Pro Ile Leu Ser Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr	
	175 180 185 190	
20	aag cta gta gac cct gaa cgg gac atg agc ttg agg ttg aat gaa cag	807
	Lys Leu Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln	
	195 200 205	
25	tat gaa cat gcc tcc att cac ctg tgg gac ctg ctg gaa ggg aag gaa	855
	Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu	
	210 215 220	
30	aaa cct gta tgt gga acc acc tat aaa gtt cta aag gaa att gtt gag	903
	Lys Pro Val Cys Gly Thr Thr Tyr Lys Val Leu Lys Glu Ile Val Glu	
	225 230 235	
35	cgt gtt ttt cag tca aac tac ttt gac agc acc cac aac cac cag aat	951
	Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn	
	240 245 250	
40	ggg ctg tgt gag gaa gaa gag gca gcc tca gca cct gca gtt gaa gac	999
	Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp	
	255 260 265 270	
45	cag gta cct gaa gct gaa cct gag cca gca gaa gag tac act gag caa	1047
	Gln Val Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln	
	275 280 285	
50	agt gaa gtt gaa tca aca gag tat gta aat aga cag ttc atg gca gaa	1095
	Ser Glu Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu	
	290 295 300	
55	aca cag ttc acc agt ggt gaa aag gag cag gta gat gag tgg aca gtt	1143
	Thr Gln Phe Thr Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val	
	305 310 315	
60	gaa acg gtt gag gtg gta aat tca ctc cag cag caa cct cag gct gca	1191
	Glu Thr Val Glu Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala	
	320 325 330	
65	tcc cct tca gta cca gag ccc cac tct ttg act cca gtg gct cag gca	1239
	Ser Pro Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala	
	335 340 345 350	
70	gat ccc ctt gtg aga aga cag cga gta caa gac ctt atg gca caa atg	1287
	Asp Pro Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met	
	355 360 365	
75	cag ggt ccc tat aat ttc ata cag gat tca atg ctg gat ttt gaa aat	1335
	Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn	

EP 2 740 796 B1

	370							375					380					
5	cag	aca	ctt	gat	cct	gcc	att	gta	tct	gca	cag	cct	atg	aat	cca	aca	1383	
	Gln	Thr	Leu	Asp	Pro	Ala	Ile	Val	Ser	Ala	Gln	Pro	Met	Asn	Pro	Thr		
			385					390					395					
	caa	aac	atg	gac	atg	ccc	cag	ctg	gtt	tgc	cct	cca	gtt	cat	tct	gaa	1431	
	Gln	Asn	Met	Asp	Met	Pro	Gln	Leu	Val	Cys	Pro	Pro	Val	His	Ser	Glu		
		400					405					410						
10	tct	aga	ctt	gct	cag	cct	aat	caa	gtt	cct	gta	caa	cca	gaa	gcg	aca	1479	
	Ser	Arg	Leu	Ala	Gln	Pro	Asn	Gln	Val	Pro	Val	Gln	Pro	Glu	Ala	Thr		
	415					420					425					430		
15	cag	gtt	cct	ttg	gta	tca	tcc	aca	agt	gag	ggg	tac	aca	gca	tct	caa	1527	
	Gln	Val	Pro	Leu	Val	Ser	Ser	Thr	Ser	Glu	Gly	Tyr	Thr	Ala	Ser	Gln		
					435					440					445			
	ccc	ttg	tac	cag	cct	tct	cat	gct	aca	gag	caa	cga	cca	cag	aag	gaa	1575	
	Pro	Leu	Tyr	Gln	Pro	Ser	His	Ala	Thr	Glu	Gln	Arg	Pro	Gln	Lys	Glu		
				450					455					460				
20	cca	att	gat	cag	att	cag	gca	aca	atc	tct	tta	aat	aca	gac	cag	act	1623	
	Pro	Ile	Asp	Gln	Ile	Gln	Ala	Thr	Ile	Ser	Leu	Asn	Thr	Asp	Gln	Thr		
			465				470						475					
25	aca	gca	tca	tca	tcc	ctt	cct	gct	gcg	tct	cag	cct	caa	gta	ttt	cag	1671	
	Thr	Ala	Ser	Ser	Ser	Leu	Pro	Ala	Ala	Ser	Gln	Pro	Gln	Val	Phe	Gln		
		480					485					490						
	gct	ggg	aca	agc	aaa	cct	tta	cat	agc	agt	gga	atc	aat	gta	aat	gca	1719	
	Ala	Gly	Thr	Ser	Lys	Pro	Leu	His	Ser	Ser	Gly	Ile	Asn	Val	Asn	Ala		
30	495					500					505					510		
	gct	cca	ttc	caa	tcc	atg	caa	acg	gtg	ttc	aat	atg	aat	gcc	cca	gtt	1767	
	Ala	Pro	Phe	Gln	Ser	Met	Gln	Thr	Val	Phe	Asn	Met	Asn	Ala	Pro	Val		
					515					520					525			
35	cct	cct	gtt	aat	gaa	cca	gaa	act	tta	aaa	cag	caa	aat	cag	tac	cag	1815	
	Pro	Pro	Val	Asn	Glu	Pro	Glu	Thr	Leu	Lys	Gln	Gln	Asn	Gln	Tyr	Gln		
				530					535					540				
40	gcc	agt	tat	aac	cag	agc	ttt	tct	agt	cag	cct	cac	caa	gta	gaa	caa	1863	
	Ala	Ser	Tyr	Asn	Gln	Ser	Phe	Ser	Ser	Gln	Pro	His	Gln	Val	Glu	Gln		
			545					550					555					
	aca	gag	ctt	cag	caa	gaa	cag	ctt	caa	aca	gtg	gtt	ggc	act	tac	cat	1911	
	Thr	Glu	Leu	Gln	Gln	Glu	Gln	Leu	Gln	Thr	Val	Val	Gly	Thr	Tyr	His		
		560					565					570						
45	ggg	tcc	cca	gac	cag	tcc	cat	caa	gtg	act	ggg	aac	cac	cag	cag	cct	1959	
	Gly	Ser	Pro	Asp	Gln	Ser	His	Gln	Val	Thr	Gly	Asn	His	Gln	Gln	Pro		
	575					580					585					590		
50	cct	cag	cag	aac	act	gga	ttt	cca	cgt	agc	aat	cag	ccc	tat	tac	aat	2007	
	Pro	Gln	Gln	Asn	Thr	Gly	Phe	Pro	Arg	Ser	Asn	Gln	Pro	Tyr	Tyr	Asn		
					595				600						605			
55	agt	cgt	ggg	gtg	tct	cgt	gga	ggc	tcc	cgt	ggg	gct	aga	ggc	ttg	atg	2055	
	Ser	Arg	Gly	Val	Ser	Arg	Gly	Gly	Ser	Arg	Gly	Ala	Arg	Gly	Leu	Met		
				610					615					620				
	aat	gga	tac	cgg	ggc	cct	gcc	aat	gga	ttc	aga	gga	gga	tat	gat	ggg	2103	

EP 2 740 796 B1

	Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly	
	625 630 635	
5	tac cgc cct tca ttc tct aac act cca aac agt ggt tat aca cag tct Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser	2151
	640 645 650	
10	cag ttc agt gct ccc cgg gat tac tct ggc tat caa cgg gat gga tat Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr	2199
	655 660 665 670	
15	cag cag aat ttc aag cga ggc tct ggg cag agt gga cca cgg gga gcc Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala	2247
	675 680 685	
20	cca cga ggt cgt gga ggg ccc cca aga ccc aac aga ggg atg ccg caa Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln	2295
	690 695 700	
25	atg aac act cag caa gtg aat taa tctgattcac aggattatgt ttaatcgcca Met Asn Thr Gln Gln Val Asn	2349
	705	
30	aaaacacact ggccagtgtt ccataatatg ttaccagaag agttattatc tatttggttct	2409
35	ccctttcagg aaacttattg taaagggact gttttcatcc cataaagaca ggactacaat	2469
40	tgctcagcttt ctattacctg gatatggaag gaaactatgt ttactctgca tgttctgtcc	2529
45	taagcgtcat cttgagcctt gcacatgata ctcagattcc tcacccttgc ttaggagtaa	2589
50	aacaatatac tttacagggt gataataatc tccatagtta tttgaagtgg cttgaaaaag	2649
55	gcaagattga cttttatgac attggataaa atctacaaat cagccctcga gttattcaat	2709
	gataactgac aaactaaatt atttccctag aaaggaagat gaaaggagtg gagtgtggtt	2769
	tggcagaaca actgcatttc acagcttttc cagttaaatt ggagcactga acgttcagat	2829
	gcataccaaa ttatgcatgg gtcctaatac cacaataaag gctggctacc agctttgaca	2889
	cagcactggt catctggcca aacaactgtg gtaaaaaaca catgtaaaat gctttttaac	2949
	agctgatact gtataagaca aagccaagat gcaaaattag gctttgattg gcaacttttg	3009
	aaaaatatgc aacaaatatg ggatgtaatc cggatggccg cttctgtact taatgtgaaa	3069
	tatttagata cctttttgaa cacttaacag tttctttgag acaatgactt ttgtaaggat	3129
	tggtactatc tatcattcct tatgacatgt acattgtctg tcactaatcc ttggattttg	3189
	ctgtattgtc acctaaattg gtacaggtac tgatgaaaat ctctagtgga taatcataac	3249
	actctcggtc acatgttttt ccttcagctt gaaagctttt ttttaaaggg aaaagatacc	3309
	aaatgcctgc tgctaccacc cttttcaatt gctatctttt gaaaggcacc agtatgtgtt	3369
	ttagattgat ttccctgttt cagggaaatc acggacagta gtttcagttc tgatggtata	3429
	agcaaaaaca ataaaacgtt tataaaagtt gtatcttgaa aactgggtgt tcaacagcta	3489
	gcagcttatg tgattcacc catgccacgt tagtgtcaca aattttatgg tttatctcca	3549

EP 2 740 796 B1

	gcaacatttc	tctagtactt	gcacttatta	tcttttgtct	aatttaacct	taactgaatt	3609
	ctccgtttct	cctggaggca	tttatattca	gtgataattc	cttcccttag	atgcataggg	3669
5	agagtctcta	aatttgatgg	aaatggacac	ttgagtagtg	acttagcctt	atgtactctg	3729
	ttggaatttg	tgctagcagt	ttgagcacta	gttctgtgtg	cctaggaagt	taatgctgct	3789
	tattgtctca	ttctgacttc	atggagaatt	aatcccacct	ttaagcaaag	gctactaagt	3849
10	taatggattt	ttctgtgcag	aaattaaatt	ttattttcag	catttagccc	aggaattctt	3909
	ccagtaggtg	ctcagctatt	taaaaacaaa	actattctca	aacattcatc	attagacaac	3969
	tggagttttt	gctggttttg	taacctacca	aatggatag	gctgttgaac	attccacatt	4029
15	caaaagtttt	gtagggtggt	gggaaatggg	ggatcttcaa	tgtttatttt	aaaataaaat	4089
	aaaataagtt	cttgactttt	ctcatgtgtg	gttgtggtac	atcatattgg	aagggttaac	4149
	ctgttacttt	ggcaaatgag	tatttttttg	ctagcacctc	cccttgctg	ctttaaatga	4209
20	catctgcctg	ggatgtacca	caaccatatg	ttacctgtat	cttaggggaa	tggataaaat	4269
	atgtgtggtt	tactgggtaa	tccctagatg	atgtatgctt	gcagtcctat	ataaaactaa	4329
25	atgtgtctatc	tgtgtagaaa	ataatttcat	gacatttaca	atcaggactg	aagtaagttc	4389
	ttcacacagt	gacctctgaa	tcagtttcag	agaagggatg	ggggagaaaa	tgcttcttag	4449
	gttttgaact	tctatgcatt	agtgcagatg	ttgtgaatgt	gtaaagggtg	tcatagtttg	4509
30	actgtttcta	tgtatgtttt	ttcaaagaat	tgttcctttt	tttgaactat	aatttttctt	4569
	tttttggtta	ttttaccatc	acagtttaaa	tgtatatctt	ttatgtctct	actcagacca	4629
	tattttttaa	gggtgcctc	attatggggc	agagaacttt	tcaataagtc	tcattaagat	4689
35	ctgaatcttg	gttctaagca	ttctgtataa	tatgtgattg	cttgtcctag	ctgcagaagg	4749
	ccttttggtt	ggtcaaatgc	atatttttagc	agagtttcaa	ggaaatgatt	gtcacacatg	4809
	tcactgtagc	ctcttggtgt	agcaagctca	catacaaaat	acttttgtat	atgcataata	4869
40	taaatcatct	catgtggata	tgaaacttct	ttttttaa	ttaaaaaggt	agaatgttat	4929
	tgattacctt	gattagggca	gttttatttc	cagatcctaa	taattcctaa	aaaatatgga	4989
	aaagtttttt	ttcaatcatt	gtaccttgat	attaaaacaa	atatccttta	agtatttcta	5049
45	atcagtttagc	ttctacagtt	cttttgtctc	cttttatatg	cagctcttac	gtgggagact	5109
	tttccactta	aaggagacat	agaatgtgtg	cttattctca	gaaggttcat	taactgaggt	5169
	gatgagttaa	caactagttg	agcagtcagc	ttcctaagtg	ttttaggaca	ttgtttcatt	5229
50	atattttccg	tcatataact	agaggaagtg	gaatgcagat	aagtgccgaa	ttcaaaccct	5289
	tcatttttatg	tttaagctcc	tgaatctgca	ttccacttgg	gttgttttta	agcatttcta	5349
55	attttagttg	attataagtt	agatttcaca	gaatcagtat	tgcccttgat	cttgtccttt	5409
	ttatggagtt	aacggggagg	aagaccctc	aggaaaacga	aagtaaattg	ttaaggctca	5469

EP 2 740 796 B1

tcttcatacc tttttccatt ttgaatccta caaaaatact gcaaaagact agtgaatggt 5529

taaaattaca ctagattaaa taatatgaaa gtc 5562

5

<210> 2

<211> 709

<212> PRT

<213> Homo sapiens

10

<400> 2

15

20

25

30

35

40

45

50

55

EP 2 740 796 B1

	Met	Pro	Ser	Ala	Thr	Ser	His	Ser	Gly	Ser	Gly	Ser	Lys	Ser	Ser	Gly	
	1				5					10				15			
5	Pro	Pro	Pro	Pro	Ser	Gly	Ser	Ser	Gly	Ser	Glu	Ala	Ala	Ala	Gly	Ala	
				20					25					30			
10	Gly	Ala	Ala	Ala	Pro	Ala	Ser	Gln	His	Pro	Ala	Thr	Gly	Thr	Gly	Ala	
			35					40					45				
15	Val	Gln	Thr	Glu	Ala	Met	Lys	Gln	Ile	Leu	Gly	Val	Ile	Asp	Lys	Lys	
	50						55					60					
20	Leu	Arg	Asn	Leu	Glu	Lys	Lys	Lys	Gly	Lys	Leu	Asp	Asp	Tyr	Gln	Glu	
	65					70					75					80	
25	Arg	Met	Asn	Lys	Gly	Glu	Arg	Leu	Asn	Gln	Asp	Gln	Leu	Asp	Ala	Val	
					85					90					95		
30	Ser	Lys	Tyr	Gln	Glu	Val	Thr	Asn	Asn	Leu	Glu	Phe	Ala	Lys	Glu	Leu	
				100					105					110			
35	Gln	Arg	Ser	Phe	Met	Ala	Leu	Ser	Gln	Asp	Ile	Gln	Lys	Thr	Ile	Lys	
			115					120					125				
40	Lys	Thr	Ala	Arg	Arg	Glu	Gln	Leu	Met	Arg	Glu	Glu	Ala	Glu	Gln	Lys	
		130					135					140					
45	Arg	Leu	Lys	Thr	Val	Leu	Glu	Leu	Gln	Tyr	Val	Leu	Asp	Lys	Leu	Gly	
	145					150					155					160	
50	Asp	Asp	Glu	Val	Arg	Thr	Asp	Leu	Lys	Gln	Gly	Leu	Asn	Gly	Val	Pro	
					165					170					175		
55	Ile	Leu	Ser	Glu	Glu	Glu	Leu	Ser	Leu	Leu	Asp	Glu	Phe	Tyr	Lys	Leu	
				180					185					190			
60	Val	Asp	Pro	Glu	Arg	Asp	Met	Ser	Leu	Arg	Leu	Asn	Glu	Gln	Tyr	Glu	
			195					200					205				

EP 2 740 796 B1

	His	Ala	Ser	Ile	His	Leu	Trp	Asp	Leu	Leu	Glu	Gly	Lys	Glu	Lys	Pro	
	210						215					220					
5	Val	Cys	Gly	Thr	Thr	Tyr	Lys	Val	Leu	Lys	Glu	Ile	Val	Glu	Arg	Val	
	225					230					235					240	
10	Phe	Gln	Ser	Asn	Tyr	Phe	Asp	Ser	Thr	His	Asn	His	Gln	Asn	Gly	Leu	
				245						250					255		
15	Cys	Glu	Glu	Glu	Glu	Ala	Ala	Ser	Ala	Pro	Ala	Val	Glu	Asp	Gln	Val	
				260					265					270			
20	Pro	Glu	Ala	Glu	Pro	Glu	Pro	Ala	Glu	Glu	Tyr	Thr	Glu	Gln	Ser	Glu	
			275					280					285				
25	Val	Glu	Ser	Thr	Glu	Tyr	Val	Asn	Arg	Gln	Phe	Met	Ala	Glu	Thr	Gln	
	290						295					300					
30	Phe	Thr	Ser	Gly	Glu	Lys	Glu	Gln	Val	Asp	Glu	Trp	Thr	Val	Glu	Thr	
	305					310					315					320	
35	Val	Glu	Val	Val	Asn	Ser	Leu	Gln	Gln	Gln	Pro	Gln	Ala	Ala	Ser	Pro	
					325					330					335		
40	Ser	Val	Pro	Glu	Pro	His	Ser	Leu	Thr	Pro	Val	Ala	Gln	Ala	Asp	Pro	
				340					345					350			
45	Leu	Val	Arg	Arg	Gln	Arg	Val	Gln	Asp	Leu	Met	Ala	Gln	Met	Gln	Gly	
			355					360					365				
50	Pro	Tyr	Asn	Phe	Ile	Gln	Asp	Ser	Met	Leu	Asp	Phe	Glu	Asn	Gln	Thr	
	370						375					380					
55	Leu	Asp	Pro	Ala	Ile	Val	Ser	Ala	Gln	Pro	Met	Asn	Pro	Thr	Gln	Asn	
	385					390					395					400	
60	Met	Asp	Met	Pro	Gln	Leu	Val	Cys	Pro	Pro	Val	His	Ser	Glu	Ser	Arg	
					405					410					415		
65	Leu	Ala	Gln	Pro	Asn	Gln	Val	Pro	Val	Gln	Pro	Glu	Ala	Thr	Gln	Val	
				420					425					430			
70	Pro	Leu	Val	Ser	Ser	Thr	Ser	Glu	Gly	Tyr	Thr	Ala	Ser	Gln	Pro	Leu	
		435						440					445				
75	Tyr	Gln	Pro	Ser	His	Ala	Thr	Glu	Gln	Arg	Pro	Gln	Lys	Glu	Pro	Ile	

EP 2 740 796 B1

	450		455		460											
5	Asp 465	Gln	Ile	Gln	Ala	Thr 470	Ile	Ser	Leu	Asn	Thr 475	Asp	Gln	Thr	Thr	Ala 480
10	Ser	Ser	Ser	Leu	Pro 485	Ala	Ala	Ser	Gln	Pro 490	Gln	Val	Phe	Gln	Ala	Gly 495
15	Thr	Ser	Lys	Pro 500	Leu	His	Ser	Ser	Gly 505	Ile	Asn	Val	Asn	Ala	Ala	Pro 510
20	Phe	Gln	Ser	Met 515	Gln	Thr	Val	Phe	Asn 520	Met	Asn	Ala	Pro 525	Val	Pro	Pro
25	Val	Asn 530	Glu	Pro	Glu	Thr	Leu	Lys	Gln 535	Gln	Asn	Gln 540	Tyr	Gln	Ala	Ser
30	Tyr 545	Asn	Gln	Ser	Phe 550	Ser	Ser	Gln	Pro	His	Gln 555	Val	Glu	Gln	Thr	Glu 560
35	Leu	Gln	Gln	Glu	Gln 565	Leu	Gln	Thr	Val	Val 570	Gly	Thr	Tyr	His	Gly 575	Ser
40	Pro	Asp	Gln	Ser 580	His	Gln	Val	Thr	Gly 585	Asn	His	Gln	Gln	Pro 590	Pro	Gln
45	Gln	Asn	Thr 595	Gly	Phe	Pro	Arg	Ser 600	Asn	Gln	Pro	Tyr	Tyr 605	Asn	Ser	Arg
50	Gly	Val 610	Ser	Arg	Gly	Gly	Ser	Arg 615	Gly	Ala	Arg	Gly 620	Leu	Met	Asn	Gly
55	Tyr 625	Arg	Gly	Pro	Ala	Asn 630	Gly	Phe	Arg	Gly 635	Gly	Tyr	Asp	Gly	Tyr	Arg 640
60	Pro	Ser	Phe	Ser	Asn 645	Thr	Pro	Asn	Ser	Gly 650	Tyr	Thr	Gln	Ser	Gln	Phe 655
65	Ser	Ala	Pro	Arg	Asp 660	Tyr	Ser	Gly	Tyr 665	Gln	Arg	Asp	Gly	Tyr	Gln	Gln 670
70	Asn	Phe	Lys	Arg	Gly 675	Ser	Gly	Gln 680	Ser	Gly	Pro	Arg	Gly 685	Ala	Pro	Arg
75	Gly 690	Arg	Gly	Gly	Pro	Pro	Arg 695	Pro	Asn	Arg	Gly 700	Met	Pro	Gln	Met	Asn

EP 2 740 796 B1

Thr Gln Gln Val Asn
705

5 <210> 3
<211> 3553
<212> DNA
<213> Homo sapiens

10 <220>
<221> CDS
<222> (190)..(2274)
<223>

15 <400> 3

20

25

30

35

40

45

50

55

EP 2 740 796 B1

	cagagggctg ctggctggct aagtcctcc cgctcccgcc tctcgctca ctaggagcgg	60
	ctctcggtgc agcgggacag ggcgaagcgg cctgcgcca cggagcgcg gacactgccc	120
5	ggaagggacc gccacccttg cccctcagc tgcccactcg tgatttccag cggcctccgc	180
	gcgcgcacg atg ccc tcg gcc acc agc cac agc ggg agc ggc agc aag tcg	231
	Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser	
	1 5 10	
10	tcc gga ccg cca ccg ccg tcg ggt tcc tcc ggg agt gag gcg gcc gcg	279
	Ser Gly Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala	
	15 20 25 30	
15	gga gcc ggg gcc gcc gcg ccg gct tct cag cac ccc gca acc ggc acc	327
	Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr	
	35 40 45	
20	ggc gct gtc cag acc gag gcc atg aag cag att ctc ggg gtg atc gac	375
	Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp	
	50 55 60	
25	aag aaa ctt ccg aac ctg gag aag aaa aag ggt aag ctt gat gat tac	423
	Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr	
	65 70 75	
30	cag gaa cga atg aac aaa ggg gaa agg ctt aat caa gat cag ctg gat	471
	Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp	
	80 85 90	
35	gcc gtt tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca aaa	519
	Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys	
	95 100 105 110	
40	gaa tta cag agg agt ttc atg gca cta agt caa gat att cag aaa aca	567
	Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr	
	115 120 125	
45	ata aag aag aca gca cgt ccg gag cag ctt atg aga gaa gaa gct gaa	615
	Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu	
	130 135 140	
50	cag aaa cgt tta aaa act gta ctt gag cta cag tat gtt ttg gac aaa	663
	Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys	
	145 150 155	
55	ttg gga gat gat gaa gtg ccg act gac ctg aaa caa ggt ttg aat gga	711
	Leu Gly Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly	

EP 2 740 796 B1

	160				165				170								
5	gtg Val 175	cca Pro 175	ata Ile 175	ttg Leu 175	tcc Ser 180	gaa Glu 180	gag Glu 180	gag Glu 180	ttg Leu 185	tca Ser 185	ttg Leu 185	ttg Leu 185	gat Asp 185	gaa Glu 190	ttc Phe 190	tat Tyr 190	759
	aag Lys	cta Leu	gta Val	gac Asp	cct Pro 195	gaa Glu	cgg Arg	gac Asp	atg Met	agc Ser 200	ttg Leu	agg Arg	ttg Leu	aat Asn	gaa Glu	cag Gln	807
10	tat Tyr	gaa Glu	cat His	gcc Ala 210	tcc Ser	att Ile	cac His	ctg Leu	tgg Trp 215	gac Asp	ctg Leu	ctg Leu	gaa Glu	ggg Gly 220	aag Lys	gaa Glu	855
15	aaa Lys	cct Pro	gta Val	tgt Cys 225	gga Gly	acc Thr	acc Thr	tat Tyr 230	aaa Lys	gtt Val	cta Leu	aag Lys	gaa Glu	att Ile	gtt Val	gag Glu	903
	cgt Arg	gtt Val	ttt Phe	cag Gln	tca Ser	aac Asn	tac Tyr	ttt Phe	gac Asp	agc Ser	acc Thr	cac His	aac Asn	cac His	cag Gln	aat Asn	951
20	ggg Gly 255	ctg Leu	tgt Cys	gag Glu	gaa Glu	gaa Glu	gag Glu	gca Ala	gcc Ala	tca Ser	gca Ala	cct Pro	gca Ala	gtt Val	gaa Glu	gac Asp 270	999
25	cag Gln	gta Val	cct Pro	gaa Glu	gct Ala	gaa Glu	cct Pro	gag Glu	cca Pro	gca Ala	gaa Glu	gag Glu	tac Tyr	act Thr	gag Glu	caa Gln	1047
	agt Ser	gaa Glu	gtt Val	gaa Glu	tca Ser	aca Thr	gag Glu	tat Tyr	gta Val	aat Asn	aga Arg	cag Gln	ttc Phe	atg Met	gca Ala	gaa Glu	1095
30	aca Thr	cag Gln	ttc Phe	acc Thr	agt Ser	ggt Gly	gaa Glu	aag Lys	gag Glu	cag Gln	gta Val	gat Asp	gag Glu	tgg Trp	aca Thr	gtt Val	1143
35	gaa Glu	acg Thr	gtt Val	gag Glu	gtg Val	gta Val	aat Asn	tca Ser	ctc Leu	cag Gln	cag Gln	caa Gln	cct Pro	cag Gln	gct Ala	gca Ala	1191
	tcc Ser	cct Pro	tca Ser	gta Val	cca Pro	gag Glu	ccc Pro	cac His	tct Ser	ttg Leu	act Thr	cca Pro	gtg Val	gct Ala	cag Gln	gca Ala	1239
40	gat Asp	ccc Pro	ctt Leu	gtg Val	aga Arg	aga Arg	cag Gln	cga Arg	gta Val	caa Gln	gac Asp	ctt Leu	atg Met	gca Ala	caa Gln	atg Met	1287
45	cag Gln	ggt Gly	ccc Pro	tat Tyr	aat Asn	ttc Phe	ata Ile	cag Gln	gat Asp	tca Ser	atg Met	ctg Leu	gat Asp	ttt Phe	gaa Glu	aat Asn	1335
50	cag Gln	aca Thr	ctt Leu	gat Asp	cct Pro	gcc Ala	att Ile	gta Val	tct Ser	gca Ala	cag Gln	cct Pro	atg Met	aat Asn	cca Pro	aca Thr	1383
	caa Gln	aac Asn	atg Met	gac Asp	atg Met	ccc Pro	cag Gln	ctg Leu	gtt Val	tgc Cys	cct Pro	cca Pro	gtt Val	cat His	tct Ser	gaa Glu	1431
55	tct	aga	ctt	gct	cag	cct	aat	caa	gtt	cct	gta	caa	cca	gaa	gcg	aca	1479

EP 2 740 796 B1

	Ser 415	Arg	Leu	Ala	Gln	Pro 420	Asn	Gln	Val	Pro	Val 425	Gln	Pro	Glu	Ala	Thr 430	
5	cag Gln	gtt Val	cct Pro	ttg Leu	gta Val	tca Ser	tcc Ser	aca Thr	agt Ser	gag Glu	ggg Gly	tac Tyr	aca Thr	gca Ala	tct Ser	caa Gln	1527
					435					440						445	
10	ccc Pro	ttg Leu	tac Tyr	cag Gln	cct Pro	tct Ser	cat His	gct Ala	aca Thr	gag Glu	caa Gln	cga Arg	cca Pro	cag Gln	aag Lys	gaa Glu	1575
				450						455						460	
	cca Pro	att Ile	gat Asp	cag Gln	att Ile	cag Gln	gca Ala	aca Thr	atc Ile	tct Ser	tta Leu	aat Asn	aca Thr	gac Asp	cag Gln	act Thr	1623
			465					470						475			
15	aca Thr	gca Ala	tca Ser	tca Ser	tcc Ser	ctt Leu	cct Pro	gct Ala	gcg Ala	tct Ser	cag Gln	cct Pro	caa Gln	gta Val	ttt Phe	cag Gln	1671
		480						485				490					
20	gct Ala	ggg Gly	aca Thr	agc Ser	aaa Lys	cct Pro	tta Leu	cat His	agc Ser	agt Ser	gga Gly	atc Ile	aat Asn	gta Val	aat Asn	gca Ala	1719
	495					500					505					510	
25	gct Ala	cca Pro	ttc Phe	caa Gln	tcc Ser	atg Met	caa Gln	acg Thr	gtg Val	ttc Phe	aat Asn	atg Met	aat Asn	gcc Ala	cca Pro	gtt Val	1767
					515					520					525		
	cct Pro	cct Pro	gtt Val	aat Asn	gaa Glu	cca Pro	gaa Glu	act Thr	tta Leu	aaa Lys	cag Gln	caa Gln	aat Asn	cag Gln	tac Tyr	cag Gln	1815
				530					535					540			
30	gcc Ala	agt Ser	tat Tyr	aac Asn	cag Gln	agc Ser	ttt Phe	tct Ser	agt Ser	cag Gln	cct Pro	cac His	caa Gln	gta Val	gaa Glu	caa Gln	1863
			545					550					555				
35	aca Thr	gag Glu	ctt Leu	cag Gln	caa Gln	gaa Glu	cag Gln	ctt Leu	caa Gln	aca Thr	gtg Val	gtt Val	ggc Gly	act Thr	tac Tyr	cat His	1911
		560						565				570					
40	ggg Gly	tcc Ser	cca Pro	gac Asp	cag Gln	tcc Ser	cat His	caa Gln	gtg Val	act Thr	ggg Gly	aac Asn	cac His	cag Gln	cag Gln	cct Pro	1959
	575					580					585					590	
	cct Pro	cag Gln	cag Gln	aac Asn	act Thr	gga Gly	ttt Phe	cca Pro	cgt Arg	agc Ser	aat Asn	cag Gln	ccc Pro	tat Tyr	tac Tyr	aat Asn	2007
					595					600					605		
45	agt Ser	cgt Arg	ggg Gly	gtg Val	tct Ser	cgt Arg	gga Gly	ggc Gly	tcc Ser	cgt Arg	ggg Gly	gct Ala	aga Arg	ggc Gly	ttg Leu	atg Met	2055
				610					615					620			
50	aat Asn	gga Gly	tac Tyr	cgg Arg	ggc Gly	cct Pro	gcc Ala	aat Asn	gga Gly	ttc Phe	aga Arg	gga Gly	gga Gly	tat Tyr	gat Asp	ggg Gly	2103
			625					630					635				
	tac Tyr	cgc Arg	cct Pro	tca Ser	ttc Phe	tct Ser	aac Asn	act Thr	cca Pro	aac Asn	agt Ser	ggg Gly	tat Tyr	aca Thr	cag Gln	tct Ser	2151
		640					645					650					
55	cag Gln	ttc Phe	agt Ser	gct Ala	ccc Pro	cgg Arg	gat Asp	tac Tyr	tct Ser	ggc Gly	tat Tyr	caa Gln	cgg Arg	gat Asp	gga Gly	tat Tyr	2199
	655					660					665					670	

EP 2 740 796 B1

	cag cag aat ttc aag cga ggc tct ggg cag agt gga cca cgg gga gcc Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala 675 680 685	2247
5	cca cga ggt aat att ttg tgg tgg tga tcctagctcc taagtggagc Pro Arg Gly Asn Ile Leu Trp Trp 690	2294
10	ttctgttctg gccttggaag agctgttaat agtctgcatg ttaggaatac atttatcctt	2354
	tccagacttg ttgctaggga ttaaataaaa tgctctgttt ctaaaactta atcttggacc	2414
	caaattttta tttttgaatg atttaatttt ccctgttact atataaactg tcttgaaaac	2474
15	tagaacatat tctctttctca gaaaaagtgt ttttccaact gaaaattatt tttcaggtcc	2534
	taaaacctgc taaatgtttt taggaagtac ttactgaaac atttttgtaa gacatttttg	2594
	gaatgagatt gaacatttat ataaatttat tattcctctt tcattttttt gaaacatgcc	2654
20	tattatatatt tagggccaga caccctttaa tggccggata agccatagtt aacatttaga	2714
	gaaccattta gaagtgatag aactaatgga atttgcaatg ctttttggac ctctattagt	2774
	gatataaata tcaagttatt tctgactttt aaacaaaact cccaaattcc taacttattg	2834
25	agctatactt aaaaaaaatt acagggttag agagtttttt gtttttcttt tactgttgga	2894
	aaactacttc ccattttggc aggaagttaa cctatttaac aattagagct agcatttcat	2954
30	gtagtctgaa attctaaatg gttctctgat ttgaggaggg ttaaacaatca aacagggttc	3014
	ctctattggc cataacatgt ataaaatgtg tgtaaggag gaattacaac gtactttgat	3074
	ttgaatacta gtagaaaactg gccaggaaaa aggtacattt ttctaaaaat taatggatca	3134
35	cttggaatt actgacttga ctagaagtat caaaggatgt ttgcatgtga atgtgggtta	3194
	tgttctttcc caccttgtag catattcgat gaaagttgag ttaactgata gctaaaaatc	3254
	tgttttaaca gcatgtaaaa agttatttta tctgttaaaa gtcattatac agttttgaat	3314
40	gttatgtagt ttctttttta cagttaggt aataaggtct gttttcattc tgggtgctttt	3374
	attaattttg atagtatgat gttacttact actgaaatgt aagctagagt gtacactaga	3434
45	atgtaagctc catgagagca ggtaccttgt ctgtcttctc tgctgtatct attcccaacg	3494
	cttgatgatg gtgcctggca catagtaggc actcaataaa tatttggtga atgaatgaa	3553
	<210> 4	
	<211> 694	
50	<212> PRT	
	<213> Homo sapiens	
	<400> 4	
55		

EP 2 740 796 B1

Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
 1 5 10 15

5 Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala

10

15

20

25

30

35

40

45

50

55

EP 2 740 796 B1

	20	25	30
5	Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala 35 40 45		
10	Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys 50 55 60		
15	Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu 65 70 75 80		
20	Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val 85 90 95		
25	Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu 100 105 110		
30	Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys 115 120 125		
35	Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys 130 135 140		
40	Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly 145 150 155 160		
45	Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly Val Pro 165 170 175		
50	Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu 180 185 190		
55	Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu 195 200 205		
	His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro 210 215 220		
	Val Cys Gly Thr Thr Tyr Lys Val Leu Lys Glu Ile Val Glu Arg Val 225 230 235 240		
	Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu 245 250 255		
	Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp Gln Val 260 265 270		

EP 2 740 796 B1

	Pro	Glu	Ala	Glu	Pro	Glu	Pro	Ala	Glu	Glu	Tyr	Thr	Glu	Gln	Ser	Glu	
			275					280					285				
5	Val	Glu	Ser	Thr	Glu	Tyr	Val	Asn	Arg	Gln	Phe	Met	Ala	Glu	Thr	Gln	
		290					295					300					
	Phe	Thr	Ser	Gly	Glu	Lys	Glu	Gln	Val	Asp	Glu	Trp	Thr	Val	Glu	Thr	
10		305				310					315					320	
	Val	Glu	Val	Val	Asn	Ser	Leu	Gln	Gln	Gln	Pro	Gln	Ala	Ala	Ser	Pro	
					325					330					335		
15	Ser	Val	Pro	Glu	Pro	His	Ser	Leu	Thr	Pro	Val	Ala	Gln	Ala	Asp	Pro	
				340					345					350			
	Leu	Val	Arg	Arg	Gln	Arg	Val	Gln	Asp	Leu	Met	Ala	Gln	Met	Gln	Gly	
20			355					360					365				
	Pro	Tyr	Asn	Phe	Ile	Gln	Asp	Ser	Met	Leu	Asp	Phe	Glu	Asn	Gln	Thr	
		370					375					380					
25	Leu	Asp	Pro	Ala	Ile	Val	Ser	Ala	Gln	Pro	Met	Asn	Pro	Thr	Gln	Asn	
		385				390					395					400	
	Met	Asp	Met	Pro	Gln	Leu	Val	Cys	Pro	Pro	Val	His	Ser	Glu	Ser	Arg	
30					405					410					415		
	Leu	Ala	Gln	Pro	Asn	Gln	Val	Pro	Val	Gln	Pro	Glu	Ala	Thr	Gln	Val	
35				420					425					430			
	Pro	Leu	Val	Ser	Ser	Thr	Ser	Glu	Gly	Tyr	Thr	Ala	Ser	Gln	Pro	Leu	
			435					440					445				
40	Tyr	Gln	Pro	Ser	His	Ala	Thr	Glu	Gln	Arg	Pro	Gln	Lys	Glu	Pro	Ile	
		450					455					460					
	Asp	Gln	Ile	Gln	Ala	Thr	Ile	Ser	Leu	Asn	Thr	Asp	Gln	Thr	Thr	Ala	
45		465				470					475					480	
	Ser	Ser	Ser	Leu	Pro	Ala	Ala	Ser	Gln	Pro	Gln	Val	Phe	Gln	Ala	Gly	
				485						490					495		
50	Thr	Ser	Lys	Pro	Leu	His	Ser	Ser	Gly	Ile	Asn	Val	Asn	Ala	Ala	Pro	
				500					505					510			
55	Phe	Gln	Ser	Met	Gln	Thr	Val	Phe	Asn	Met	Asn	Ala	Pro	Val	Pro	Pro	
			515					520					525				

EP 2 740 796 B1

	Val	Asn	Glu	Pro	Glu	Thr	Leu	Lys	Gln	Gln	Asn	Gln	Tyr	Gln	Ala	Ser
	530						535					540				
5	Tyr	Asn	Gln	Ser	Phe	Ser	Ser	Gln	Pro	His	Gln	Val	Glu	Gln	Thr	Glu
	545					550					555					560
10	Leu	Gln	Gln	Glu	Gln	Leu	Gln	Thr	Val	Val	Gly	Thr	Tyr	His	Gly	Ser
					565					570					575	
15	Pro	Asp	Gln	Ser	His	Gln	Val	Thr	Gly	Asn	His	Gln	Gln	Pro	Pro	Gln
				580					585					590		
20	Gln	Asn	Thr	Gly	Phe	Pro	Arg	Ser	Asn	Gln	Pro	Tyr	Tyr	Asn	Ser	Arg
			595					600					605			
25	Gly	Val	Ser	Arg	Gly	Gly	Ser	Arg	Gly	Ala	Arg	Gly	Leu	Met	Asn	Gly
	610						615					620				
30	Tyr	Arg	Gly	Pro	Ala	Asn	Gly	Phe	Arg	Gly	Gly	Tyr	Asp	Gly	Tyr	Arg
	625					630					635					640
35	Pro	Ser	Phe	Ser	Asn	Thr	Pro	Asn	Ser	Gly	Tyr	Thr	Gln	Ser	Gln	Phe
					645					650					655	
40	Ser	Ala	Pro	Arg	Asp	Tyr	Ser	Gly	Tyr	Gln	Arg	Asp	Gly	Tyr	Gln	Gln
				660					665				670			
45	Asn	Phe	Lys	Arg	Gly	Ser	Gly	Gln	Ser	Gly	Pro	Arg	Gly	Ala	Pro	Arg
			675					680					685			
50	Gly	Asn	Ile	Leu	Trp	Trp										
	690															
	<210>	5														
	<211>	18														
	<212>	PRT														
	<213>	Homo sapiens														
	<400>	5														
55	Val	Phe	Asn	Met	Asn	Ala	Pro	Val	Pro	Pro	Val	Asn	Glu	Pro	Glu	Thr
	1				5					10					15	
	Leu	Lys														
60	<210>	6														
	<211>	5														
	<212>	PRT														
	<213>	Mus musculus														

EP 2 740 796 B1

<400> 6

Ser Tyr Gly Met Ser
1 5

5

<210> 7
<211> 14
<212> PRT
<213> Mus musculus

10

<400> 7

Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala
1 5 10

15

<210> 8
<211> 11
<212> PRT
<213> Mus musculus

20

<400> 8

Leu Ala Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
1 5 10

25

<210> 9
<211> 110
<212> PRT
<213> Mus musculus

30

<400> 9

Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala
1 5 10 15

35

Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met Ser Trp Val Arg Gln
20 25 30

40

Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly
35 40 45

45

Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
50 55 60

50

Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg
65 70 75 80

Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Ser Leu Ala Ser Tyr Tyr
85 90 95

55

Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
100 105 110

EP 2 740 796 B1

<210> 10
 <211> 15
 <212> PRT
 <213> Mus musculus
 5
 <400> 10
 Thr Met Thr Cys Gln Ala Ser Gln Gly Thr Ser Ile Asn Leu Asn
 1 5 10 15
 10
 <210> 11
 <211> 7
 <212> PRT
 <213> Mus musculus
 15
 <400> 11
 Gly Ala Ser Ser Leu Glu Asp
 1 5
 20
 <210> 12
 <211> 11
 <212> PRT
 <213> Mus musculus
 25
 <400> 12
 Leu Gln His Ser Tyr Leu Pro Pro Leu Thr Phe
 1 5 10
 30
 <210> 13
 <211> 113
 <212> PRT
 <213> Mus musculus
 35
 <400> 13
 Gly Ala Arg Cys Asp Val Gln Met Ile Gln Ser Pro Ser Ser Leu Ser
 1 5 10 15
 40
 Ala Ser Leu Gly Asp Ile Val Thr Met Thr Cys Gln Ala Ser Gln Gly
 20 25 30
 45
 Thr Ser Ile Asn Leu Asn Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro
 35 40 45
 50
 Lys Leu Leu Ile Tyr Gly Ala Ser Ser Leu Glu Asp Gly Val Pro Ser
 50 55 60
 55
 Arg Phe Ser Gly Ser Cys Phe Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80
 Ser Leu Glu Asp Glu Asp Met Ala Thr Tyr Phe Cys Leu Gln His Ser

EP 2 740 796 B1

85

90

95

5 Tyr Leu Pro Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

Arg

10 <210> 14
<211> 330
<212> DNA
<213> Mus musculus

15 <400> 14

gggggaggct tagtgaagcc tggagggtcc ctgaaactct cctgtgcagc ctctggattc 60
actttcagta gctatggcat gtcttgggtt cgccagactc cggagaagag gctggagtgg 120
gtcgcaacca ttagtagtgg tggtagttac acctactatc cagacagtgt gaagggtcga 180
ttcaccatct ccagagacaa tgccaagaac accctgtacc tgcaaagatg cagtctgagg 240
tctgaggaca cggccatgta ttactgtgca agcctggcct cctactactt tgactactgg 300
ggccaaggca ccactctcac agtctcctca 330

30 <210> 15
<211> 339
<212> DNA
<213> Mus musculus

35 <400> 15

ggtgccagat gtgatgtcca gatgattcag tctccatcct ccctgtctgc atctttggga 60
gacatagtca ccatgacttg ccaggcaagt cagggcacta gcattaattt aaactggttt 120
cagcaaaaac cagggaaagc tcctaagctc ctgatctatg gtgcaagcag cttggaagat 180
gggggtcccat caagggttcag tggcagttgt tttgggacag atttcactct caccatcagc 240
agcctggagg atgaagatat ggcaacttat ttctgtctac agcatagtta tctccctccg 300
ctcacgttcg gtgctgggac caagctggag ctgaaacgt 339

50 <210> 16
<211> 5
<212> PRT
<213> Mus musculus

<400> 16

55 Thr Tyr Asp Leu His
1 5

<210> 17

EP 2 740 796 B1

<211> 16
 <212> PRT
 <213> Mus musculus

5 <400> 17

Val Ile Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile Ser
 1 5 10 15

10 <210> 18
 <211> 11
 <212> PRT
 <213> Mus musculus

15 <400> 18

Asn Tyr Gly Tyr Ser Ala Trp Phe Ala Tyr Trp
 1 5 10

20 <210> 19
 <211> 111
 <212> PRT
 <213> Mus musculus

25 <400> 19

Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr
 1 5 10 15

30 Val Ser Gly Phe Ser Leu Thr Thr Tyr Asp Leu His Trp Val Arg Gln
 20 25 30

35 Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly
 35 40 45

40 Ser Thr Asp Tyr Asn Ala Ala Phe Ile Ser Arg Leu Ser Ile Ser Lys
 50 55 60

45 Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala
 65 70 75 80

Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Asn Tyr Gly Tyr Ser Ala
 85 90 95

50 Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
 100 105 110

<210> 20
 <211> 15
 55 <212> PRT
 <213> Mus musculus

<400> 20

EP 2 740 796 B1

Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser Asn
1 5 10 15

<210> 21
<211> 7
<212> PRT
<213> Mus musculus

<400> 21

Lys Val Ser Asn Arg Phe Ser
1 5

<210> 22
<211> 9
<212> PRT
<213> Mus musculus

<400> 22

Phe Gln Gly Ser His Val Pro Leu Thr
1 5

<210> 23
<211> 118
<212> PRT
<213> Mus musculus

<400> 23

EP 2 740 796 B1

	Pro	Ala	Ser	Ser	Ser	Asp	Val	Leu	Met	Thr	Gln	Thr	Pro	Leu	Ser	Leu	
	1				5					10					15		
5	Pro	Val	Ser	Leu	Gly	Asp	Gln	Ala	Ser	Ile	Ser	Cys	Arg	Ser	Ser	Gln	
				20					25					30			
10	Ser	Ile	Val	His	Ser	Asn	Gly	Asn	Thr	Tyr	Leu	Glu	Trp	Tyr	Leu	Gln	
			35					40					45				
15	Lys	Pro	Gly	Gln	Ser	Pro	Lys	Leu	Leu	Ile	Tyr	Lys	Val	Ser	Asn	Arg	
		50					55					60					
20	Phe	Ser	Gly	Val	Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	
	65					70				75						80	
25	Phe	Thr	Leu	Lys	Ile	Ser	Arg	Val	Glu	Ala	Glu	Asp	Leu	Gly	Val	Tyr	
					85					90					95		
30	Tyr	Cys	Phe	Gln	Gly	Ser	His	Val	Pro	Leu	Thr	Phe	Gly	Ala	Gly	Thr	
				100					105					110			
35	Lys	Leu	Glu	Leu	Lys	Arg											
				115													
40	<210> 24																
	<211> 333																
	<212> DNA																
	<213> Mus musculus																
45	<400> 24																
50	ggac	cctg	ggcc	tagt	gcag	cc	ctca	cagag	c	ctgt	ccat	ca	cctg	cacag	t	ctct	ggtttc
																	60
55	tcatt	gacta	cctat	gat	ttt	acact	gggt	cgcc	agt	ctc	cagg	aaagg	tctg	gagt	gg		120
60	ctggg	agtga	tatgg	agt	gg	tgga	agc	aca	gact	ata	atg	cag	cttt	cat	atcc	agact	g
																	180
65	agcat	cagca	aggaca	attc	caag	agc	caa	gtttt	cttta	aaat	gaac	ag	tctg	caag	ct		240
70	aatga	cacag	ccatat	atta	ctgt	gcc	aga	aact	acgg	ct	actc	gcct	g	gttt	gctt	ac	300
75	tgggg	ccta	ag	ggact	ctg	gt	cact	gtct	ct	gca							333
80	<210> 25																
	<211> 354																
	<212> DNA																
	<213> Mus musculus																
85	<400> 25																

EP 2 740 796 B1

cctgcttcca gcagtgatgt tttgatgacc caaactccac tctccctgcc tgtcagtctt 60
 ggagatcaag cctccatctc ttgcagatct agtcagagca ttgtacatag taatggaaac 120
 5 acctattttag aatgggtacct gcagaaacca ggccagtctc caaagctcct gatctacaaa 180
 gtttccaacc gattttctgg ggtcccagac aggttcagtg gcagtggatc agggacagat 240
 ttcacactca agatcagcag agtggaggct gaggatctgg gagtttatta ctgctttcaa 300
 10 ggttcacatg ttccgctcac gttcgggtgct gggaccaagc tggagctgaa acgt 354

<210> 26

<211> 148

15 <212> PRT

<213> Mus musculus

<400> 26

20 Met Glu Trp Ser Gly Val Phe Ile Phe Leu Leu Ser Gly Thr Ala Gly
 1 5 10 15
 Val Leu Ser Glu Val Gln Leu His Gln Phe Gly Ala Glu Leu Val Lys
 25 20 25 30
 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe
 35 40 45
 30 Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu
 50 55 60
 Glu Trp Ile Gly Asp Ile Asn Pro Asn Tyr Asp Ser Thr Ser Tyr Asn
 35 65 70 75 80
 Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser
 40 85 90 95
 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val
 100 105 110
 45 Tyr Tyr Cys Ala Arg Ser Arg Ser Tyr Asp Tyr Glu Gly Phe Ala Tyr
 115 120 125
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro
 50 130 135 140
 Pro Ser Val Tyr
 55 145

<210> 27

<211> 139

<212> PRT

EP 2 740 796 B1

<213> Mus musculus

<400> 27

```

5      Met Ser Val Leu Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr
      1          5          10          15

10     Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
      20          25          30

15     Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
      35          40          45

20     Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
      50          55          60

25     Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
      65          70          75          80

30     Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn
      85          90          95

35     Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp
      100         105         110

40     Ser Thr Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala
      115         120         125

45     Asp Ala Ala Pro Thr Val Ser Asn Pro Tyr Asp
      130         135

```

<210> 28

<211> 148

40 <212> PRT

<213> Mus musculus

<400> 28

45

50

55

EP 2 740 796 B1

	Met	Glu	Trp	Ser	Gly	Val	Phe	Ile	Phe	Leu	Leu	Ser	Gly	Thr	Ala	Gly	
	1				5					10					15		
5	Val	Leu	Ser	Glu	Val	Gln	Leu	His	Gln	Phe	Gly	Ala	Glu	Leu	Val	Lys	
				20					25					30			
10	Pro	Gly	Ala	Ser	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	
			35					40					45				
15	Thr	Asp	Tyr	Asn	Met	Asp	Trp	Val	Lys	Gln	Ser	His	Gly	Lys	Ser	Leu	
		50					55					60					
20	Glu	Trp	Ile	Gly	Asp	Ile	Asn	Pro	Asn	Tyr	Asp	Ser	Thr	Ser	Tyr	Asn	
	65					70					75					80	
25	Gln	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	
					85					90					95		
30	Thr	Ala	Tyr	Met	Glu	Leu	Arg	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	
				100					105					110			
35	Tyr	Tyr	Cys	Ala	Arg	Ser	Arg	Ser	Tyr	Asp	Tyr	Glu	Gly	Phe	Ala	Tyr	
			115					120					125				
40	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ala	Ala	Lys	Thr	Thr	Pro	
		130					135					140					
45	Pro	Ser	Val	Tyr													
	145																
50	<210>	29															
	<211>	132															
	<212>	PRT															
	<213>	Mus musculus															
55	<400>	29															
60	Ala	Val	Leu	Arg	Cys	Ser	Arg	Gly	Leu	Leu	Val	Ile	Trp	Ile	Ser	Asp	
	1				5					10					15		
65	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ala	Val	Thr	Ala	Gly	Glu	
				20					25					30			

EP 2 740 796 B1

	Lys	Val	Thr	Met	Ser	Cys	Lys	Ser	Ser	Gln	Ser	Leu	Leu	Trp	Ser	Val	
			35					40					45				
5	Asn	Gln	Lys	Asn	Tyr	Leu	Ser	Trp	Tyr	Gln	Gln	Lys	Gln	Arg	Gln	Pro	
		50					55					60					
10	Pro	Lys	Leu	Leu	Ile	Tyr	Gly	Ala	Ser	Ile	Arg	Glu	Ser	Trp	Val	Pro	
	65					70					75					80	
	Asp	Arg	Phe	Thr	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	
					85					90					95		
15	Ser	Asn	Val	His	Ala	Glu	Asp	Leu	Ala	Val	Tyr	Tyr	Cys	Gln	His	Asn	
				100					105					110			
20	His	Gly	Ser	Phe	Leu	Pro	Ser	Arg	Ser	Glu	Gln	Val	Pro	Ser	Trp	Arg	
				115				120					125				
	Ser	Asn	Asn	Arg													
25				130													
	<210> 30																
	<211> 148																
	<212> PRT																
30	<213> Mus musculus																
	<400> 30																
35	Met	Glu	Trp	Ser	Gly	Val	Phe	Ile	Phe	Leu	Leu	Ser	Gly	Thr	Ala	Gly	
	1				5					10					15		
	Val	Leu	Ser	Glu	Val	Gln	Leu	His	Gln	Phe	Gly	Ala	Glu	Leu	Val	Lys	
40				20					25					30			
	Pro	Gly	Ala	Ser	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	
			35					40					45				
45	Thr	Asp	Tyr	Asn	Met	Asp	Trp	Val	Lys	Gln	Ser	His	Gly	Lys	Ser	Leu	
		50					55					60					
50	Glu	Trp	Ile	Gly	Asp	Ile	Asn	Pro	Asn	Tyr	Asp	Ser	Thr	Ser	Tyr	Asn	
	65					70				75						80	
	Gln	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	
55					85					90					95		
	Thr	Ala	Tyr	Met	Glu	Leu	Arg	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	
				100					105					110			

EP 2 740 796 B1

Tyr Tyr Cys Ala Arg Ser Arg Ser Tyr Asp Tyr Glu Gly Phe Ala Tyr
 115 120 125

5 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro
 130 135 140

10 Pro Ser Val Tyr
 145

<210> 31
 <211> 117
 <212> PRT
 15 <213> Mus musculus

<400> 31

20 Arg Thr Thr Ser His Met Asp Ser Asp Ile Gln Leu Thr Gln Ser Pro
 1 5 10 15

25 Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg
 20 25 30

30 Ala Ser Gly Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln
 35 40 45

Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp
 50 55 60

35 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser
 65 70 75 80

40 Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys
 85 90 95

Gln His Phe Trp Ser Thr Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu
 100 105 110

45 Ile Lys Gln Ser Asp
 115

50 <210> 32
 <211> 148
 <212> PRT
 <213> Mus musculus

<400> 32

55 Met Glu Trp Ser Gly Val Phe Ile Phe Leu Leu Ser Gly Thr Ala Gly
 1 5 10 15

EP 2 740 796 B1

	Val	Leu	Ser	Glu	Val	Gln	Leu	His	Gln	Phe	Gly	Ala	Glu	Leu	Val	Lys	
				20					25					30			
5	Pro	Gly	Ala	Ser	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	
			35					40					45				
10	Thr	Asp	Tyr	Asn	Met	Asp	Trp	Val	Lys	Gln	Ser	His	Gly	Lys	Ser	Leu	
		50					55					60					
15	Glu	Trp	Ile	Gly	Asp	Ile	Asn	Pro	Asn	Tyr	Asp	Ser	Thr	Ser	Tyr	Asn	
	65					70					75					80	
20	Gln	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	
					85					90					95		
25	Thr	Ala	Tyr	Met	Glu	Leu	Arg	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	
				100					105					110			
30	Tyr	Tyr	Cys	Ala	Arg	Ser	Arg	Ser	Tyr	Asp	Tyr	Glu	Gly	Phe	Ala	Tyr	
			115					120					125				
35	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ala	Ala	Lys	Thr	Thr	Pro	
		130					135					140					
40	Pro	Ser	Val	Tyr													
	145																
45	<210>	33															
	<211>	94															
	<212>	PRT															
	<213>	Mus musculus															
50	<400>	33															
55	Ser	Gly	Asp	Arg	Val	Ser	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Ser	Ile	Ser	
	1				5					10					15		
60	Asn	Tyr	Leu	His	Trp	Tyr	Gln	Gln	Lys	Ser	His	Glu	Ser	Pro	Arg	Leu	
				20					25					30			
65	Leu	Ile	Lys	Tyr	Ala	Ser	Gln	Ser	Ile	Ser	Gly	Ile	Pro	Ser	Arg	Phe	
			35					40					45				
70	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Ser	Ile	Asn	Ser	Val	
	50						55					60					
75	Glu	Thr	Glu	Asp	Phe	Gly	Met	Tyr	Phe	Cys	Gln	Gln	Ser	Asn	Ser	Trp	
	65					70					75					80	

EP 2 740 796 B1

Pro Tyr Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys Gln
85 90

<210> 34
<211> 148
<212> PRT
<213> Mus musculus

<400> 34

Met Glu Trp Ser Gly Val Phe Ile Phe Leu Leu Ser Gly Thr Ala Gly
1 5 10 15

Val Leu Ser Glu Val Gln Leu His Gln Phe Gly Ala Glu Leu Val Lys
20 25 30

Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu
50 55 60

Glu Trp Ile Gly Asp Ile Asn Pro Asn Tyr Asp Ser Thr Ser Tyr Asn
65 70 75 80

Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser
85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val
100 105 110

Tyr Tyr Cys Ala Arg Ser Arg Ser Tyr Asp Tyr Glu Gly Phe Ala Tyr
115 120 125

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro
130 135 140

Pro Ser Val Tyr
145

<210> 35
<211> 105
<212> PRT
<213> Mus musculus

<400> 35

EP 2 740 796 B1

	Gly	Leu	Phe	Cys	Ser	Val	Glu	Arg	Cys	His	Tyr	Gln	Leu	Gln	Ser	Ser	
	1				5					10					15		
5		Gln	Asn	Leu	Leu	Ser	Ile	Val	Asn	Arg	Tyr	His	Tyr	Met	Ser	Gly	Asn
					20					25					30		
10	Pro	Pro	Lys	Leu	Leu	Val	Tyr	Pro	Ala	Leu	Leu	Ile	Tyr	Glu	Ala	Ser	
			35					40					45				
15	Ile	Thr	Lys	Ser	Cys	Val	Pro	Asp	Arg	Phe	Thr	Arg	Ser	Gly	Ser	Gly	
		50					55					60					
20	Thr	Asn	Phe	Thr	Leu	Thr	Ile	Asn	Phe	Val	His	Ala	Asp	Asp	Leu	Ile	
	65					70					75					80	
	Phe	Tyr	Tyr	Cys	Gln	His	Asn	Arg	Gly	Ser	Phe	Leu	Pro	Ser	Ser	Ser	
					85					90					95		
25	Val	Gln	Val	Pro	Arg	Arg	Arg	Ser	Asn								
				100					105								
30	<210> 36																
	<211> 100																
	<212> PRT																
	<213> Mus musculus																
	<400> 36																
35																	
40																	
45																	
50																	
55																	

EP 2 740 796 B1

	Asp	Ile	Leu	Gln	Ala	Ser	Gly	Tyr	Ser	Phe	Thr	Gly	Tyr	Thr	Met	Asn
	1				5					10					15	
5	Trp	Val	Lys	Gln	Ser	His	Gly	Lys	Asn	Leu	Glu	Trp	Ile	Gly	Leu	Ile
				20					25					30		
10	Asn	Pro	Tyr	Asn	Gly	Gly	Thr	Ser	Tyr	Asn	Gln	Lys	Phe	Lys	Gly	Lys
			35					40					45			
15	Ala	Thr	Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr	Met	Glu	Leu
		50					55					60				
20	Leu	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	Trp
	65					70					75					80
25	Gly	Val	Trp	Ser	Ala	Met	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr
					85					90					95	
30	Val	Ser	Ser	Lys												
				100												
	<210> 37															
	<211> 90															
	<212> PRT															
	<213> Mus musculus															
	<400> 37															
35	Asp	Arg	Val	Ser	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Asn	Val	Arg	Thr	Ala
	1				5					10					15	
40	Val	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Arg	Gln	Ser	Pro	Lys	Ala	Leu	Ile
				20					25					30		
45	Tyr	Leu	Ala	Ser	Asn	Arg	Asp	Thr	Gly	Leu	Pro	Asp	Arg	Phe	Pro	Gly
			35					40					45			
50	Arg	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Asn	Ile	Thr	Asn	Val	Gln	Ser
		50					55					60				
55	Glu	Asp	Leu	Glu	Asp	Tyr	Phe	Cys	Leu	Gln	His	Cys	Asn	Tyr	Pro	Asn
	65					70					75					80
	Glu	Phe	Arg	Gly	Cys	Thr	Lys	Val	Pro	Ile						
					85					90						
	<210> 38															
	<211> 116															
	<212> PRT															

EP 2 740 796 B1

<213> Mus musculus

<400> 38

```

5      Leu Gln Glu Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys
      1          5          10          15

10     Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met Gln
      20          25          30

15     Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile
      35          40          45

20     Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Thr Gln Lys Phe Lys Gly Lys
      50          55          60

25     Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu
      65          70          75

30     Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly
      85          90          95

35     Glu Tyr Gly Asn Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr
      100         105         110

40     Val Ser Ser Asn
      115

```

35 <210> 39
 <211> 100
 <212> PRT
 <213> Mus musculus

40 <400> 39

45

50

55

EP 2 740 796 B1

	Thr	Ser	Asp	Ala	Ser	Leu	Gly	Glu	Arg	Val	Thr	Ile	Thr	Cys	Lys	Ala
	1				5					10					15	
5	Ser	Gln	Asp	Ile	Asn	Ser	Tyr	Leu	Ser	Trp	Phe	Gln	Gln	Lys	Pro	Gly
				20					25					30		
10	Lys	Ser	Pro	Lys	Thr	Leu	Ile	Tyr	Arg	Ala	Asn	Arg	Leu	Val	Asp	Gly
			35					40					45			
15	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Gln	Asp	Tyr	Ser	Leu
		50					55					60				
20	Thr	Ile	Ser	Ser	Leu	Glu	Tyr	Glu	Asp	Met	Gly	Ile	Tyr	Tyr	Cys	Leu
	65					70					75					80
25	Gln	Tyr	Asp	Glu	Phe	Pro	Leu	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu
					85					90					95	
30	Ile	Lys	Gln	Lys												
				100												
	<210> 40															
	<211> 108															
	<212> PRT															
	<213> Mus musculus															
	<400> 40															
35	Ala	Trp	Leu	Ser	Gln	Leu	Ser	Cys	Thr	Ala	Ser	Gly	Phe	Asn	Ile	Lys
	1				5					10					15	
40	Asp	Thr	Tyr	Met	His	Trp	Val	Lys	Gln	Arg	Pro	Glu	Gln	Gly	Leu	Glu
				20					25					30		
45	Trp	Ile	Gly	Arg	Ile	Asp	Pro	Ala	Asn	Gly	Asn	Thr	Lys	Tyr	Asp	Pro
			35					40					45			
50	Lys	Phe	Gln	Gly	Lys	Ala	Thr	Ile	Thr	Ala	Asp	Thr	Ser	Ser	Asn	Thr
		50					55					60				
55	Ala	Tyr	Leu	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	Tyr
	65					70					75					80
	Tyr	Cys	Ala	Arg	Pro	Ile	His	Tyr	Tyr	Tyr	Gly	Ser	Ser	Leu	Ala	Tyr
					85					90					95	
	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	Lys				
				100					105							

EP 2 740 796 B1

<210> 41
 <211> 104
 <212> PRT
 <213> Mus musculus

5

<400> 41

10

Glu Phe His Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg
 1 5 10 15

15

Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr
 20 25 30

20

Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser
 35 40 45

25

Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg
 50 55 60

Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala
 65 70 75 80

30

Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Gly Arg Ser Glu Val
 85 90 95

Val Pro Ser Trp Arg Ser Asn Lys
 100

35

<210> 42
 <211> 109
 <212> PRT
 <213> Mus musculus

40

<400> 42

Pro Arg Ala Ser Leu Gly Val Ser Glu Thr Leu Leu Cys Thr Ser Gly
 1 5 10 15

45

Phe Thr Phe Thr Asp Tyr Tyr Met Ser Trp Val Arg Gln Pro Pro Gly
 20 25 30

50

Lys Ala Leu Glu Trp Leu Gly Phe Ile Arg Asn Lys Ala Asn Gly Tyr
 35 40 45

55

EP 2 740 796 B1

	Thr	Thr	Glu	Tyr	Ser	Ala	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	
	50						55					60					
5	Asp	Asn	Ser	Gln	Ser	Ile	Leu	Tyr	Leu	Gln	Met	Asn	Thr	Leu	Arg	Ala	
	65					70					75					80	
10	Glu	Asp	Ser	Ala	Thr	Tyr	Tyr	Cys	Ala	Arg	Ala	Asn	Trp	Ala	Phe	Asp	
					85					90					95		
15	Tyr	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	Lys				
				100					105								
	<210> 43																
	<211> 94																
	<212> PRT																
	<213> Mus musculus																
20	<400> 43																
25	Ser	Gly	Asp	Arg	Val	Ser	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Ser	Ile	Ser	
	1				5					10					15		
30	Asn	Tyr	Leu	His	Trp	Tyr	Gln	Gln	Lys	Ser	His	Glu	Ser	Pro	Arg	Leu	
				20					25					30			
35	Leu	Ile	Lys	Tyr	Ala	Ser	Gln	Ser	Ile	Ser	Gly	Ile	Pro	Ser	Arg	Phe	
			35					40					45				
40	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Ser	Ile	Asn	Ser	Val	
	50						55					60					
45	Glu	Thr	Glu	Asp	Phe	Gly	Met	Tyr	Phe	Cys	Gln	Gln	Ser	Asn	Ser	Trp	
	65					70					75					80	
50	Pro	Tyr	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Gln			
					85					90							
55	<210> 44																
	<211> 111																
	<212> PRT																
	<213> Mus musculus																
50	<400> 44																

EP 2 740 796 B1

Pro Ala Cys Leu Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser
1 5 10 15

5 Gly Phe Thr Phe Thr Asp Tyr Tyr Met Ser Trp Val Arg Gln Pro Pro
20 25 30

10 Gly Lys Ala Leu Glu Trp Leu Gly Phe Ile Arg Asn Lys Ala Asn Gly
35 40 45

15 Tyr Thr Thr Glu Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser
50 55 60

20 Arg Asp Asn Ser Gln Ser Ile Leu Tyr Leu Gln Met Asn Thr Leu Arg
65 70 75 80

Ala Glu Asp Ser Ala Thr Tyr Tyr Cys Ala Arg Ala Pro Leu Leu Tyr
85 90 95

25 Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser
100 105 110

30 <210> 45
<211> 102
<212> PRT
<213> Mus musculus

35 <400> 45

40

45

50

55

EP 2 740 796 B1

	Arg	Leu	Pro	Phe	Tyr	Ser	Leu	Glu	Gln	Arg	Ala	Thr	Ile	Ser	Tyr	Arg	
	1				5					10					15		
5	Ala	Ser	Lys	Asn	Val	Ser	Thr	Ser	Gly	Tyr	Ser	Tyr	Met	His	Trp	Asn	
				20					25					30			
10	Gln	Gln	Lys	Pro	Gly	Gln	Pro	Pro	Lys	Leu	Leu	Ile	Tyr	Leu	Val	Ser	
			35					40					45				
15	Asn	Leu	Glu	Ser	Gly	Val	Pro	Ala	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	
	50						55					60					
20	Thr	Asp	Phe	Thr	Leu	Asn	Ile	His	Pro	Val	Glu	Glu	Glu	Asp	Ala	Ala	
	65					70					75				80		
25	Thr	Tyr	Tyr	Cys	Gln	His	Ile	Arg	Glu	Leu	Thr	Arg	Ser	Glu	Leu	Val	
				85						90					95		
30	Pro	Ser	Trp	Lys	Ser	Asn											
				100													
	<210> 46																
	<211> 101																
	<212> PRT																
	<213> Mus musculus																
	<400> 46																
35	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr	Trp	Met	His	
	1				5					10					15		
40	Trp	Val	Lys	Gln	Arg	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Ile	Gly	Met	Ile	
				20					25					30			
45	Asp	Pro	Ser	Asn	Ser	Glu	Thr	Arg	Leu	Asn	Gln	Lys	Phe	Lys	Asp	Lys	
			35					40					45				
50	Ala	Thr	Leu	Asn	Val	Asp	Lys	Ser	Ser	Asn	Thr	Ala	Tyr	Met	Gln	Leu	
	50						55					60					
55	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	Gly	
	65					70					75				80		
60	Leu	Arg	His	Tyr	Trp	Tyr	Phe	Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	
					85					90					95		
65	Thr	Val	Ser	Ser	Lys												
					100												

EP 2 740 796 B1

<210> 47
 <211> 99
 <212> PRT
 <213> Mus musculus

5

<400> 47

10

Thr Ile Leu Trp Arg Glu Gly Pro Phe Ser Tyr Arg Ala Ser Lys Ser
 1 5 10 15

15

Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Asn Gln Gln Lys Pro
 20 25 30

20

Gly Gln Pro Pro Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser
 35 40 45

Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 50 55 60

25

Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys
 65 70 75 80

Gln His Ile Arg Glu Leu Thr Arg Ser Glu Glu Val Pro Ser Trp Arg
 85 90 95

30

Ser Asn Lys

35

<210> 48
 <211> 330
 <212> PRT
 <213> Homo sapiens

<400> 48

40

45

50

55

EP 2 740 796 B1

	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	
	1				5					10					15		
5	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	
				20					25					30			
10	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	
			35					40					45				
15	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	
	50						55					60					
20	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	
	65					70					75					80	
25	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	
				85						90					95		
30	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	
				100					105					110			
35	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	
				115				120					125				
40	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	
		130					135					140					
45	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	
	145					150					155					160	
50	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	
				165						170					175		
55	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	
				180				185					190				
60	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	
			195				200						205				
65	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	
		210					215					220					
70	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu	
	225					230					235					240	

EP 2 740 796 B1

	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	
					245					250					255		
5	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	
				260					265					270			
10	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	
			275					280					285				
15	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	
		290					295					300					
20	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	
	305					310					315					320	
25	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys							
					325					330							
	<210> 49																
	<211> 106																
	<212> PRT																
	<213> Homo sapiens																
	<400> 49																
30	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	
	1				5					10					15		
35	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	
				20					25					30			
40	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	
			35					40					45				
45	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	
		50					55					60					
50	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	
	65					70					75					80	
55	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	
					85					90					95		
	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys							
					100				105								
	<210> 50																
	<211> 11																
	<212> PRT																

EP 2 740 796 B1

<213> Mus musculus

<400> 50

5 Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn
 1 5 10

<210> 51

<211> 7

10 <212> PRT

<213> Mus musculus

<400> 51

15 Trp Ala Ser Thr Arg Glu Ser
 1 5

<210> 52

<211> 9

20 <212> PRT

<213> Mus musculus

<400> 52

25 Gln Gln Tyr Tyr Ser Tyr Pro Phe Thr
 1 5

<210> 53

<211> 115

30 <212> PRT

<213> Mus musculus

<400> 53

35 Gly Val Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Leu
 1 5 10 15

40 Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr
 20 25 30

 Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly
 35 40 45

45 Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly
 50 55 60

50 Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
 65 70 75 80

55 Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln
 85 90 95

Gln Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu

EP 2 740 796 B1

100

105

110

Ile Lys Arg
115

5

<210> 54

<211> 345

<212> DNA

10

<213> Mus musculus

<400> 54

15

ggggtcattg tgatgtcaca gtctccatcc tccctagctg tgtcacttgg agagaagggtt 60

actatgagct gcaagtccag tcagagcctt ttatatagta gcaatcaaaa gaactacttg 120

gcctgggtacc agcagaaaacc agggcagtct cctaaactgc tgatttactg ggcattccact 180

20

agggaaatctg ggggccctga tcgcttcaca ggcagtggat ctgggacaga ttctactctc 240

accatcagca gtgtgaaggc tgaagacctg gcagtttatt actgtcagca atattatagc 300

tatccattca cggttcggctc ggggacaaaag ttggaaataa aacgt 345

25

<210> 55

<211> 4

<212> PRT

<213> Gallus gallus

30

<400> 55

His Ser Met Phe
1

35

<210> 56

<211> 17

<212> PRT

<213> Gallus gallus

40

<400> 56

Gly Ile Tyr Gly Val Gly Arg Ser Ile Arg Tyr Gly Ser Ala Val Lys
1 5 10 15

45

Gly

<210> 57

50

<211> 20

<212> PRT

<213> Gallus gallus

<400> 57

55

Ser Gly Tyr Phe Ser Asn Ser Arg Tyr Trp Asp Ser Gly Ala Tyr Phe
1 5 10 15

EP 2 740 796 B1

Ile Asp Ala Trp
20

5 <210> 58
<211> 127
<212> PRT
<213> Gallus gallus

10 <400> 58

Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly
1 5 10 15

15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Arg Ser His
20 25 30

20 Ser Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val
35 40 45

Ala Gly Ile Tyr Gly Val Gly Arg Ser Ile Arg Tyr Gly Ser Ala Val
50 55 60

25 Lys Gly Arg Ala Thr Met Ser Arg Asp Asn Gly Gln Ser Thr Val Arg
65 70 75 80

30 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

35 Ala Lys Ser Gly Tyr Phe Ser Asn Ser Arg Tyr Trp Asp Ser Gly Ala
100 105 110

Tyr Phe Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile Val Ser
115 120 125

40 <210> 59
<211> 8
<212> PRT
<213> Gallus gallus

45 <400> 59

50 Ser Gly Gly Tyr Ser Asn Tyr Gly
1 5

<210> 60
<211> 7
<212> PRT
<213> Gallus gallus

55 <400> 60

EP 2 740 796 B1

Tyr Asn Asp Lys Arg Pro Ser
1 5

5
<210> 61
<211> 12
<212> PRT
<213> Gallus gallus

10
<400> 61

Gly Gly Tyr Asp Ser Ser Thr Asp Ala Gly Ile Phe
1 5 10

15
<210> 62
<211> 103
<212> PRT
<213> Gallus gallus

20
<400> 62

Ala Leu Thr Gln Pro Ala Ser Val Ser Ala Asn Pro Gly Glu Thr Val
1 5 10 15

25
Glu Ile Thr Cys Ser Gly Gly Tyr Ser Asn Tyr Gly Trp Tyr Gln Gln
20 25 30

30
Lys Ser Pro Gly Ser Ala Pro Val Thr Val Ile Tyr Tyr Asn Asp Lys
35 40 45

Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ser Lys Ser Gly Ser
50 55 60

35
Thr Ala Thr Leu Thr Ile Thr Gly Val Gln Ala Glu Asp Glu Ala Val
65 70 75 80

40
Tyr Phe Cys Gly Gly Tyr Asp Ser Ser Thr Asp Ala Gly Ile Phe Gly
85 90 95

45
Ala Gly Thr Thr Leu Thr Val
100

50
<210> 63
<211> 127
<212> PRT
<213> Gallus gallus

<400> 63

55

EP 2 740 796 B1

	Ala	Val	Thr	Leu	Asp	Glu	Ser	Gly	Gly	Gly	Leu	Gln	Thr	Pro	Gly	Gly
	1				5					10					15	
5	Ala	Leu	Ser	Leu	Val	Cys	Lys	Ala	Ser	Gly	Phe	Thr	Phe	Arg	Ser	His
				20					25					30		
	Ser	Met	Phe	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Tyr	Val
10			35					40					45			
	Ala	Gly	Ile	Tyr	Gly	Val	Gly	Arg	Ser	Ile	Arg	Tyr	Gly	Ser	Ala	Val
		50					55					60				
15	Lys	Gly	Arg	Ala	Thr	Met	Ser	Arg	Asp	Asn	Gly	Gln	Ser	Thr	Val	Arg
	65					70					75					80
	Leu	Gln	Leu	Asn	Asn	Leu	Arg	Ala	Glu	Asp	Thr	Gly	Thr	Tyr	Tyr	Cys
20					85					90					95	
	Ala	Lys	Ser	Gly	Tyr	Phe	Ser	Asn	Arg	Arg	Tyr	Trp	Asp	Ser	Gly	Ala
25				100					105					110		
	Tyr	Phe	Ile	Asp	Ala	Trp	Gly	His	Gly	Thr	Glu	Val	Ile	Val	Ser	
			115					120					125			

30 <210> 64
 <211> 7
 <212> PRT
 <213> Gallus gallus

35 <400> 64

Glu Asn Asp Lys Arg Pro Ser
1 5

40

<210>	65
<211>	103
<212>	PRT
<213>	Gallus gallus

45 <400> 65

50

55

EP 2 740 796 B1

[illegible]

EP 2 740 796 B1

Asn Ala Tyr Val Gly Arg Gly Cys Cys Phe Ser Tyr Ser Ile Asp Ala
1 5 10 15

5 Trp

<210> 69

<211> 124

<212> PRT

10 <213> Gallus gallus

<400> 69

15 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly
1 5 10 15

Gly Leu Ser Leu Val Cys Lys Gly Ser Gly Phe Thr Phe Ser Ser Phe
20 25 30

20

Gly Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Phe Val
35 40 45

25 Ala Ser Ile Ser Asp Asn Gly Arg Ser Thr Tyr Tyr Gly Ser Ala Val
50 55 60

30 Lys Gly Arg Ala Thr Ile Ser Arg Asp Asp Gly Gln Ser Thr Val Arg
65 70 75 80

Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr Tyr Cys
85 90 95

35

Ala Lys Asn Ala Tyr Val Gly Arg Gly Cys Cys Phe Ser Tyr Ser Ile
100 105 110

40 Asp Ala Trp Gly His Gly Thr Glu Val Ile Val Ser
115 120

<210> 70

<211> 11

45 <212> PRT

<213> Gallus gallus

<400> 70

50 Ser Gly Gly Gly Ser Ser Ser Asp Ala Tyr Gly
1 5 10

<210> 71

<211> 7

55 <212> PRT

<213> Gallus gallus

<400> 71

EP 2 740 796 B1

Asn Gly Ser Asn Arg Pro Ser
1 5

5
<210> 72
<211> 12
<212> PRT
<213> Gallus gallus

10
<400> 72

Gly Ser Thr Asp Thr Ser Thr Ser Val Gly Ile Phe
1 5 10

15
<210> 73
<211> 106
<212> PRT
<213> Gallus gallus

20
<400> 73

Ala Leu Thr Gln Pro Ala Ser Val Ser Val Asn Pro Gly Glu Thr Val
1 5 10 15

25
Lys Ile Thr Cys Ser Gly Gly Gly Ser Ser Ser Asp Ala Tyr Gly Trp
20 25 30

30
Tyr Gln Gln Lys Ser Pro Gly Ser Ala Pro Val Thr Leu Ile Tyr Asn
35 40 45

Gly Ser Asn Arg Pro Ser His Ile Pro Ser Arg Phe Ser Gly Ser Thr
50 55 60

35
Ser Gly Ser Thr Asn Thr Leu Thr Ile Thr Gly Val Gln Val Glu Asp
65 70 75 80

40
Glu Ala Ile Tyr Phe Cys Gly Ser Thr Asp Thr Ser Thr Ser Val Gly
85 90 95

45
Ile Phe Gly Ala Gly Thr Thr Leu Thr Val
100 105

50
<210> 74
<211> 4
<212> PRT
<213> Gallus gallus

<400> 74

55
Tyr Gly Met Gly
1

<210> 75
<211> 16

EP 2 740 796 B1

<212> PRT
<213> Gallus gallus

<400> 75

5
Ala Ile Arg Lys Asp Gly Ser Thr Asn Tyr Gly Pro Ala Val Lys Gly
1 5 10 15

<210> 76
<211> 14
<212> PRT
<213> Gallus gallus

<400> 76

15
Arg Ser His Thr Gly Val Asn Ala Ala Lys Ile Asp Ala Trp
1 5 10

<210> 77
<211> 120
<212> PRT
<213> Gallus gallus

<400> 77

25
Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly
1 5 10 15

30
Ala Val Ser Leu Val Cys Lys Gly Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

35
Gly Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val
35 40 45

40
Ala Ala Ile Arg Lys Asp Gly Ser Thr Asn Tyr Gly Pro Ala Val Lys
50 55 60

Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg Leu
65 70 75 80

45
Gln Leu Ser Asn Leu Arg Ala Glu Asp Thr Ala Thr Tyr Tyr Cys Ala
85 90 95

50
Lys Arg Ser His Thr Gly Val Asn Ala Ala Lys Ile Asp Ala Trp Gly
100 105 110

Arg Gly Thr Glu Val Ile Val Ser
115 120

55
<210> 78
<211> 8
<212> PRT

EP 2 740 796 B1

<213> Gallus gallus

<400> 78

5 Ser Gly Ala Ser His Asn Tyr Gly
1 5

<210> 79

<211> 7

10 <212> PRT

<213> Gallus gallus

<400> 79

15 Ser Asn Asp Lys Arg Pro Ser
1 5

<210> 80

<211> 10

20 <212> PRT

<213> Gallus gallus

<400> 80

25 Gly Gly Tyr Asn Ile Tyr Gly Pro Thr Phe
1 5 10

<210> 81

<211> 101

30 <212> PRT

<213> Gallus gallus

<400> 81

35

40

45

50

55

EP 2 740 796 B1

	Ala	Leu	Thr	Gln	Pro	Ala	Ser	Val	Ser	Ala	Asn	Pro	Gly	Glu	Thr	Val
	1				5					10					15	
5	Lys	Ile	Thr	Cys	Ser	Gly	Ala	Ser	His	Asn	Tyr	Gly	Trp	Phe	Gln	Gln
				20					25					30		
	Lys	Ser	Pro	Gly	Ser	Ala	Pro	Val	Thr	Val	Ile	Tyr	Ser	Asn	Asp	Lys
10			35					40					45			
	Arg	Pro	Ser	Asp	Ile	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Lys	Ser	Gly	Ser
		50					55					60				
15	Thr	Ala	Thr	Leu	Thr	Ile	Thr	Gly	Val	Gln	Ala	Asp	Asp	Glu	Ala	Val
	65					70					75					80
	Tyr	Phe	Cys	Gly	Gly	Tyr	Asn	Ile	Tyr	Gly	Pro	Thr	Phe	Gly	Ala	Gly
20					85					90					95	
	Thr	Thr	Leu	Thr	Val											
25					100											

Claims

- 30 1. An antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5.
2. The antibody or the fragment thereof according to claim 1, wherein the antibody or the fragment thereof has cytotoxic activity against a cancer cell expressing a CAPRIN-1 protein.
- 35 3. The antibody or the fragment thereof according to claim 1 or 2, wherein the antibody is a monoclonal antibody.
4. The antibody or the fragment thereof according to claim 1 or 2, wherein the antibody is a polyclonal antibody.
- 40 5. The antibody or the fragment thereof according to any one of claims 1 to 4, wherein the antibody is a human antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, or a multispecific antibody.
- 45 6. The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 10, 11, and 12 and has immunological reactivity with the CAPRIN-1 protein.
- 50 7. The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 16, 17, and 18 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 20, 21, and 22 and has immunological reactivity with the CAPRIN-1 protein.
- 55 8. The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 50, 51, and 52 and has immunological reactivity with the CAPRIN-1 protein.
9. The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain

variable region comprising complementarity determining regions of SEQ ID NOs: 55, 56, and 57 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 59, 60, and 61 and has immunological reactivity with the CAPRIN-1 protein.

- 5 10. The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 55, 56, and 57 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 59, 64, and 61 and has immunological reactivity with the CAPRIN-1 protein.
- 10 11. The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 66, 67, and 68 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 70, 71, and 72 and has immunological reactivity with the CAPRIN-1 protein.
- 15 12. The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 74, 75, and 76 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 78, 79, and 80 and has immunological reactivity with the CAPRIN-1 protein.
- 20 13. The antibody or the fragment thereof according to any one of claims 1 to 12, wherein the antibody or the fragment thereof is conjugated with an antitumor agent.
14. The antibody or the fragment thereof according to any preceding claim, for use in a method for treating and/or preventing cancer.
- 25 15. The antibody or the fragment thereof for use according to claim 14, wherein the cancer is breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.
- 30 16. A pharmaceutical composition comprising the antibody or the fragment thereof according to any one of claims 1 to 13 as an active ingredient.
17. The pharmaceutical composition according to claim 16, for use in a method for treating and/or preventing cancer.
- 35 18. The pharmaceutical composition for use according to claim 17, wherein the cancer is breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.
- 40 19. A pharmaceutical combination comprising a pharmaceutical composition according to claim 16 and a pharmaceutical composition comprising an antitumor agent.
20. The pharmaceutical combination according to claim 19, for use in a method for treating and/or preventing cancer.
- 45 21. The pharmaceutical combination for use according to claim 20, wherein the cancer is breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.
- 50 22. A DNA encoding the antibody or the fragment thereof according to any one of claims 1 to 12.

Patentansprüche

- 55 1. Antikörper oder Fragment davon mit immunologischer Reaktivität mit einem CAPRIN-1-Teilpolypeptid, das aus der durch Seq.-ID Nr. 5 dargestellten Aminosäuresequenz besteht.

2. Antikörper oder Fragment davon nach Anspruch 1, wobei der Antikörper oder das Fragment davon zytotoxische Aktivität gegen eine Krebszelle aufweist, die ein CAPRIN-1-Protein exprimiert.
3. Antikörper oder Fragment davon nach Anspruch 1 oder 2, wobei der Antikörper ein monoklonaler Antikörper ist.
4. Antikörper oder Fragment davon nach Anspruch 1 oder 2, wobei der Antikörper ein polyklonaler Antikörper ist.
5. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 4, wobei der Antikörper ein menschlicher Antikörper, ein humanisierter Antikörper, ein chimärer Antikörper, ein einkettiger Antikörper oder ein multispezifischer Antikörper ist.
6. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerekettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 6, 7 und 8 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 10, 11 und 12 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
7. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerekettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 16, 17 und 18 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 20, 21 und 22 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
8. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerekettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 6, 7 und 8 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 50, 51 und 52 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
9. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerekettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 55, 56 und 57 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 59, 60 und 61 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
10. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerekettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 55, 56 und 57 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 59, 64 und 61 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
11. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerekettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 66, 67 und 68 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 70, 71 und 72 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
12. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerekettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 74, 75 und 76 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 78, 79 und 80 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
13. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 12, wobei der Antikörper oder das Fragment davon mit einem Antitumormittel konjugiert ist.
14. Antikörper oder Fragment davon nach einem der vorangegangenen Ansprüche zur Verwendung in einem Verfahren zur Behandlung und/oder Prävention von Krebs.
15. Antikörper oder Fragment davon zur Verwendung nach Anspruch 14, wobei der Krebs Brustkrebs, Nierenkrebs, Pankreaskrebs, Kolorektalkrebs, Lungenkrebs, Hirntumor, Magenkrebs, Gebärmutterhalskrebs, Ovarialkrebs, Prostatakrebs, Harnblasenkrebs, Ösophaguskrebs, Leukämie, ein Lymphom, ein Fibrosarkom, ein Mastozytom oder ein Melanom ist.
16. Pharmazeutische Zusammensetzung, die einen Antikörper oder ein Fragment davon nach einem der Ansprüche 1

bis 13 als Wirkbestandteil umfasst.

17. Pharmazeutische Zusammensetzung nach Anspruch 16 zur Verwendung in einem Verfahren zur Behandlung und/oder Prävention von Krebs.

18. Pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 17, wobei der Krebs Brustkrebs, Nierenkrebs, Pankreaskrebs, Kolorektalkrebs, Lungenkrebs, Hirntumor, Magenkrebs, Gebärmutterhalskrebs, Ovarialkrebs, Prostatakrebs, Harnblasenkrebs, Ösophaguskrebs, Leukämie, ein Lymphom, ein Fibrosarkom, ein Mastozytom oder ein Melanom ist.

19. Pharmazeutische Kombination, die eine pharmazeutische Zusammensetzung nach Anspruch 16 und eine pharmazeutische Zusammensetzung umfasst, die ein Antitumormittel umfasst.

20. Pharmazeutische Kombination nach Anspruch 19 zur Verwendung in einem Verfahren zur Behandlung und/oder Prävention von Krebs.

21. Pharmazeutische Kombination zur Verwendung nach Anspruch 20, wobei der Krebs Brustkrebs, Nierenkrebs, Pankreaskrebs, Kolorektalkrebs, Lungenkrebs, Hirntumor, Magenkrebs, Gebärmutterhalskrebs, Ovarialkrebs, Prostatakrebs, Harnblasenkrebs, Ösophaguskrebs, Leukämie, ein Lymphom, ein Fibrosarkom, ein Mastozytom oder ein Melanom ist.

22. DNA, die für einen Antikörper oder ein Fragment davon nach einem der Ansprüche 1 bis 12 kodiert.

Revendications

1. Anticorps ou fragment de celui-ci qui possède une réactivité immunologique avec un polypeptide CAPRINE-1 partiel consistant en la séquence d'acides aminés montrée par SEQ ID NO: 5.

2. Anticorps ou fragment de celui-ci selon la revendication 1, où l'anticorps ou le fragment de celui-ci possède une activité cytotoxique contre une cellule cancéreuse exprimant une protéine CAPRINE-1.

3. Anticorps ou fragment de celui-ci selon la revendication 1 ou 2, où l'anticorps est un anticorps monoclonal.

4. Anticorps ou fragment de celui-ci selon la revendication 1 ou 2, où l'anticorps est un anticorps polyclonal.

5. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 4, où l'anticorps est un anticorps humain, un anticorps humanisé, un anticorps chimérique, un anticorps simple chaîne, ou un anticorps multispécifique.

6. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 6, 7 et 8 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 10, 11 et 12 et possède une réactivité immunologique avec la protéine CAPRINE-1.

7. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 16, 17 et 18 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 20, 21 et 22 et possède une réactivité immunologique avec la protéine CAPRINE-1.

8. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 6, 7 et 8 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 50, 51 et 52 et possède une réactivité immunologique avec la protéine CAPRINE-1.

9. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 55, 56 et 57 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 59, 60 et 61 et possède une réactivité immunologique avec la protéine CAPRINE-1.

10. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 55, 56 et 57 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 59, 64 et 61 et possède une réactivité immunologique avec la protéine CAPRINE-1.
11. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 66, 67 et 68 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 70, 71 et 72 et possède une réactivité immunologique avec la protéine CAPRINE-1.
12. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 74, 75 et 76 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 78, 79 et 80 et possède une réactivité immunologique avec la protéine CAPRINE-1.
13. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 12, où l'anticorps ou le fragment de celui-ci est conjugué avec un agent antitumoral.
14. Anticorps ou fragment de celui-ci selon une quelconque revendication précédente, destiné à être utilisé dans un procédé de traitement et/ou de prévention du cancer.
15. Anticorps ou fragment de celui-ci destiné à être utilisé selon la revendication 14, où le cancer est le cancer du sein, le cancer du rein, le cancer du pancréas, le cancer colorectal, le cancer du poumon, une tumeur cérébrale, le cancer de l'estomac, le cancer du col de l'utérus, le cancer de l'ovaire, le cancer de la prostate, le cancer de la vessie, le cancer de l'oesophage, une leucémie, un lymphome, un fibrosarcome, un mastocytome, ou un mélanome.
16. Composition pharmaceutique comprenant l'anticorps ou le fragment de celui-ci selon l'une quelconque des revendications 1 à 13 en tant qu'ingrédient actif.
17. Composition pharmaceutique selon la revendication 16, destinée à être utilisée dans un procédé de traitement et/ou de prévention du cancer.
18. Composition pharmaceutique destinée à être utilisée selon la revendication 17, où le cancer est le cancer du sein, le cancer du rein, le cancer du pancréas, le cancer colorectal, le cancer du poumon, une tumeur cérébrale, le cancer de l'estomac, le cancer du col de l'utérus, le cancer de l'ovaire, le cancer de la prostate, le cancer de la vessie, le cancer de l'oesophage, une leucémie, un lymphome, un fibrosarcome, un mastocytome, ou un mélanome.
19. Combinaison pharmaceutique comprenant une composition pharmaceutique selon la revendication 16 et une composition pharmaceutique comprenant un agent antitumoral.
20. Combinaison pharmaceutique selon la revendication 19, destinée à être utilisée dans un procédé de traitement et/ou de prévention du cancer.
21. Combinaison pharmaceutique destinée à être utilisée selon la revendication 20, où le cancer est le cancer du sein, le cancer du rein, le cancer du pancréas, le cancer colorectal, le cancer du poumon, une tumeur cérébrale, le cancer de l'estomac, le cancer du col de l'utérus, le cancer de l'ovaire, le cancer de la prostate, le cancer de la vessie, le cancer de l'oesophage, une leucémie, un lymphome, un fibrosarcome, un mastocytome, ou un mélanome.
22. ADN codant pour l'anticorps ou le fragment de celui-ci selon l'une quelconque des revendications 1 à 12.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5698396 A [0006]
- WO 2010016526 A [0006] [0123] [0124] [0125] [0126] [0129] [0133] [0136] [0151]
- WO 0243478 A [0054]
- WO 02092812 A [0054]
- JP 2007530068 A [0055]
- WO 9846777 A [0055]
- EP 239400 A [0061]
- WO 9602576 A [0061]
- WO 9951743 A [0061]
- WO 2011096519 A [0138] [0152] [0160]
- WO 2011096517 A [0160]
- WO 2011096528 A [0160]
- WO 2011096533 A [0160]
- WO 2011096534 A [0160]
- JP 2011171300 A [0165]

Non-patent literature cited in the description

- **BOON et al.** *Ludwig Institute for Cancer Research*, 1991 [0003]
- **TSUYOSHI AKIYOSHI.** Japanese Journal of Cancer and Chemotherapy. Japanese Journal of Cancer and Chemotherapy Publishers Inc, 1997, vol. 24, 55-519 [0007]
- **BRUGGEN P. et al.** *Science*, 1991, vol. 254, 1643-1647 [0007]
- *Proc. Natl. Acad. Sci. USA*, 1995, vol. 92, 11810-11813 [0007]
- *Int. J. Cancer*, 1997, vol. 72, 965-971 [0007]
- *Cancer Res.*, 1998, vol. 58, 1034-1041 [0007]
- *Int. J. Cancer*, 1998, vol. 29, 652-658 [0007]
- *Int. J. Oncol.*, 1999, vol. 14, 703-708 [0007]
- *Cancer Res.*, 1996, vol. 56, 4766-4772 [0007]
- *Hum. Mol. Genet.*, 1997, vol. 6, 33-39 [0007]
- **KARLIN ; ALTSCHUL.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 5873-5877 [0021]
- **ALTSCHUL et al.** *Nucleic Acids Res.*, 1997, vol. 25, 3389-3402 [0021]
- Seikagaku Jikken Koza (Biochemical Experimentation Course in English). Protein Chemistry IV, Chemical Modification and Peptide Synthesis. Tokyo Kagaku Dojin Co., Ltd, 1981, vol. 1 [0024]
- Current Protocols in Molecular Biology. **SAMBROOK et al.** Molecular Cloning. Cold Spring Harbor Laboratory Press, 1989 [0025]
- A compendium of Methods from Current Protocols in Molecular Biology. **AUSUBEL et al.** Short Protocols in Molecular Biology. John Wiley & Sons, 1995 [0025]
- A Compendium of Methods from Current Protocols in Molecular Biology. **AUSUBEL et al.** Short Protocols in Molecular Biology. John Wiley & Sons, 1995 [0026]
- Current Protocols in Molecular Biology. **SAMBROOK et al.** Molecular Cloning. 1989 [0027]
- *J. Immunol.*, 1979, vol. 123, 1548-1550 [0043]
- *Current Topics in Microbiology and Immunology*, 1978, vol. 81, 1-7 [0043]
- **KOHLER. G. ; MILSTEIN, C.** *Eur. J. Immunol.*, 1976, vol. 6, 511-519 [0043]
- **MARGULIES. D.H. et al.** *Cell*, 1976, vol. 8, 405-415 [0043]
- **SHULMAN, M. et al.** *Nature*, 1978, vol. 276, 269-270 [0043]
- **GROTH, S.F. et al.** *J. Immunol. Methods*, 1980, vol. 35, 1-21 [0043]
- **TROWBRIDGE, I.S.** *J. Exp. Med.*, 1978, vol. 148, 313-323 [0043]
- **GALFRE, G. et al.** *Nature*, 1979, vol. 277, 131-133 [0043]
- **KOHLER, G. ; MILSTEIN, C.** *Methods Enzymol.*, 1981, vol. 73, 3-46 [0044]
- **CARL, A.K. BORREBAECK ; JAMES, W. LAR-RICK.** THERAPEUTIC MONOCLONAL ANTIBODIES. United Kingdom by MACMILLAN PUBLISHERS LTD, 1990 [0056]
- **SATO K. et al.** *Cancer Research*, 1993, vol. 53, 851-856 [0061] [0062]
- **HASHIMOTO-GOTOH, T. et al.** *Gene*, 1995, vol. 152, 271-275 [0067]
- **ZOLLER, M.J. ; SMITH, M.** *Methods Enzymol.*, 1983, vol. 100, 468-500 [0067]
- **KRAMER, W. et al.** *Nucleic Acids Res.*, 1984, vol. 12, 9441-9456 [0067]
- **KRAMER, W. ; FRITZ, HJ.** *Methods Enzymol.*, 1987, vol. 154, 350-367 [0067]
- **KUNKEL, TA.** *Proc. Natl. Acad. Sci. USA.*, 1985, vol. 82, 488-492 [0067]
- **KUNKEL.** *Methods Enzymol.*, 1988, vol. 85, 2763-2766 [0067]
- **KABAT et al.** Sequences of Proteins of Immunological Interest. Public Health Service, National Institute of Health, 1991 [0070]

EP 2 740 796 B1

- **SAMBROOK et al.** Molecular Cloning A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1989 [0071]
- **G.B. KIM et al.** *Protein Engineering Design and Selection*, 2007, vol. 20 (9), 425-432 [0074]
- **P.J. DELVES.** ANTIBODY PRODUCTION ESSENTIAL TECHNIQUES. WILEY, 1997 [0076]
- **P. SHEPHERD ; C. DEAN.** Monoclonal Antibodies. OXFORD UNIVERSITY PRESS, 2000 [0076]
- **J.W. GODING.** Monoclonal Antibodies: principles and practice. ACADEMIC PRESS, 1993 [0076]
- **NIWA R.** *Clinical Cancer Research*, 15 March 2005, vol. 11 (6), 2327-2336 [0094]

10305D



SZTNH-100070402

EP 2 740 796

GYÓGYÁSZATI KÉSZÍTMÉNY RÁK KEZELÉSÉRE ÉS/VAGY MEGELŐZÉSÉRE

Szabadalmi igénypontok:

1. Antitest vagy fragmense, amely immunológiai reaktivitással rendelkezik egy olyan részleges CAPRIN-1 polipeptid felé, amely a SEQ ID NO: 5 (azaz 5-ös azonosítási számú szekvencia) által bemutatott aminosav-szekvenciából áll.
2. Az 1. igénypont szerinti antitest vagy fragmense, ahol az antitest vagy fragmense citotoxikus aktivitással rendelkezik egy olyan rákos sejttel szemben, amely expresszál egy CAPRIN-1 fehérjét.
3. Az 1. vagy 2. igénypont szerinti antitest vagy fragmense, ahol az antitest monoklonális antitest.
4. Az 1. vagy 2. igénypont szerinti antitest vagy fragmense, ahol az antitest poliklonális antitest.
5. Az 1-4. igénypontok bármelyike szerinti antitest vagy fragmense, ahol az antitest humán antitest, humanizált antitest, kiméra antitest, egyláncú antitest vagy multispecifikus antitest.
6. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 6, 7 és 8 szerinti komplementaritás-meghatározó régiókat, és olyan könnyűlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 10, 11 és 12 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.

7. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 16, 17 és 18 szerinti komplementaritás-meghatározó régiókat, és olyan könnyűlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 20, 21 és 22 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.
8. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 6, 7 és 8 szerinti komplementaritás-meghatározó régiókat, és olyan könnyűlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 50, 51 és 52 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.
9. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 55, 56 és 57 szerinti komplementaritás-meghatározó régiókat, és olyan könnyűlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 59, 60 és 61 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.
10. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 55, 56 és 57 szerinti komplementaritás-meghatározó régiókat, és olyan könnyűlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 59, 64 és 61 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.
11. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 66, 67 és 68 szerinti komplementaritás-meghatározó régiókat, és olyan könnyűlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 70, 71 és 72 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.

12. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 74, 75 és 76 szerinti komplementaritás-meghatározó régiókat, és olyan könnyűlánc variábilis régiót, amely tartalmaz a SEQ ID NO: 78, 79 és 80 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.
13. Az 1-12. igénypontok bármelyike szerinti antitest vagy fragmense, ahol az antitest vagy fragmense tumorellenes ágenssel van konjugálva.
14. Az előző igénypontok bármelyike szerinti antitest vagy fragmense rák kezelésére és/vagy megelőzésére szolgáló eljárásban történő alkalmazásra.
15. Az antitest vagy fragmense alkalmazásra a 14. igénypont szerint, ahol a rák mellrák, veserák, hasnyálmirigyrák, colorektális rák, tüdőrák, agytumor, gyomorrák, méhnyakrák, petefészekrák, prosztatarák, húgyhólyagrák, nyelöcsőrák, leukémia, limfóma, fibroszarkóma, masztocitóma vagy melanóma.
16. Gyógyászati készítmény, amely hatóanyagként tartalmazza az 1-13. igénypontok bármelyike szerinti antitestet vagy fragmensét.
17. A 16. igénypont szerinti gyógyászati készítmény rák kezelésére és/vagy megelőzésére szolgáló eljárásban történő alkalmazásra.
18. A gyógyászati készítmény alkalmazásra a 17. igénypont szerint, ahol a rák mellrák, veserák, hasnyálmirigyrák, colorektális rák, tüdőrák, agytumor, gyomorrák, méhnyakrák, petefészekrák, prosztatarák, húgyhólyagrák, nyelöcsőrák, leukémia, limfóma, fibroszarkóma, masztocitóma vagy melanóma.

19. Gyógyászati kombináció, amely tartalmaz a 16. igénypont szerinti gyógyászati készítményt, valamint tumorellenes ágenst tartalmazó gyógyászati készítményt.
20. A 19. igénypont szerinti gyógyászati kombináció rák kezelésére és/vagy megelőzésére szolgáló eljárásban történő alkalmazásra.
21. A gyógyászati kombináció alkalmazásra a 20. igénypont szerint, ahol a rák mellrák, veserák, hasnyálmirigyrák, kolorektális rák, tüdőrák, agytumor, gyomorrák, méhnyakrák, petefészekrák, prosztatarák, húgyhólyagrák, nyelvcsőrák, leukémia, limfóma, fibroszarkóma, masztocitóma vagy melanóma.
22. DNS, amely kódolja az 1-12. igénypontok bármelyike szerinti antitestet vagy fragmensét.